The FTLD risk factor TMEM106B controls lysosomal trafficking and dendrite outgrowth by Schwenk, Benjamin
Aus dem Adolf-Butenandt-Institut der 
Ludwig-Maximilians-Universität München 
Lehrstuhl: Stoffwechselbiochemie 
Vorstand: Prof. Dr. rer. nat. Dr. h.c. Christian Haass 
 
 
 
 
 
 
 
 
The FTLD risk factor TMEM106B controls 
lysosomal trafficking and dendrite outgrowth 
 
 
- Dissertation - 
zum Erwerb des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) 
an der Medizinischen Fakultät der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
 
 
 
 
 
vorgelegt von 
Benjamin Michael Schwenk 
aus Augsburg 
 
2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit Genehmigung der Medizinischen Fakultät der Ludwig-Maximilians-Universität 
München 
Betreuer: Prof. Dr. rer. nat. Dr. h.c. Christian Haass 
Zweitgutachter: PD Dr. rer. nat. Ingrid Boeckhoff 
Dekan: Prof. Dr. med. Dr. h.c. Maximilian Reiser, FACR, FRCR 
 
Tag der mündlichen Prüfung: 26.03.2015  
 
 
Eidesstattliche Versicherung 
 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation mit dem 
Thema The FTLD risk factor TMEM106B controls lysosomal trafficking and 
dendrite outgrowth selbständig verfasst, mich außer der angegebenen keiner 
weiteren Hilfsmittel bedient und alle Erkenntnisse, die aus dem Schrifttum ganz 
oder annähernd übernommen sind, als solche kenntlich gemacht und nach ihrer 
Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen habe.  
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder 
in ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen 
Grades eingereicht wurde.  
 
München,  
 
 
 
Benjamin Michael Schwenk 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Life is what happens while you are busy making other plans. 
 John  Lennon 
Summary 
 
5 
 
Summary 
Frontotemporal dementia is the second most common neurodegenerative disease in 
people younger than 65 years. Patients suffer from behavioral changes, language 
deficits and speech impairment. Unfortunately, there is no effective treatment 
available at the moment. Cytoplasmic inclusions of the DNA/RNA-binding protein 
TDP-43 are the pathological hallmark in the majority of FTLD cases, which are 
accordingly classified as FTLD-TDP. Mutations in GRN, the gene coding for the 
trophic factor progranulin, are responsible for the majority of familiar FTLD-TDP 
cases. The first genome-wide association study performed for FTLD-TDP led to the 
identification of risk variants in the so far uncharacterized gene TMEM106B. Initial 
cell culture studies revealed intracellular localization of TMEM106B protein in 
lysosomes but its neuronal function remained elusive.  
Based on these initial findings, I investigated the physiological function of 
TMEM106B in primary rat neurons during this thesis. I demonstrated that 
endogenous TMEM106B is localized to late endosomes and lysosomes in primary 
neurons, too. Notably, knockdown of the protein does neither impair general 
neuronal viability nor the protein level of FTLD associated proteins, such as GRN or 
TDP-43. However, shRNA-mediated knockdown of TMEM106B led to a pronounced 
withering of the dendritic arbor in developing and mature neurons. Moreover, the 
strong impairment of dendrite outgrowth and maintenance was accompanied by 
morphological changes and loss of dendritic spines. To gain mechanistic insight into 
the loss-of-function phenotypes, I searched for coimmunoprecipitating proteins by 
LC-MS/MS. I specifically identified the microtubule-binding protein MAP6 as 
interaction partner and was able to validate binding. Strikingly, overexpression of 
MAP6 in primary neurons phenocopied the TMEM106B knockdown effect on 
dendrites and loss of MAP6 restored dendritic branching in TMEM106B knockdown 
neurons, indicating functional interaction of the two proteins. The link between a 
lysosomal and a microtubule-binding protein made me study the microtubule 
dependent transport of dendritic lysosomes. Remarkably, live cell imaging studies 
revealed enhanced movement of dendritic lysosomes towards the soma in neurons 
devoid of TMEM106B. Again, MAP6 overexpression phenocopied and MAP6 
knockdown rescued this effect, strengthening the functional link. The MAP6-
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independent rescue of dendrite outgrowth by enhancing anterograde lysosomal 
movement provided additional evidence that dendritic arborization is directly 
controlled by lysosomal trafficking.  
From these findings I suggest the following model: TMEM106B and MAP6 together 
act as a molecular brake for the retrograde transport of dendritic lysosomes. 
Knockdown of TMEM106B and (the presumably dominant negative) overexpression 
of MAP6 release this brake and enhance the retrograde movement of lysosomes. 
Subsequently, the higher protein turnover and the net loss of membranes in distal 
dendrites may cause the defect in dendrite outgrowth. The findings of this study 
suggest that lysosomal misrouting in TMEM106B risk allele carrier might further 
aggravate lysosomal dysfunction seen in patients harboring GRN mutations and 
thereby contribute to disease progression.  
Taken together, I discovered the first neuronal function for the FTLD-TDP risk 
factor TMEM106B: This lysosomal protein acts together with its novel, 
microtubule-associated binding partner MAP6 as molecular brake for the 
dendritic transport of lysosomes and thereby controls dendrite growth and 
maintenance.  
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Zusammenfassung 
Frontotemporale Demenz ist die zweithäufigste Form neurodegenerativer 
Erkrankungen bei Menschen unter 65 Jahren. Patienten leiden an 
Verhaltensauffälligkeiten und Sprach- sowie Artikulationsstörungen. Leider steht 
zurzeit keine wirksame medikamentöse Therapie zur Verfügung. Das pathologische 
Hauptmerkmal der meisten FTLD-Fälle sind zytoplasmatische Einschlüsse des 
DNA/RNA-bindenden Proteins TDP-43. Diese Fälle werden entsprechend als FTLD-
TDP klassifiziert. Für einen Großteil der familiären FTLD-TDP Fälle sind 
Mutationen in GRN, dem für den Wachstumsfaktor Progranulin kodierenden Gen, 
verantwortlich. Die erste für FTLD-TDP durchgeführte genomweite 
Assoziationsstudie führte zur Entdeckung von genetischen Varianten im bis dato 
uncharakterisierten Gen TMEM106B. Diese Varianten sind mit einem erhöten Risiko 
an FTLD zu erkranken assoziiert. Initiale Studien in Zellkultur zeigten eine 
Lokalisierung des TMEM106B Proteins in Lysosomen, die Frage nach der neuronale 
Funktion des Proteins blieb allerdings bisher unbeantwortet.  
Auf diesen ersten Ergebnissen aufbauend untersuchte ich während meiner 
Dissertation die physiologische Funktion von TMEM106B in primären Ratten-
neuronen. Ich konnte zeigen, dass endogenes TMEM106B auch in primären 
Neuronen in späten Endsosomen und Lysosomen lokalisiert ist. 
Beachtenswerterweise verminderte die Herunterregulierung (shRNA-vermittelter 
Gen-Knockdown) des Proteins weder das generelle Überleben der Neuronen noch 
die Level von anderen FTLD-assoziierten Proteinen, wie GRN oder TDP-43. Die 
Herunterregulierung von TMEM106B führte jedoch zu einem ausgeprägten Verlust 
von Dendriten in sich entwickelnden und ausgereiften Neuronen. Des Weiteren war 
die starke Beeinträchtigung dendritischen Wachstums und Aufrechterhaltung von 
einer morphologischen Veränderung und dem Verlust der Dornfortsätze begleitet. 
Um den Mechanismus dieser Phänotypen zu erklären, suchte ich nach TMEM106B 
coimmunopräzipitierenden Proteinen mittels Massenspektrometrie. Ich konnte das 
Mikrotubuli bindende Protein MAP6 als spezifischen Bindungspartner identifizieren 
und die Interaktion beider Proteine validieren. Hervorzuheben ist, dass die 
Überexpression von MAP6 in primären Neuronen den Effekt der Herunterregulation 
von TMEM106B auf die Dendriten kopierte und die Herunterregulation von MAP6 
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die dendritischen Verästelungen in TMEM106B depletierten Neuronen sogar 
wiederherstellen konnte. Diese Ergebnisse legen eine funktionelle Interaktion beider 
Proteine nahe. Die Verbindung zwischen einem lysosomalen und einem an die 
Mikrotubuli bindenden Protein brachte mich dazu, den Mikrotubuli abhängigen 
Transport von dendritischen Lysosomen zu untersuchen. Bemerkenswerterweise 
zeigten mittels Lebendzellmikroskopie erzeugte Aufnahmen eine erhöhte Bewegung 
dendritischer Lysosomen Richtung Zellsoma in TMEM106B depletierten Neuronen. 
Auch in diesem Kontext konnte die Überexpression von MAP6 den Effekt kopieren 
und die Herunterregulation von MAP6 den Effekt aufheben und somit die These 
einer funktionellen Interaktion festigen. Die MAP6 unabhängige Wiederherstellung 
des dendritischen Wachstums durch die Erhöhung des lysosomalen Transports in 
anterograder Richtung lieferte einen zusätzlichen Beweis dafür, dass das 
dendritische Wachstum direkt von lysosomalem Transport abhängt. 
Ausgehend von diesen Ergebnissen schlage ich folgendes Modell vor: TMEM106B 
und MAP6 wirken zusammen als molekulare Bremse für den retrograden Transport 
dendritischer Lysosomen. Die Herunterregulation von TMEM106B und die 
(wahrscheinlich dominant negative wirkende) Überexpression von MAP6 lösen diese 
Bremse und verstärken die retrograde Bewegung von Lysosomen. Daraufhin könnten 
der gestiegene Proteinumsatz und der Verlust von Plasmamembranbestandteilen zu 
einem Fehler im dendritischen Wachstum führen. Die Ergebnisse dieser Arbeit legen 
nahe, dass fehlerhafter, lysosomaler Transport in TMEM106B Risikoallelträgern zu 
einer Verstärkung der lysosomalen Fehlfunktion in Patienten mit GRN Mutation 
führt und dabei zur Krankheitsentwicklung beiträgt. 
Zusammengefasst habe ich die erste neuronale Funktion für den FTLD-TDP 
Risikofaktor TMEM106B entdeckt: Dieses lysosomale Protein wirkt zusammen 
mit seinem neuentdeckten, Mikrotubuli assoziierten Bindungspartner MAP6 als 
molekulare Bremse für den dendritischen Transport von Lysosomen und 
kontrolliert dadurch Wachstum und Aufrechterhaltung von Dendriten. 
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I. Introduction  
1. FTLD 
1.1 Clinical presentation 
Frontotemporal dementia (FTD) was first described by Czech neurologist and 
psychiatrist Arnold Pick in 1892. The patient, a 71-year old man, presented with 
gradual mental retardation and speech disturbances, autopsy revealed cerebral 
atrophy primarily in the left hemisphere (Pick, 1892). Two decades later, Alois 
Alzheimer found and stained characteristic inclusions in these patients, henceforth 
called Pick bodies (Alzheimer, 1911). However, not until the last 20 years 
pathological and mechanistic findings helped researchers to understand disease 
mechanisms and provided potential drug targets. 
1.1.1 Clinical Symptoms of FTLD 
Frontotemporal lobar degeneration (FTLD) is the pathological syndrome underlying 
a group of diseases classified by the overarching term of frontotemporal dementia. 
In the following the term FTLD is used to designate both disease and pathology. 
FTLD is a presenile neurodegenerative disease with an average onset of 58 years 
(Johnson et al., 2005). The clinical presentation of FTLD is subclassified into 
behavioral variant of FTD (bvFTD), progressive non fluent aphasia (PNFA) and 
semantic dementia (SD). More than 50 % of all cases group into the first category. 
Patients suffering from bvFTD usually present with changes in behavior and 
personality (disinhibition, apathy, loss of empathy and social competence, 
stereotypic behavior) while learning and memory are preserved (Rascovsky et al., 
2011). PNFA and SD as of late combined in the term ‘primary progressive aphasia’ 
(PPA) both occur in approximately similar probability in the rest of the patients 
(Gorno-Tempini et al., 2011). Main symptoms in patients suffering from PNFA are 
‘non fluent’, agrammatic speech and anomia. These are often accompanied by 
apraxia of speech, which designates the inability to plan and coordinate the 
movements necessary for speech (Josephs et al., 2011). In contrast, patients affected 
by semantic dementia develop impaired comprehension, impaired conceptual 
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knowledge and anomia while speech production is still functional (Sieben et al., 
2012). 
1.1.2 Epidemiology of FTLD  
FTLD is the second most common neurodegenerative disease in people under the 
age of 65 years (Harvey et al., 2003). The disease has a prevalence of 10-20 patients 
per 100,000 people and an incidence of 3.5-4.1 per 100,000 / year in the age group 
of 45 – 64 years (reviewed in (Van Langenhove et al., 2012)). FTLD has a strong 
genetic component, as between 30-50 % of all patients have at least one relative 
with similar clinical symptoms. And in up to 25 % of patients the disease actually 
segregates with an autosomal dominant pattern. Proteins whose underlying genes are 
found to be mutated in patients, often aggregate in the brain and exhibit the 
characteristic neuropathology (Goldman et al., 2007; Goldman et al., 2005). 
Interestingly, aggregates of these proteins are also found in sporadic cases without 
known mutations rendering these proteins a likely cause of the disease (Dormann 
and Haass, 2011). Moreover, just recently variants in the so far undescribed gene 
transmembrane protein 106B (TMEM106B) were discovered to increase the risk for 
a subclass of sporadic and familial cases of FTLD (Van Deerlin et al., 2010).  
FTLD has a pronounced overlap with another presenile neurodegenerative disease, 
amyotrophic lateral sclerosis (ALS). Both diseases share many genetic and 
pathological features. Transactive response (TAR)-DNA-binding protein 43 (TDP-
43) and Fused-in-sarcoma (FUS) inclusions are found in both diseases and TARDBP 
and FUS mutations – usually a cause for ALS – lead in rare cases to FTLD. And 
with the discovery of the C9orf72 hexanucleotide-repeat-expansion a common 
genetic denominator was found that can cause either disease or a combined form. 
Moreover, 15 % of ALS patient develop FTLD symptoms and vice versa thus 
suffering from a hybrid forms both diseases (Ringholz et al., 2005; Wheaton et al., 
2007). Remarkably, in up to 75 % of ALS patients cognitive symptoms are found in 
late stages of the disease (Strong et al., 2009). However, pure genetic forms of the 
disease are observed as well. For example progranulin (GRN) mutations lead 
exclusively to FTLD while superoxide dismutase 1 (SOD1) mutations cause always 
ALS. These observations render FTLD and ALS a disease continuum with the pure 
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forms as distinct ends (Ling et al., 2013; Morris et al., 2012; Van Langenhove et al., 
2012). 
1.1.3 Pathology of FTLD 
The gross pathological changes seen in almost all patients are selective atrophy in 
the frontal and temporal lobe, with neuronal degeneration or neuron loss, spongy 
changes of the brain structure, neuroinflammation, gliosis and intracellular 
proteinaceous inclusions. However, apart from the clinical sub-classification the 
disease can also be sub-grouped according to the aggregating proteins and the 
neuropathology seen in affected brain. FTLD-TAU, the subgroup which is defined 
by inclusions of hyperphosphorylated Tau protein accounts for approximately 40% 
of all FTLD cases (Joachim et al., 1987). Most of the remaining patients present 
with Tau-negative, ubiquitin-positive inclusions and thus are diagnosed with FTLD-
U. These cases can be further subdivided in mainly FTLD-TDP – patients show 
TDP-43 positive inclusions, and rarer cases of FTLD-FUS and FTLD-UPS – patients 
show FUS inclusions respectively inclusions whose only known constituents are 
components of the ubiquitin-proteasome system (UPS) such as p62. Other types or 
even dementia lacking distinctive histopathology are found but are very rare (Pan 
and Chen, 2013). An association between neuropathological and the clinical subtype 
is observed but is not very strict: FTLD-TDP mainly leads to bvFTD or SD whereas 
FTLD-Tau causes usually PNFA. If patients are additionally diagnosed with motor 
neuron disease (MND), it is very likely that a TDP-43 or FUS proteinopathy is 
observed (reviewed in (Pan and Chen, 2013; Rademakers et al., 2012)).  
1.1.4 Diagnosis of FTLD  
Consensus diagnostic criteria for FTLD were originally defined in 1998 by Neary 
and colleagues and later partially revised by Rascovsky et al., based on clinical 
inclusion and exclusion features, neuropsychological investigations and brain 
imaging. Core diagnostic features include insidious onset and gradual progression 
for each of the three subgroups of FTLD. Decline in social conduct and emotional 
blunting are key symptoms for bvFTD, non-fluent spontaneous speech for PNFA and 
language and perceptual disorder for SD. Furthermore clinicians examine patients 
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with neuropsychological examinations especially for frontal lobe function, speech 
and language abilities (Neary et al., 1998; Rascovsky et al., 2011). In contrast to 
patients suffering from stroke, individuals affected by FTLD have normal activity in 
the electroencephalography (EEG) but structural and functional brain imaging 
reveals often asymmetrical abnormalities and atrophy in the frontal or temporal 
lobe. While structural and functional magnetic resonance imaging (MRI) help to 
define the areas of atrophy, functional connectivity MRI (fcMRI) and diffusion 
tensor imaging (DTI) are used to sub-classify FTLD and to establish a differential 
diagnosis of bvFTD. Other imaging techniques such as fluordesoxyglucose-positron 
emission tomography (FDG-PET) and single-photon emission computed tomography 
(SPECT) can help to distinguish FTLD from other dementias (McGinnis, 2012). 
1.1.5 Therapy of FTLD  
So far no FDA approved treatment for FTLD exists, even though several studies are 
ongoing e.g. with the N-methyl-D-aspartic acid receptor (NMDAR) antagonist 
memantine, typically used for Alzheimer´s disease (AD) (Boxer et al., 2009). In the 
past also other AD drugs as the acetylcholinesterase inhibitors (AChEI) donepezil 
and rivastigmine were tested but with largely negative outcome (Mendez, 2009). 
Apart from that, FTLD patients primarily receive symptomatic treatment with 
psychotropic drugs as selective serotonin reuptake inhibitors (SSRI) or atypical 
antipsychotics for behavioral abnormalities (Mendez, 2009). Additional non-
pharmacological interventions, such as education, behavioral management and 
interventions, are an important relief for patients and caregivers (Manoochehri and 
Huey, 2012). Future, more causal treatment strategies may include interference with 
the expression and splicing of disease related proteins, the regulation of microtubule 
stability, the prevention of protein aggregation and the restoration of the cellular 
degradation systems (Trojanowski et al., 2008; Vossel and Miller, 2008).  
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1.2 Molecular genetics of the FTLD subtypes 
 
 
Figure 1: Genetic and pathological Classification of FTLD 
The disease is subcategorized according to the aggregating proteins. Disease subtypes are depicted in blue 
boxes, underlying mutations in yellow boxes and aggregating proteins in orange boxes. Gene in 
parentheses has no definite association with FTLD. Asterisk denotes that rare DPR-positive cases are 
observed without TDP-43 pathology. Adapted from (Dormann and Haass, 2013). 
 
1.2.1 FTLD-TAU 
The first gene identified causing FTLD was Microtubule-associated protein Tau 
(MAPT). Mutations in the MAPT gene result in hyperphosphorylated intracellular 
inclusions (neurofibrillary tangles) of the Tau protein and almost exclusively to 
FTLD-TAU (Hutton et al., 1998). Tau is a microtubule-binding protein expressed 
primarily in the nervous system. Apart from the stabilization of microtubules its 
main functions lie in regulation of microtubule-dependent transport and scaffolding 
of signaling complexes thereby controlling their activity (Morris et al., 2011). Most 
pathogenic MAPT mutations cluster around exon 9 to 13, which encode the 
microtubule binding domains of the protein. These mutations either change the ratio 
of the MAPT splice variants which consequentially leads to impaired microtubule 
binding of Tau or directly affect the binding. Numerous studies report that reduced 
binding to the cytoskeleton causes altered microtubule stability and disturbed 
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microtubule-dependent axonal transport by now unbound and eventually miss-
localized Tau (reviewed in (Pan and Chen, 2013; Rademakers et al., 2004; Sieben et 
al., 2012)). Additionally, aggregated Tau protein – depending on its phosphorylation 
status – as well as dendritically redistributed soluble tau seems to mediate toxic 
signaling (Haass and Mandelkow, 2010; Ittner et al., 2010).  
1.2.2 FTLD-TDP 
1.2.2.1 GRN 
The first causative gene for Tau negative FTLD was independently described by two 
groups in 2006. Interestingly, the mutations were found in GRN, a gene located 
close to the MAPT locus on chromosome 17 (Baker et al., 2006; Cruts et al., 2006). 
GRN mutations lead exclusively to and are one of the major causes of FTLD-TDP 
pathology (Nicholson et al., 2012). GRN is a secreted glycoprotein that can be 
further cleaved by extracellular proteases into 7.5 cysteine-rich granulin peptides. 
Although general, trophic functions of GRN in wound healing and tumorogenesis as 
well as its anti-inflammatory capacity are relatively well understood, the exact role 
in brain is not completely clear (He and Bateman, 2003). In dissociated neurons 
GRN seems to promote neurite outgrowth and neuronal survival (Gass et al., 2012; 
Van Damme et al., 2008). Especially the role of the small granulin peptides remains 
mostly elusive. They seem to antagonize some aspects of GRN function as they are 
proinflammatory (Zhu et al., 2002), but may act similarly to the full length protein 
in terms of neurite outgrowth and neuronal survival (Gass et al., 2012). Moreover, 
every granulin peptide acts differently and they seem to inhibit and antagonize each 
other (Cenik et al., 2012). GRN mutations are inherited in an autosomal dominant 
pattern. Most heterozygous mutations are null mutations due to nonsense mediated 
RNA decay, thus leading to GRN haploinsufficiency in patients. In rarer cases, 
mutations rather lead to mislocalization, reduced expression or impaired secretion of 
the protein than to a complete loss of the mRNA. The genetic findings argue for a 
loss of function pathogenesis in GRN mutation carriers (reviewed in (Nicholson et 
al., 2012; Ward and Miller, 2011)).  
To study the impact of GRN loss on FTLD, GRN knockout mice were generated. 
Similar to FTLD patients, mice show decreased survival and behavioral 
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abnormalities. Further phenotypes include pronounced microgliosis, especially in 
hippocampus and cortex and ubiquitinated protein aggregates in neurons (Kayasuga 
et al., 2007; Yin et al., 2010). More comprehensive analysis of the knockout animals 
revealed Cathepsin D pathology and lipofuscin aggregates in the brain – typically a 
sign of lysosomal deficiency (Ahmed et al., 2010; Wils et al., 2012). Strikingly, just 
recently two human siblings with homozygous GRN loss of function mutations have 
been identified. Both suffer from adult neuronal ceroid lipofuscinosis (NCL), a 
lysosomal storage disease, instead of FTLD-TDP as seen in heterozygous carriers 
(Smith et al., 2012). Another link between GRN and the lysosome is the recent 
identification of sortilin as scavenger receptor for the protein in neurons. Upon 
binding to sortilin, GRN is re-endocytosed and rapidly transported to the lysosome. 
In line with these findings, GRN level are elevated in the brain of sortilin knockout 
mice (Hu et al., 2010).  
In 2010, TMEM106B was identified as the first genetic risk factor for FTLD-TDP 
with GRN mutations. TMEM106B risk variants elevate the penetrance of GRN 
mutations and decrease the age of onset in mutation carriers (Van Deerlin et al., 
2010). It was suggested that these risk variant influence GRN mRNA or protein 
level (Cruchaga et al., 2011; Finch et al., 2011), but the physiological function of 
TMEM106B was unclear. 
1.2.2.2 TDP-43 
Although TDP-43 is the eponymous protein for FTLD-TDP, mutations in its coding 
gene TARDBP usually lead to ALS-TDP. Only in very rare cases these mutations 
cause FTLD-TDP ((Benajiba et al., 2009; Borroni et al., 2009; Gitcho et al., 2009; 
Tamaoka et al., 2010). TDP-43 is a DNA/RNA-binding protein with functions in 
transcription, RNA-splicing and microRNA processing (Sieben et al., 2012). 
TARDBP mutations cluster in the C-terminal glycine-rich domain involved in 
protein-protein interaction (Pesiridis et al., 2009). Major pathological hallmark of 
FTLD-TDP are TDP-43-positive, ubiquitin-positive, α-Synuclein-negative, Tau-
negative inclusions in neurons and glia cells (Arai et al., 2006; Neumann et al., 
2006). These inclusions contain full-length and C-terminal fragments of 
hyperphophorylated and ubiquitinated TDP-43 as well as proteins responsible for 
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stress granule formation, such as poly(A)-binding protein (PABA) and cytotoxic 
granule-associated RNA binding protein 1 (Tia1) (Fujita et al., 2008; Liu-
Yesucevitz et al., 2010). These findings suggest a possible pathomechanism: stress 
granules might be precursors of the insoluble aggregates and mediate toxicity 
(Dormann and Haass, 2011). Another possible disease mechanism leading to 
neurotoxicity of TDP-43 mutations are deficits in RNA splicing or metabolism as 
the inclusion bearing cells are mostly devoid of intra-nuclear TDP-43 (Arai et al., 
2006; Neumann et al., 2006). Notably, pronounced toxicity was observed in 
overexpression and knockout animal models (Feiguin et al., 2009; Johnson et al., 
2009). Therefore the question arises if loss of TDP-43 function or toxic gain of 
function of the aggregates is the disease causing mechanism. So far neither animal 
models nor cell culture experiments could answer this question satisfactorily 
(Sleegers et al., 2010). 
1.2.2.3 C9orf72 
The most common genetic cause for FTLD-TDP (as well as for ALS-TDP and 
overlapping forms of the disease) are mutations in C9orf72, coding for a so far 
uncharacterized protein. A GGGGCC hexanucleotide-repeat expansion in the 
promoter region or the first intron, depending on the transcript, was found in 
patients. In healthy controls 0 - 20 GGGGCC repeats are observed, whereas up to 
several thousand exist in patients. The classical FTLD-TDP pathology is 
accompanied by RNA foci and a reduction of the mRNA level of the longer isoform 
of C9orf72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011). In most 
hexanucleotide-repeat-expansion carriers TDP-43-positive, p62-positive, Tau-
negative neuronal and glial inclusions in the cortex, the hippocampus and 
remarkably also the cerebellum – usually free of other aggregates in FTLD – are 
found (Al-Sarraj et al., 2011). Strikingly, many aggregates in the brain of C9orf72-
patients are TDP-43-negative and consist mainly of di-peptide-repeat-proteins 
(DPRs) which are ATG-independently translated from the repeat mRNA (Ash et al., 
2013; Mori et al., 2013c). So far three independent but not mutually exclusive 
scenarios for the pathomechanism of the C9orf72 hexanucleotide-repeat expansion 
have been proposed: haplo-insufficiency thus loss of function of the C9orf72 protein 
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(DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012), RNA mediated toxicity by 
sequestration of RNA binding proteins by the repeat RNA (Mori et al., 2013b) and 
ATG-independent translation of the repeat into aggregating dipeptide repeat proteins 
and DPR-toxicity (Mori et al., 2013c). Interestingly, so-called repeat associated 
non-ATG (RAN) translation was first described in another neurodegenerative 
disease, spinocerebellar ataxia type 8 (SCA8), where polyalanin, polyglutamine and 
polyserine peptides are translated from a trinucleotide-repeat expansion (Zu et al., 
2011). Rare C9orf72 FTLD cases without TDP-43 pathology suggest that primarily 
TDP-43 independent mechanisms cause disease in C9orf72-patients. Moreover, DPR 
aggregation might be a potential prerequisite for TDP-43 pathology in the C9orf72 
cases (Brettschneider et al., 2012; Mori et al., 2013a; Proudfoot et al., 2014).  
1.2.3 FTLD-FUS 
Another rare subgroup of FTLD cases was redefined in 2009 as FTLD-FUS with the 
discovery of FUS aggregates as a common pathological hallmark in patients with 
atypical FTLD with ubiquitin pathology (aFTLD-U), basophilic inclusion body 
disease (BIBD) and neuronal intermediate filament inclusion diseases (NIFID) 
(Mackenzie et al., 2010). Similar to TDP-43, FUS is a DNA/RNA-binding protein 
with main functions in transcriptional regulation, mRNA transport and splicing 
(Dormann and Haass, 2013). Although rare cases of FTLD-FUS with FUS/TLS  
mutations have been reported (Kwiatkowski et al., 2009; Vance et al., 2009), they 
usually cause ALS-FUS. FUS inclusions in FTLD are mainly observed in sporadic 
cases without mutations (Munoz et al., 2009; Neumann et al., 2009). FUS mutations 
causing FTLD or ALS cluster in the C-terminal region of the gene . This region 
encodes the non-canonical PY-nuclear localization signal (PY-NLS) whose function 
is consequently impaired by a reduced affinity to the nuclear import factor 
transportin (Dormann et al., 2010). Hence, redistribution of FUS from the nucleus to 
the soma and cytoplasmic aggregation of the protein is observed in patient brains. 
So far known constituents of the ubiquitinated, p62-positive inclusions are the other 
two members of the FET family of proteins Ewing sarcoma protein (EWS) and 
TATA box-binding protein (TBP)-associated factor 15 (TAF-15) (Neumann et al., 
2011) and stress granule marker (Dormann et al., 2010). Nuclear clearance of FUS 
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and FUS aggregation in turn opens the question whether the pathomechanism of 
FTLD-FUS comprises loss of nuclear function of FUS or toxic gain of function of 
the aggregates. Similar to FTLD with TDP-43 pathology, the answer remains 
elusive. Loss-of-function studies suggest FUS as an important regulator of neuronal 
health (Fujii et al., 2005). Deficits seen in knockout neurons and animals may be 
due to an impairment of alternative splicing events since the level and splicing of 
many mRNAs are affected by depletion of FUS (Ishigaki et al., 2012; Lagier-
Tourenne et al., 2012; Rogelj et al., 2012). The misregulated mRNAs are enriched 
for neuronal targets, among them Tau, a protein already implicated in the 
pathogenesis of FTLD (Orozco et al., 2012).  
1.2.4 FTLD-UPS 
Other mutations leading to pure FTLD or ASL-FTLD have been reported in the 
genes coding for valosin containing protein (VCP) (Watts et al., 2004), charged 
multivesicular body protein 2b (CHMP2B) (Momeni et al., 2006b) and ubiquilin2 
(UBQLN2) (Deng et al., 2011; Synofzik et al., 2012). Since all these proteins are 
implicated in protein sorting and degradation, the dysfunction of the ubiquitin-
proteasome system leading to impaired protein degradation might be one of the key 
pathomechanisms of FTLD. Consequentially, all remaining cases, devoid of TDP-43, 
FUS or Tau pathology but positive for ubiquitin and p62 aggregates, are summarized 
in the term FTLD-UPS (Mackenzie et al., 2010). 
 
In summary three main pathomechanisms become evident for the FTLD-continuum: 
disturbed RNA-metabolism, toxicity of the aggregating proteins and dysfunction of 
the cellular degradation system.  
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1.3 TMEM106B 
1.3.1 Identification as risk factor 
In 2010, a single linkage disequilibrium (LD) block on chromosome 7p21 was 
identified as the first risk locus for FTLD. Three single nucleotide polymorphisms 
(SNPs) clustering in and around TMEM106B, a gene of unknown function, reached 
genome-wide significance. These variants increased the risk of developing FTLD-
TDP, especially in individuals with GRN mutations (GRN+/FTLD-TDP) (Van 
Deerlin et al., 2010). Most replication studies confirmed the association of 
TMEM106B SNPs with GRN+/FTLD-TDP risk (Cruchaga et al., 2011; Finch et al., 
2011; van der Zee et al., 2011). Homozygosity for the protective minor allele CC of 
the most statistically significant SNP rs1990622 - 7kb downstream of TMEM106B – 
was found in 2.6 % of patients and 19.1 % of controls (Finch et al., 2011). Some 
studies found even a correlation of the risk variants with disease age of onset or 
GRN plasma levels. The increased risk especially in GRN mutation carriers, 
changed GRN mRNA level and the additionally reported correlation between 
TMEM106B protein and GRN mRNA level strongly point to a functional 
relationship of both proteins (Cruchaga et al., 2011; Finch et al., 2011; Rollinson et 
al., 2011; van der Zee et al., 2011). The impact of the risk SNPs on TMEM106B 
mRNA or protein levels is still under debate. The original study showed elevated 
TMEM106B mRNA levels in risk SNP carriers whereas replications in other patient 
cohorts did not confirm this (Van Deerlin et al., 2010; van der Zee et al., 2011). 
Nicholson and colleagues reported that the protein level of the protective 
TMEM106B T185S variant is decreased compared to the wild-type (wt) protein. 
However, the SNP leading to the amino-acid exchange in the protein, although in 
perfect LD with rs1990622, is itself not statistically significant towards the risk of 
FTLD-TDP (Nicholson et al., 2013). Several recent studies suggest a role for 
TMEM106B not only in FTLD but also in broader field of neurodegeneration: 
Although TMEM106B risk variants are not genetically associated with ALS per se, 
they decrease the cognitive abilities in these patients (Vass et al., 2011). 
Furthermore, the protective allele of rs1990622 reduced the risk for TDP-43 
pathology and hippocampal sclerosis in AD patients (Rutherford et al., 2012). 
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Interestingly, the same polymorphism seems to influence – in interaction with 
apolipoprotein E (APOE) variant ε4 – the risk of late onset Alzheimer’s disease 
(LOAD) in a big Chinese population (Lu et al., 2013).  
1.3.2 Localization and function 
Busch et al. demonstrated that TMEM106B is expressed in neurons, glia and 
endothelial cells in cortex and parts of the hippocampus, but not in the dentate gyrus 
and the cerebellum of the human brain (Busch et al., 2013). Cell culture studies 
revealed that TMEM106B is an integral type 2 transmembrane protein which is 
highly N- but not O-glycosylated. Endoglycosidase-H-resistant complex 
glycosylation suggest transport of the protein beyond the early Golgi apparatus into 
the late secretory pathway. The glycosylation pattern influences targeting of the 
protein as mutations in the different glycosylation sites either led to retention in the 
ER or transport to the plasma membrane. Immunofluorescence (IF) studies in cell-
lines revealed that overexpressed as well as endogenous TMEM106B is located 
mainly in Lamp1-positive late-endosomes and lysosomes. Inhibiting lysosomal 
proteases by leupeptine or inhibiting the acidification of the lysosome by 
Bafilomycin A1 leads to an accumulation of TMEM106B, providing further proof of 
lysosomal targeting (Lang et al., 2012). Overexpression of TMEM106B is reported 
to increase lysosomal size and change lysosomal morphology. Additionally, 
lysosomal acidification and thus their degradative capacity are reduced (Brady et 
al., 2013; Chen-Plotkin et al., 2012). Interestingly, degradation of the wild type 
TMEM106B seems to be slower compared to protective T185S variant. The 
increased protein stability argues for elevated TMEM106B levels in risk SNP carrier 
since messenger RNA (mRNA) level remain similar. Nicholson and colleagues 
ascribe this effect to a different glycosylation pattern at the N-glycosylation site 
affected by the amino-acid exchange (Nicholson et al., 2013).  
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Figure 2: Domain structure and topology of TMEM106B 
Schematic representation of the domain structure and topology of the type-two transmembrane protein 
TMEM106B. TMD: transmembrane domain; N1-N5: confirmed N-glycosylation sites; Adapted from 
(Lang et al., 2012). 
 
Despite the genetic association, the effect of TMEM106B on GRN is not entirely 
clear. Although several studies reported an elevated GRN protein level or changes in 
GRN localization upon exogenous TMEM106B expression, this is possibly an 
unspecific effect attributed to lysosomal impairment as knockdown of TMEM106B 
does not influence GRN levels at all. Moreover, no differential effect of the 
TMEM106B T185S variant could be detected regarding these findings (Brady et al., 
2013; Chen-Plotkin et al., 2012; Lang et al., 2012; Nicholson et al., 2013).  
In FTLD-TDP patients with GRN mutations TMEM106B mRNA and protein levels 
are up-regulated and intracellular localization of the protein seems to be affected. 
The protein appears to be more disorganized and accumulated in the soma and the 
primary dendrites arguing for transport deficits of TMEM106B containing vesicles 
(Busch et al., 2013; Chen-Plotkin et al., 2012). 
 
Although the genetic association of TMEM106B to FTLD-TDP is undisputed and the 
intracellular localization of the protein is elucidated, only minor progress was made 
in unravelling the physiological function of the protein. Especially the role of the 
protein at the lysosome and the probable participation in cellular functions already 
implicated in the disease need further studies.  
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2. Lysosomes and lysosomal transport 
Lysosomes are an important part of the intracellular degradation system (Saftig and 
Klumperman, 2009). Deficits in this system are highly associated with 
neurodegenerative disease in general and FTLD in particular (Nixon, 2013; Pan and 
Chen, 2013). This association becomes especially apparent as TMEM106B a protein 
whose genetic variants influence the risk of many neurodegenerative diseases (Lu et 
al., 2013; van Blitterswijk et al., 2014; Van Deerlin et al., 2010) is demonstrated to 
localize to the lysosomal compartment (Lang et al., 2012). 
 
2.1 Function – degradative and non degradative 
The lysosome is the primary degradative compartment of the cell. More than 50 
different hydrolases degrade proteins, lipids, polysaccharides and nucleic acids. 
Extracellular substrates reach the lysosome through endocytosis, phagocytosis or 
pinocytosis, intracellular material through autophagy. Three types of autophagy are 
known: 1. Microautophagy, the direct engulfment of cytoplasm by the lysosome 
(Mijaljica et al., 2011); 2. Chaperone-mediated autophagy, the direct delivery of 
proteins by hsc70 and subsequent lysosomal degradation (Kaushik and Cuervo, 
2012); 3. Macroautophagy, the fusion of lysosomes with autophagosomes containing 
the material marked for degradation to autolysosomes (Ravikumar et al., 2010). 
Lysosomes control the ratio between biosynthesis and degradation thus overall cell 
metabolism, by regulating mammalian target of rapamycin complex 1 (mTORC1) 
(one of the key regulator of cell growth and autophagy (Laplante and Sabatini, 
2012)) activity and signaling (Sancak et al., 2010). However, lysosomes are 
implicated in other important cellular functions such as cholesterol homoeostasis, 
tissue remodeling, pathogen defense as well as cell death (reviewed in (Saftig and 
Klumperman, 2009)), Moreover, lysosomal exocytosis is a crucial step in plasma 
membrane repair (Rao et al., 2004; Reddy et al., 2001). Lysosomal exocytosis was 
long thought to be specific to secretory cells, that contain so called lysosome related 
organelles (LROs), but one and a half decades ago it was demonstrated that any cell 
can perform this task (Rodriguez et al., 1997). For example, the delivery of new 
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membranes to neurites in developing neurons relies on this process (Arantes and 
Andrews, 2006).  
 
2.2 Biogenesis 
Lysosomes are single membrane bounded vesicles with an acidic pH-optimum (pH: 
4.5-5) in which most biomolecules of the cell are degraded. The resident proteome 
of lysosomes consists of two major classes of proteins. The first category of 
lysosomal proteins is soluble hydrolases responsible for the degradation of specific 
substrates. Apart from their catabolic activity they play a role in antigen processing 
and initiation of apoptosis (Conus and Simon, 2008). The second group are integral 
lysosomal membrane proteins responsible for the acidification of the lysosomal 
lumen, protein import and export and membrane fusion and trafficking (Eskelinen et 
al., 2003).  
The biogenesis of lysosomes is a coordinated process arising from the endocytic and 
biosynthetic pathway. Newly synthesized lysosomal proteins are delivered directly 
through the trans-Golgi network (TGN) to the endocytic system and further to the 
lysosome. This direct pathway functions mainly through mannose-6-phosphate 
receptors (M6PR) trafficking (Kornfeld and Mellman, 1989). Proteins become 
tagged with Mannose-6-phosphate residues in the early Golgi, are recognized by 
M6PR in the TGN and are transported to endosomes. Other pathways involve 
indirect delivery through exocytosis at the plasma membrane and subsequent 
endocytosis and the targeting of lysosomal hydrolases by vacuolar protein sorting 
homolog receptor 10 (VPS10) family proteins such as sortilin (Canuel et al., 2009).  
The formation of the actual membrane vesicle is a continuous process. Early 
endosomes that bud from the TGN mature stepwise to late endosomes and lysosomes 
through a spatiotemporal sequence of intermediates. During the maturation a 
continuous exchange of cargo, membranes and regulating proteins occurs while the 
intraluminal pH value drops gradually from around 6 in early endosomes to 4.5 – 5 
in lysosomes (reviewed in (Saftig and Klumperman, 2009)). The lysosomal pH 
gradient is established and maintained mainly by v-Type H+ ATPases (Mindell, 
2012).  
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Figure 3: Secretory and endocytic pathway 
A cell with its secretory and endocytic transport pathways which build a complex network of vesicular 
trafficking and the localizations of selected Rab-GTPases. Secretory vesicles bud from the TGN and go 
directly to the plasma membrane to release their content into the extracellular space. Early endosomes 
receive their contents from endocytosis or from the TGN. During their life cycle, EE go through a 
continuous process of fusion events i.e. with clathrin-coated vesicles or other endosomal vesicles. The 
endosomes end up either as recycling endosomes and release their cargo again in the extracellular space or 
gradually develop an acidic environment and become late endosomes than lysosomes. Lysosomes in the 
end either fuse with the plasma membrane and release their contents in the extracellular space as well or 
fuse with autophagosomes to become autolysosomes one of the most important degradative compartments 
of the cell. Most transport and fusion events are mediated by distinct RAB-GTPases. 
 
TGN: Trans-Golgi-network; SV: secretory vesicle; EE: early endosome; CV: clathrin-coated vesicle; RE: 
recycling endosome; LE: late endosome; L: lysosome; EL: exocytosed lysosome; A: autophagosome; AL: 
autolysosome; Adapted from (Galvez et al., 2012; Lamb et al., 2013; Schwartz et al., 2007; Stenmark, 
2009). 
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2.3 Regulation 
Several classes of signaling molecules and regulatory proteins control endosomal or 
lysosomal fusion events and lysosomal maturation. Examples are the 
assembly/adaptor complexes adaptin 1-4 (AP1-4), which mediate vesicle formation, 
soluble N-ethylmaleimide-sensitive-factor attachment receptor (SNARE) proteins 
(e.g. Vesicle-associated membrane protein 7 (VAMP7) and synaptotagmin 7), which 
mediate vesicle fusion, and member RAS-oncogene family-GTPases (RAB-
GTPases), important regulators of vesicle transport (Ohya et al., 2009). Moreover, 
v-type ATPases are required for cargo transport into the lysosome in addition to 
their role to maintain the intravesicular pH (Reviewed in (Bagshaw et al., 2005)).  
Rab-GTPases are master regulators of membrane trafficking and vesicle fusion and 
fission events. Interestingly, Rab7 is the only lysosomal Rab-GTPase known so far. 
As for all other Rab-GTPases, GTP hydrolysis provides the biological energy for its 
downstream effects (Pfeffer, 1994). For lysosomal fusion, Rab7 acts in concert with 
the tethering homotypic fusion and protein sorting complex (HOPS) consisting of 
several VPS proteins (Zhu et al., 2009). In contrast, distribution and transport of 
lysosomes is controlled by the interaction of Rab7 with Rab-interacting lysosomal 
protein (RILP) and the dynein/dynactin complex (Jordens et al., 2001). The 
importance of tight lysosomal regulation becomes apparent through the functional or 
genetic link of Rab7 to a variety of neurological and non-neurological diseases (e.g. 
AD, Charcot-Marie-Tooth Type 2B (CMT2B) and cancer) (reviewed in (Zhang et 
al., 2009a)). Just recently, the main switch for the regulation of lysosomal processes 
was discovered: transcription factor EB (TFEB) promotes transcription of the 
coordinated lysosomal expression and regulation (CLEAR) network proteins which 
share a common target sequence in their promoter region. Almost all CLEAR 
network proteins are implicated in lysosomal biosynthesis, maintenance and 
function. By that TFEB provides a global transcriptional control of the coordinated 
synthesis and action of lysosomal proteins (Sardiello et al., 2009). Furthermore, 
TFEB promotes the transcription of proteins that are involved in the broader process 
of endosomal, autophagosomal and lysosomal function (Settembre et al., 2011). 
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Remarkably, both TMEM106B and GRN have one or more CLEAR target sequences 
in their predicted promoter regions (Sardiello et al., 2009). 
 
3. Microtubules and Microtubule-dependent transport 
Microtubules (MT) are important mediators of intracellular transport events and 
most organelles are transport along them through the cell. Already early in the 
research on neurodegeneration, malfunction of MT-dependent transport processes 
were implicated in the pathogenesis of various diseases (Breuer et al., 1987; 
Gajdusek, 1985; Praprotnik et al., 1996). In this thesis I could demonstrate that the 
FTLD-TDP risk factor TMEM106B affects the microtubule dependent transport in 
primary neurons. TMEM106B acts together with its novel interactor microtubule-
associated protein 6 (MAP6) as a molecular brake for lysosomes in dendrites. 
Lysosomes are already strongly implicated in the pathogenesis of FTLD and the 
misrouting of these organelles may further aggravate neurodegeneration in patients. 
  
3.1 Microtubules  
Microtubules form together with actin filaments and intermediate filaments the 
cytoskeleton of a cell. Fundamental cellular processes such as mitosis or organelle 
transport critically depend on microtubules. In neurons, microtubules act as rail 
tracks for directed intracellular transport into axons and dendrites. Moreover, they 
are regulators of neuronal polarization and differentiation and have a crucial role in 
spine remodeling and synaptic function (Jaworski et al., 2009). Microtubules are 
hollow fibers assembled from α- and ß-tubulin heterodimers. These dimers 
polymerize in a GTP consuming process end-to-end into long chains. Thirteen of 
these so called protofilaments form the actual microtubule, which can reach a length 
of up to 100 µm in axons. Microtubule nucleation starts from a γ-tubulin ring 
complex, the microtubule-organizing center (MTOC). Due to its heterodimeric 
composition, microtubules have distinct ends, a fast-growing plus-end, and a slow 
growing minus-end. Usually, elongation proceeds to the plus-end. However, this is a 
dynamic process - growth (rescue) and shrinkage (catastrophe) of microtubules are 
in a balanced ratio (Amos and Schlieper, 2005). The structure of microtubules is the 
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same in neuronal and non-neuronal cells. However, organization is different and 
much more complex in neurons, especially owed to their highly polarized shape and 
their complex function (Kapitein and Hoogenraad, 2011). The dynamics and 
organization of microtubules is tightly regulated by the expression of different 
tubulin isotypes, their post-translational modifications and microtubule-associated 
proteins (MAPs) (Amos and Schlieper, 2005). 
 
 
 
Figure 4: Microtubule assembly and dynamics 
Schematic representation of microtubule structure and dynamics. Microtubules are comprised of 13 
protofilaments that form a 24 nm wide hollow structure. They are polar structures due to the head to tail 
assembly of the ab-tubulin heterodimers. GTP bound tubulin dimers bind to the fast growing plus-end of 
microtubules and form the fiber (rescue). The last β-tubulin layer retains it GTP cap to maintain stability. 
All other layers hydrolyze the bound GTP during or directly after polymerization. As soon as the outer 
GTP cap is lost, microtubules depolymerize at the plus-end (catastrophe). Rescue and catastrophe are 
alternating and dynamic processes. Adapted from (Conde and Caceres, 2009) 
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Microtubules are located in the soma, the axon and dendrites and transiently in the 
actin rich spines (Hu et al., 2008). Axonal microtubules are uniformly orientated 
with all plus-ends to the tip, whereas dendritic microtubules have a mixed 
orientation but for the very distal part (Baas et al., 1988). However, this is not an 
irreversible process as neurons losing their axon can develop a new one out of an 
already existing dendrite, a process requiring major cytoskeletal reorganization 
(Bradke and Dotti, 2000). In mature neurons two distinct populations of 
microtubules exist: stable microtubules with a half live of several hours that are 
resistant to cold shock and depolymerizing drugs such as nocodazole and dynamic 
microtubules, prone to catastrophe with a half live of just minutes (Baas and Black, 
1990; Sahenk and Brady, 1987). Both populations differ in in the way tubulins are 
posttranslationally modified (Song et al., 2013) and in the abundance of cofactors 
such as MAP6 (Slaughter and Black, 2003). 
 
3.2 Microtubule dependent transport 
3.2.1 Motor and adaptor proteins 
Directed cargo transport is apart from maintenance of cell structure and shape one 
of the main function of microtubules. In mammalian cells three classes of transport 
proteins exist which carry organelles, proteins and RNAs in an ATP dependent 
manner along the microtubules: myosins, kinesins and cytoplasmic dyneins.  
Myosins are responsible for short range, actin-filament dependent transport. In 
neurons these transport events take place in dynamic structures as spines, 
presynaptic buttons and growth cones. There, myosins influence such important 
processes as remodeling of the actin cytoskeleton, synaptic plasticity or spine 
growth but also interact with MT-dependent events (Kneussel and Wagner, 2013). In 
contrast, kinesins and dyneins account for long-range microtubule-dependent 
transport.  
Kinesin superfamily proteins (KIFs) mainly promote microtubule plus-end-directed 
transport. In axons with their unipolar (plus-end out) microtubules, KIFs mediate 
anterograde trafficking of their respective cargos. All family members share a 
similar globular motor domain but have different class-specific cargo binding 
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domains (Akhmanova and Hammer, 2010). The different KIFs form homo- or 
heterodimers and in rare cases also monomeric KIFs exist (Hirokawa and Takemura, 
2005). 
Cytoplasmic dyneins exclusively promote microtubule minus-end-directed transport, 
and thereby mediate retrograde transport in axons. The multiprotein transport 
complex consists of heavy, intermediate, intermediate-light and light chains 
(Akhmanova and Hammer, 2010). All dynein family members have very similar 
isotypes however they interact with a variety of different adaptor proteins as 
dynactin, dynamitin, p150glued which are responsible for specific cargo recognition 
and interaction (Vallee et al., 2004). In dendrites, where microtubules are of mixed 
orientation, it is still unclear what transport complex conveys certain cargos in 
which direction. Although often the same motor proteins are used, distinct cargos 
have their specific adaptor proteins.  
Temporal and spatial control of cargo transport is a multifactorial process but the 
exact regulatory mechanisms are heavily debated: Microtubule stability, influenced 
by microtubule-associated proteins and posttranslational modification of tubulin, 
regulate motor protein activity (Westermann and Weber, 2003). Furthermore the 
availability of cargo and motor itself (Coy et al., 1999) and the cargo-motor 
interaction have an impact on microtubule-dependent transport: some motor proteins 
bind directly to their cargo e.g. membrane lipids or internalized receptors (Tai et al., 
1999), others can only bind via specific adaptor proteins such as scaffolding 
proteins (glutamate receptor-interacting protein (GRIP) for glutamate receptor 2 
(GluA2) (Setou et al., 2002) or RAB GTPases (RAB7/RILP for lysosomes (Jordens 
et al., 2001). Additional factors such as ion concentration affect transport locally, 
for example mitochondrial movement in axons is reduced upon Ca2+ influx (Chang 
et al., 2006) (or reviewed in (Akhmanova and Hammer, 2010; Schlager and 
Hoogenraad, 2009)).  
3.2.2 Bidirectional transport 
Bidirectional transport in neurites with frequent stopping and alternation between 
anterograde and retrograde transport is observed for almost all types of cargos. In 
axons with their unipolar microtubules, transport requires both, kinesins and 
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dyneins. In contrast, in dendrites bidirectional transport could also work with only 
one type of motor proteins due to the mixed polarity of microtubules. However, also 
in dendrites both protein families mediate bidirectional transport. Two possibilities 
have been proposed for these bidirectional transport events. On the one hand, the 
“tug-of-war”-model: kinesins and dyneins are simultaneously attached to the same 
cargo and pull in different directions. This leads to stalling of transport or saltatory 
movement in both directions where the stronger motor proteins determine the net 
direction (Muller et al., 2008; Soppina et al., 2009). On the other hand, the 
coordination-model also assumes both motors to be attached simultaneously to the 
cargo. However, one motor is shut off when the opposing motor is active. This 
theory is supported by the fact that either kinesin or dynein knockdown in cells 
leads to an impairment of both retrograde and anterograde transport (Jolly and 
Gelfand, 2011). Nevertheless, it is unclear at the moment which models or even both 
are physiological relevant. In conclusion, much evidence arose that bidirectional 
trafficking is a complex mechanism controlled by multiprotein complexes binding to 
adaptor proteins and the transported cargos (RAB GTPases, scaffolding proteins, 
kinases,…) (Franker and Hoogenraad, 2013). 
3.2.3 Neurite selective transport 
Selective sorting of cargo into axons and dendrites is important to maintain neuronal 
polarity. This is guaranteed by selective transport into or selective retention from 
the respective neurite depending on the cargo involved (Hirokawa and Takemura, 
2005). Motor and adaptor proteins determine the fate of the cargo as well: most 
kinesins steer to the axon, dyneins usually to the dendrites. The cytoskeletal 
organization in the axonal initial segment additionally serves as a control element 
(Kapitein et al., 2010; Song et al., 2009; van Spronsen et al., 2013). 
 
The complex and tight regulation of microtubule dependent transport is most 
important in highly polarized cells such as neurons where axons grow up to 1 m 
long. Especially since crucial processes as neuronal polarity, axonal guidance and 
outgrowth or synaptic plasticity are directly dependent on a highly efficient and 
dynamic transport system (Franker and Hoogenraad, 2013).  
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3.3 Microtubule associated proteins (MAPs) 
3.3.1 MAPs in general 
Microtubule-associated proteins directly interact with microtubules and regulate 
their dynamic and organization. They are grouped into microtubule dependent motor 
proteins, which were already discussed above, microtubule plus-end tracking 
proteins (+TIPs) and structural MAPs. +TIPs typically bind to the plus-end of 
growing microtubules and mediate interaction and binding of microtubules to other 
proteins or cellular structures (Akhmanova and Steinmetz, 2010). Structural MAPs 
assist microtubule nucleation, regulate growth and stability, and control the ratio 
between catastrophe and rescue. The most abundant structural MAPs in neurons are 
dendritic MAP2 and mainly axonal tau. Their activity and localization is regulated 
by post-translational modification e.g. phosphorylation by MAP/microtubule 
affinity-regulating kinases (MARKs). Both proteins are thought to maintain 
microtubule spacing. MAP2 is further implicated in dendritic remodeling and 
synaptic plasticity, whereas Tau is involved in axonal transport. 
Hyperphosphorylated Tau inclusions are the hallmark of a variety of so called 
tauopathies including Alzheimer´s disease and FTLD (Reviewed in (Hoogenraad and 
Bradke, 2009; Jordan and Wilson, 2004; Kapitein and Hoogenraad, 2011)). 
3.3.2 The microtubule-associated protein MAP6/STOP 
3.3.2.1 MAP6 structure 
MAP6/STOP (stable tubule-only polypeptide) is a microtubule-stabilizing protein 
located both in axons and dendrites of neurons. Similar to other microtubule-binding 
proteins like Tau and MAP2, several different splice variants of MAP6 exist. These 
are differentially expressed depending on cell type and in the case of neurons also 
on the developmental state of the cell. The most widely studied homologue of the 
protein is rat MAP6. In very young rodent neurons only isoform 2 (E-STOP (early 
STOP): NP_001041632.1) is expressed, later on the longer isoform 1 (N-STOP 
(neuronal STOP): NP_034967.2) becomes upregulated, too. In non-neuronal cells 
the shortest variant, isoform 3 (F-STOP (fibroblastic STOP): NP_001036820.2) is 
the major isoform (Denarier et al., 1998). Although all three isoforms mediate 
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microtubule stability to a similar extent, only the neuronal isoforms 1 and 2 seem to 
bind constitutively to the cytoskeleton under physiological conditions (Bosc et al., 
2003). The longest isoform consists of four distinct domains: The N-terminal 
domain, the central penta-repeat domain, a linker region and the C-terminal repeat 
domain with several 11 amino acid long imperfect repeats which is lacking in the 
shorter isoform 2 (Bosc et al., 1996). For human tissue, only two isoforms are 
annotated corresponding to mouse isoforms one and two. However, both isoforms 
have lost four of the five central repeats (Bosc et al., 2003). The microtubule 
stabilizing sites, thus probably also microtubule-binding sites are mainly located in 
the N-terminal and the central repeat domain. All these sites overlap with 
calmodulin-binding sites and upon interaction with Ca2+/calmodulin MAP6 loses its 
ability to mediate microtubule cold resistance (Bosc et al., 2001).  
 
 
Figure 5: Domain structure and isoforms of MAP6 
Schematic representation of the domain structure of rat (A) and human (B) isoforms of MAP6/STOP. 5R: 
penta-repeat domain; CTR: C-terminal repeat domain; R: single repeat in human orthologous; Adapted 
from (Bosc et al., 2001). 
 
3.3.2.2 MAP6 function 
The main functions of MAP6 are maintaining microtubule stability and their 
protection from cold induced depolymerization (Andrieux et al., 2002; Bosc et al., 
1996). However, MAP6 additionally interacts with the actin cytoskeleton e.g. at 
spines, dendritic branch points and the Golgi apparatus arguing for additional, 
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microtubule-independent functions of the protein. This interaction depends on post-
translational modifications as phosphorylation and palmitoylation and the overall 
protein level of MAP6 (Baratier et al., 2006; Gory-Faure et al., 2006). In line with 
these findings, recent studies implicate MAP6 in the control of cellular morphology 
and endocytosis (Arama et al., 2012; Morderer et al., 2012).  
MAP6/STOP knockout mice are used as a model for schizophrenia as the behavioral 
profile of these animals is reminiscent of this neurological disease. The transgenic 
mice have a lower synaptic vesicle density, thereby an impaired glutamate release 
resulting in decreased synaptic plasticity (Andrieux et al., 2002; Brenner et al., 
2007). Additionally, knockout animals show an imbalance in serotonergic and 
dopaminergic neurotransmission, leading to reduced anxiety but increased 
depressive behavior (Bouvrais-Veret et al., 2008; Fournet et al., 2010). 
Neuropathological examinations revealed enlarged ventricles in the knockout 
animals leading to a decrease in the size of the cortex, thalamus and striatum 
however not the hippocampus (Powell et al., 2007). Atypical antipsychotics seem to 
alleviate the cognitive deficits on the molecular as well as the behavioral level in 
MAP6 knockout mice (Delotterie et al., 2010). However, it is still not clear how loss 
of a microtubule-binding protein and reduced microtubule stability cause these 
neurological phenotypes. 
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II. Aim of the study 
Genetic variants in the so far uncharacterized gene TMEM106B increase the risk of 
developing FTLD-TDP especially in individuals harboring GRN mutations 
(Cruchaga et al., 2011; Finch et al., 2011; Van Deerlin et al., 2010). However, the 
exact mechanism behind and the physiological function of the encoded protein 
remained unknown.  
Based on these genetic findings, the aim of my thesis was to evaluate the 
physiological role of TMEM106B in primary neurons by knockdown studies.  
First, I aimed to confirm the lysosomal localization of TMEM106B previously 
described in cancer cells (Lang et al., 2012) also in primary neurons and to examine 
general neuronal viability and lysosomal function upon TMEM106B knockdown. 
Since neurite loss, intracellular transport deficits and changes in synaptic 
transmission are early signs of pathology in most neurodegenerative diseases 
(Luebke et al., 2010; Masliah et al., 2001; Millecamps and Julien, 2013), I focused 
on these incidents in the next steps of my work. Accordingly, the second aim of my 
thesis was the phenotypical characterization of TMEM106B knockdown neurons 
focusing on the morphological analysis of dendrites, axons and spines by confocal 
microscopy and the study of intracellular transport of lysosomes by live cell 
imaging. Moreover, to shed light on the cellular context of TMEM106Bs function 
and to interpret the identified neuronal phenotypes I purposed to find and validate 
novel TMEM106B-interacting proteins by LC-MS/MS analysis. Last, I intended to 
validate the interaction functionally, seeking shared phenotypes of TMEM106B and 
its interaction partners and rescuing them by simultaneous knockdown or 
coexpression. These experiments may help to integrate TMEM106B into cellular 
pathways already implicated in the pathogenesis of FTLD. 
Together, these insights might one day help to treat or even cure patients from this 
devastating disease. 
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III. Materials and Methods 
1. Materials 
1.1 Equipment 
1.1.1 General equipment 
equipment supplier 
analytical balance (0.0001 – 200 g) Mettler-Toledo 
autoclave Systec 
balance (0.01 – 2000 g) Mettler-Toledo 
fridge  Santo electronic 
freezer (-20°C) Liebherr 
freezer (-80°C) Heraeus 
glassware  VWR 
gloves (Latex) Semperit 
gloves (Nitrile) Meditrade 
Milli Q plus filtration system Merck Millipore 
Parafilm “M“ Pechiney Plastic Packaging 
pH meter Thermo Scientific 
pH indicator strips Merck Millipore 
pipette boy Integra 
pipettes Gilson, Raynon 
pipette tips (10 µl, 200 µl, 1000 µl) Sarstedt, VWR 
serological pipettes (2 ml, 5 ml, 10 ml, 
25 ml) 
Sarstedt 
thermomixer Eppendorf 
tubes (1.5 ml, 2 ml) Sarstedt 
tubes (15 ml, 50 ml) Sarstedt 
vortex Scientific Industries 
microsurgical instruments (Dumont 
forceps and scissors) 
FST 
Scanner Epson 
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1.1.2 Centrifuges 
equipment supplier 
5417R cooling centrifuge  Eppendorf 
Megafuge 40R Heraeus 
Megafuge 1.0 Heraeus 
Avanti J-20 XP centrifuge Beckmann Coulter 
Optima LE-80K ultracentrifuge Beckmann Coulter 
Optima MAX-XP ultracentrifuge Beckmann Coulter 
rotor (SW-41) Beckmann Coulter 
rotor (JA25.50) Beckmann Coulter 
rotor (TLA-55) Beckmann Coulter 
rotor (JA10) Beckmann Coulter 
rotor (TH-641) Sorvall 
centrifuge tubes (1.5 ml for TLA-55) Beckmann Coulter 
centrifuge tubes (30 ml for JA25.50) Nalgene 
centrifuge tubes Nalgene 
 
1.1.3 Molecular biology 
equipment  supplier 
electrophoresis Thermo Scientific 
incubator B. Braun Biotech International 
microwave Sharp 
Mastercycler Pro  Eppendorf 
PCR tubes, strips, 96 well plates Sarstedt 
CFX384 Real-Time System  Bio-Rad 
384 well plates Bio-Rad 
Power supply Bio-Rad 
ultraviolet (UV) Lamp Intas 
Nano Drop Implen 
heating cabinet Binder 
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1.1.4 Protein biochemistry 
equipment supplier 
Filter paper Schleicher & Schüll 
Heating block MR Hei-Tec Heidolph instrument 
Glass plates for electrophoresis gels Bio-Rad 
Immobilon-P membrane, PVDF, 0.45 µM Merck Millipore 
Electrophoresis gel casting system Bio-Rad 
Electrophoresis system (Mini-PROTEAN 
Tetra Cell) 
Bio-Rad 
Electrophoresis Transfer Cell (Mini-
PROTEAN Trans-Blot) 
Bio-Rad 
Foam Pads Bio-Rad 
dynabead magent Life technologies 
power supply Major Science 
shaker Edmund Bühler GMBH 
Developer CaWo 
X-ray films Fuji 
X-ray film chamber G. Kisker 
scanner Epson 
Automated Potter Multifix Record Johann Gg Bachhofer 
Digital Sonifier 250 Branson 
 
1.1.5 Cell culture 
equipment supplier 
Cell culture hood Heraeus 
rubber policemen Corning Incorporated 
Bunsen burner Heraeus 
cell culture dish (3.5 cm, 6 cm, 10 cm) Nunc 
cell culture plate (12 well, 96 well) Nunc 
CO2-incubator Thermo Scientific 
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oven Memmert 
glass bottom dish (dglass = 20 mm, 3.5 
cm) 
Mattek 
Hemocytometer Optik Labor 
N2-tank Messer Griesheim 
PES membrane filter (0.45 µm) VWR International 
water bath GFL 
 
1.1.6 Imaging 
equipment supplier 
Confocal laser scanning microscope (LSM 510, LSM 710) Carl Zeiss 
Spinning disc microscope (Cellobserver SD) Carl Zeiss 
Epifluorescence microscope (Axiovert.A2) Carl Zeiss 
Objective (LD LCI Plan Apochromat, 25x/0.8 Oil, W, Gly) – 
LSM710 
Carl Zeiss 
Objective (Plan Apochromat, 40x/1.3 Oil DICII) – LSM510 Carl Zeiss 
Objective (Plan Apochromat, 40x/1.4 Oil DICII) – LSM710 Carl Zeiss 
Objective (Plan Apochromat, 63x/1.4 Oil DICII) – LSM710 Carl Zeiss 
Objective (Plan Apochromat, 63x/1.4 Oil DIC) – 
Cellobserver SD 
Carl Zeiss 
Objective (Plan Neofluar 40x/1.3 oil Ph3) – Axiovert.A2 Carl Zeiss 
climate chamber Pecon 
light microscope (Wilovert S) Hund Wetzlar 
Powerwave XS plate reader BioTek 
 
1.1.7 Mass spectrometry 
equipment supplier 
Proxeon Easy nLCII liquid 
chromatograph 
Thermo Scientific 
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2.4 µm C18 beads Dr. Maisch GmbH 
TQ Velos Orbitrap mass spectrometer Thermo Scientific 
 
1.1.8 Kits 
Kit supplier 
Amaxa primary culture kit P3  Lonza 
Cell Proliferation Kit II (XTT) Roche applied science 
NOVEX Colloidal Blue Staining Kit Life Technologies 
NucleoBond Plasmid kit Machery Nagel 
NucleoBond Xtra Midi EF kit Machery Nagel 
NucleoSpin Gel and PCR cleaning kit Machery Nagel 
RNeasy Mini Kit  Qiagen 
TaqMan MicroRNA Reverse 
Transcription Kit 
Applied Biosystems 
SsoFast™ EvaGreen Supermix Bio-Rad 
 
1.2 Chemicals, enzymes and antibodies 
1.2.1 Molecular biology 
Name  company 
Agarose Ultrapure Life Technologies 
restriction enzymes NEB 
Ampiciline Boehringer Mannheim 
deoxyribonucleic acid (DNA) polymerase (Pfu) Agilent 
DNA polymerase (Pwo) Roche Applied Science 
DNA polymerase (Taq) Roche Applied Science 
DNA polymerase (Pfu II Ultra) Agilent 
tetracycline Sigma-Aldrich 
dNTPs Roche Applied Sciences 
DNA ladder Life Technologies 
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Ethidiumbromide ROTH 
T4-Ligase NEB 
calf intestine phosphatase (CIP) NEB 
 
1.2.2 Cell culture 
Name company 
DMEM glutamax-I Life Technologies 
Neurobasal Life Technologies 
Fetal calf serum (FCS) Life Technologies 
l-glutamine Sigma-Aldrich 
l-glutamate Sigma-Aldrich 
DNase Sigma-Aldrich 
poly-D-lysine (PDL) Sigma-Aldrich 
laminine Roche Applied Science 
trypsin-EDTA Life Technologies 
trypsin (2.5 %) Life Technologies 
Penicillin/Streptomycin Life Technologies 
Non-essential amino acids (NEAA) Life Technologies 
Lipofectamine2000 Life Technologies 
B27 Life Technologies 
Bovine serum albumin (BSA) Sigma-Aldrich 
Nocodazole Sigma-Aldrich 
OptiMEM Life Technologies 
 
1.2.3 Biochemistry 
Name Company 
proteinase inhibitor Sigma-Aldrich 
phosphatase inhibitor Sigma-Aldrich 
ammonium persulfate (APS) Roche 
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tetramethylethylendiamin (TEMED) USB 
Acrylamid (19:1 / 40 % (w/v)) Bio-Rad 
ß-mercaptoethanol Merck Millipore 
SeaBlue Prestained Protein Ladder Plus 2 Life Technologies 
myc-beads Sigma-Aldrich 
Protein G Dynabeads  Life Technologies 
Protein A sepharose beads GE Healthcare 
iodixanol Sigma-Aldrich 
lysozyme Merck Millipore 
Isopropyl-β-D-1-thiogalactopyranoside (IPTG) ROTH 
glutathion sepharose 4B GE Healthcare 
Maltose beads  
Bis-sulfosuccinimidyl suberate (BS3) Sigma-Aldrich 
enhanced chemiluminescence (ECL) Thermo Scientific 
ECL plus Thermo Scientific 
I-Block Tropix 
dithiothreitol (DTT) Sigma-Aldrich 
 
1.2.4 Microscopy 
Name Company 
vectahield H-1000 mounting medium Vectorlabs 
Immersol 518 F Carl Zeiss 
Microscope Cover glasses (18 mm, 20 
mm) 
VWR 
Microscope slides Superfrost plus  Thermo Scientific 
 
1.2.5 General chemicals 
Name Company 
acetonitrile Merck Millipore 
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acetic acid Merck Millipore 
Bromophenol blue Merck Millipore 
boric acid Merck Millipore 
dimethyl sufoxide (DMSO) Roth 
ethylenediaminetetraacetic acid (EDTA) USB 
Ethanol Sigma-Aldrich 
formic acid Millipore 
gelatin powder Sigma-Aldrich 
Glycerol USB 
Glycine Biomol 
Hepes Biomol 
Isopropanol Merck Millipore 
KCl USB 
KH2PO4 Merck Millipore 
β-mercaptoethanol ROTH 
methanol Merck Millipore 
Na2[B4O5(OH)4] Sigma-Aldrich 
NaCl Merck Millipore 
NH4HCO3 Merck Millipore 
Na2HPO4 Merck Millipore 
NaH2PO4 Sigma-Aldrich 
NaOH Merck Millipore 
NaN3 Merck Millipore 
paraformaldehyde (PFA) Sigma-Aldrich 
sodium dodecylsulfate (SDS) Roth 
sucrose Sigma-Aldrich 
Staurosporine Sigma-Aldrich 
Tris AppliChem 
TritonX100 Merck Millipore 
Tryptone BD Biosciences 
Yeast extract BD Biosciences 
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1.2.6 Antibodies 
Primary antibodies 
Antigen Supplier Species Clone Dilution 
β-actin Sigma-Aldrich mouse 
monoclonal 
AC-15 WB: 
1:5,000 
γ-adaptin BD Biosciences mouse 
monoclonal 
88/Adaptin 
γ 
WB: 1:500 
calnexin Enzo Life 
Sciences 
rabbit 
polyclonal 
 WB: 
1:10,000 
FUS Bethyl mouse 
monoclonal 
A300-292A WB: 1:500 
green fluorescent 
protein (GFP) 
Neuromab mouse 
monoclonal 
N86/38 IF: 1:500 
LAMP1 Enzo Life 
Sciences 
mouse 
monoclonal 
Ly1C6 IF: 1:50 
Map6 (rat amino acids 
793 – 952 according to 
NP_058900) 
Immunization at 
Eurogentec 
rabbit 
polyclonal 
 IF: 5 µg / 
ml, WB: 1 
µg / ml 
MAP6 Cell Signaling 
Technologies 
mouse 
monoclonal 
175 IF: 1:50, 
WB: 1:500 
MAP6 Abcam mouse 
monoclonal 
ab78077 IF: 1:50, 
WB 1:500 
Myc Santa-Cruz-
Biotechnology 
mouse 
monoclonal 
9E10 IF: 1:250, 
WB: 
1:1,000 
Na+/K+-ATPase Developmental 
Studies 
Hybridoma 
Bank 
mouse 
monoclonal 
a2F WB: 
1:1,000 
postsynaptic density 
protein 95 (PSD-95) 
Neuromab mouse 
monoclonal 
K28/43 WB: 
1:1,000 
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Rab7 Cell Signaling 
Technologies 
mouse 
monoclonal 
2094 WB: 1:500 
Synaptophysin Millipore mouse 
monoclonal 
SY38 WB: 
1:1,000 
synaptic vesicle 
glycoprotein 2 (SV2) 
Developmental 
Studies 
Hybridoma 
Bank 
mouse 
monoclonal 
SP2/0 WB: 
1:2,000 
Tau Dako rabbit 
polyclonal 
A 0024 WB: 
1:10,000 
Tau-1 Millipore mouse 
monoclonal 
PC1C6 IF: 1:500 
TDP-43 Cosmo Bio rabbit 
polyclonal 
405-414 WB: 
1:1,000 
translocase of outer 
membrane 20 (TOM20) 
Santa-Cruz-
Biotechnology 
rabbit 
polyclonal 
FL-145 WB: 1:500 
TMEM106B (rat amino 
acids 1-91) 
Immunization at 
Eurogentec 
rabbit 
polyclonal 
344 IF: 5 µg / 
ml 
TMEM106B (rat amino 
acids 1-91) 
Immunization at 
Eurogentec 
rabbit 
polyclonal 
345 WB: 1 µg / 
ml 
Transferrin receptor 
(TfR) 
Life Technology mouse 
monoclonal 
H68.4 WB: 1:500 
βIII-tubulin Sigma-Aldrich mouse 
monoclonal 
SDL.3D10 IF: 1:500, 
WB: 
1:10,000 
Cathepsin D Santa-Cruz-
Biotechnology 
mouse 
monoclonal 
C-20 WB: 
1:1000 
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Secondary antibodies 
Antigen Supplier Species Labeled Dilution 
mouse IgG 
(H+L) 
Life technologies goat Alexa488, 555 or 647 IF: 1:500 
rabbit IgG 
(H+L) 
Life technologies goat Alexa488, 555 or 647 IF: 1:500 
rat IgG (H+L) Life technologies goat Alexa488, 555 or 647 IF: 1:500 
mouse IgG 
(H+L) 
Promega goat horse radish 
peroxidase (HRP) 
WB: 1:5,000 
rabbit IgG 
(H+L) 
Promega goat HRP WB: 1:5,000 
rat IgG (H+L) Santa-Cruz-
Biotechnology 
goat HRP WB: 1:5,000 
 
1.3 DNA oligonucleotides and plasmids 
1.3.1 Primer for cloning 
primer sequence sense sequence antisense 
rat TMEM106B  GGATCCGCCACCATGGGAAAGT
CTCTTTCTCATTTACC 
CATGAATTCATTGTTGTGGCTG
AAGGACATTTAGATAC 
shRNA resistant rat 
TMEM106B* 
GGGCACTGTGTAGTCGATCTGC
TTTTCATATCAAGTGGGCCAAT
G 
GCAGATCGACTACACAGTGCCC
ACAGTTATTGCCGAGG 
 GCGGCCGCAACACTACGTACCA
GTTGGCCCAGTCTG 
GGTACGTAGTGTTGCGGCCGCA
GTCAACATACTGGTACCTCTCC 
rat MAP6 isoform 1 GTGAGATCTGCCACCATGGCGT
GGCCGTGCATCACTAGG 
TGTGTCGACCTCCATGGCATTT
CAAGGGAATCAAGG 
human dnRILP (c33AA 
201-401) 
TAAGTCGACCCCGGGCACCAGC
ACGGACAGGAG 
CATGAATTCTAAGTCAGGCCTCTG
GGGCGGCTGAG 
human RAB7a-GFP AAAGGCGCGCCTATGACCTCTA
GGAAGAAAGTGTTGCTGAAGG 
CGAGAATTCTTAGCAACTGCAG
CTTTCTGCCGAGG 
human RAB7a-GFP GATTCTGGAGTTGGTAAAGCTT
CACTCATGAACCAGTATG 
CATACTGGTTCATGAGTGAATT
CTTACCAACTCCAGAATC 
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(dominant negative T22N) 
human RAB7a-GFP 
(constitutive active Q67L) 
CTGGGACACAGCAGGCCTAGAA
CGGTTCCAGTCCCTTG 
CAAGGGACTGGAACCGTTCTAG
GCCTGCTGTGTCCCAG 
GFP-TMEM-NT primer CCGCTCGAGCTGGAAAGTCTCT
TTCTCATTTGCC 
CGCGGATCCTTATGTTCTTCTT
GGCCTTAATCTCTG 
human Map6 isoform 1  CTAGTCTAGAGCCACCATGGCG
TGGCCGTG 
TTCCGCGGCCGCTATGGCCGAC
GTCGACTCAAGGGGAGCTCTCA
ATGTATTC 
human MAP6 isoform 2 CTAGTCTAGAGCCACCATGGCG
TGGCCGTG 
TTCCGCGGCCGCTATGGCCGAC
GTCGACTCACTCTTTCGCCTCA
GCCAG 
 
1.3.2 Short hairpin RNA (shRNA) 
Primers for shRNA cloning (BglII/HindIII into pSuper or pSuperSub), 19mer target 
sequence is marked in bold, reverse complement of target sequence in italic  
target sequence sense sequence antisense 
rm-
shTMEM106B#1 
gatccccGCAGATTGATTATACGGTA
ttcaagagaTACCGTATAATCAATCT
GCtttttggaaa  
agcttttccaaaaaGCAGATTGATTA
TACGGTAtctcttgaaTACCGTATAA
TCAATCTGCggg 
rm-
shTMEM106B#2 
gatccccGTGGAAGGAACACGACTTA
ttcaagagaTAAGTCGTGTTCCTTCC
ACtttttggaaa 
agcttttccaaaaaGTGGAAGGAACA
CGACTTAtctcttgaaTAAGTCGTGT
TCCTTCCACggg 
r-shMAP6 gatccccGGTGCAGATCAGCGTGACA
ttcaagagaTGTCACGCTGATCTGCA
CCtttttggaaa 
agcttttccaaaaaGGTGCAGATCAG
CGTGACAtctcttgaaTGTCACGCTG
ATCTGCACCggg 
shLuc gatccccCGTACGCGGAATACTTCGA
ttcaagagaTCGAAGTATTCCGCGTA
CGtttttggaaa 
agcttttccaaaaaCGTACGCGGAAT
ACTTCGAtctcttgaaTCGAAGTATT
CCGCGTACGggg 
r-shMAP2 gatccccCGAGAGGAAAGACGAAGGA
ttcaagagaTCCTTCGTCTTTCCTCT
CGtttttggaaa 
agcttttccaaaaaCGAGAGGAAAGA
CGAAGGAtctcttgaaTCCTTCGTCT
TTCCTCTCGggg 
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1.3.3 qPCR primers 
target sequence sense sequence antisense 
rm-TMEM106B actggaagagatagtgtcacttgtccca agccaatccagacaggagcaggc 
rm-YWHAZ tgagcagaagacggaaggtgctg tctgatggggtgtgtcggctgc 
 
1.3.4 Plasmids 
ß-actin-EGFP (XX3 – empty vector) Dieter Edbauer 
FhSynRedW-mCherry Dieter Edbauer 
FhSynW-rTMEM106B* (resistant to 
shTMEM106B #1 and #2)  
EcoRI/ BamHI into AD149 
GW1.2b-myc-rMAP6  BglII/SalI into XX7  
FhSynW-myc-rMAP6 AscI/EcoRV from GW1.2b-myc-rMap6 
into AD538 FhsynW1-myc 
pSUPER-mr-shTMEM106B#1  oligos BglII/HindIII into pSUPER 
pLL3.7-hSyn-shTMEM106B#1-pTag-
RFP  
XbaI/XhoI from pSuper into AD425 
pSUPER-mr-shTMEM106B#2  oligos BglII/HindIII into pSUPER 
pLL3.7-hSyn-shTMEM106B#2-pTag-
RFP 
XbaI/XhoI from pSuper into AD425 
pSUPERsub-r-shMAP6  oligos BglII/HindIII into pSUPERsub 
pLL3.7-hSyn-shMAP6-pTag-RFP XbaI/XhoI from pSUPERsub into AD425 
pSUPER-shLuc oligos BglII/HindIII into pSUPER 
pSUPERsub-shLuc oligos BglII/HindIII into pSUPERsub 
pLL3.7-hSyn-shLuc-pTag-RFP XbaI/XhoI from pSUPER in AD425 
GFP-TMEM-NT XhoI/BamHI Into pEGFP-C1 by 
Christina Lang 
hMap6 isoform 1 XbaI/SalI in XX7 
hMap6 isoform 2 XbaI/SalI in XX7 
hRab7a-GFP AscI/EcoRI in XX7 
MAP6-GFP GFP from XX8 AflII/AscI into GW1.2b-
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myc-rMap6 
Mito-RFP: mitochondrial targeting 
sequence of cyclooxygenase 8 (COX8) 
fused to red fluorescent protein (RFP) 
Anna Pilsl 
dnRilp c33 SalI/EcoRI into XX7 
GW1.2b-CMV-myc (XX7 – empty 
vector) 
Dieter Edbauer 
GW1.2b-CMV-EGFP (XX8 – empty 
vector) 
Dieter Edbauer 
Rab7a pEGFP-C1 Capell lab 
dn hRab7a-GFP (T22N) AscI/EcoRI in XX7 
ca hRab7a-GFP (Q67L) AscI/EcoRI in XX7 
pEYFP-C1 Sabina Tahirovic 
Lamp1-RFP Capell lab 
FhSynW2-ΔZeo (AD149 – empty vector) Dieter Edbauer 
AD538 FhsynW1-myc (AD538 – empty 
vector) 
Dieter Edbauer 
pSUPER (empty vector – H1 promoter 
for expression of shRNAs) 
Dieter Edbauer 
pLL3.7-hSyn-pTag-RFP (AD425 – empty 
vector for lentiviral expression of 
shRNAs) 
Dieter Edbauer 
FhSynW-rTMEM106B  EcoRI, BamHI into AD149 
pSUPERsub (empty vector – H1 
promoter for expression of shRNAs) 
Dieter Edbauer 
pSPAX2 (Salmon and Trono, 2007) 
pVSVg (Kuhn et al., 2010) 
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1.4 Buffer 
If not stated otherwise, components of buffers are dissolved in MilliQ water. 
1.4.1 Buffer for antibody generation 
buffer composition 
homogenization buffer 0.32 M sucrose,  
4 mM Hepes,  
2 mM EDTA  
pH 7.4 
STE-buffer 10 mM Tris–HCl  
150 mM NaCl  
1 mM EDTA 
pH 8.0 
conjugation buffer 20 mM Na2HPO4 
0.15 M NaCl 
pH 8.0 
column buffer 0.2 M Tris-HCl  
0.5 M NaCl 
pH 8.0 
glycine elution buffer 0.1 M Glycine-HCl 
0.5 M NaCl 
pH 2.5 
neutralization buffer 1 M Tris 
pH 9.5 
 
1.4.2 Buffer for Molecular Biology: 
buffer composition 
lysogeny broth (LB) medium 1 % Tryptone 
0.5 % Yeast extract 
86 mM NaCl 
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LB agar 1.5 % agar in LB medium 
5x DNA loading buffer 50 % Glycerol 
50 mM Na2EDTA 
0.05 % Bromophenol blue  
pH 8.0 
Sodium borate buffer 5mM Na2[B4O5(OH)4] x 10 H2O 
pH 8.0 (adjusted with H3BO3) 
1.4.3. Buffer for cell culture 
buffer composition 
phosphate-buffered saline (PBS) 0.14 M NaCl 
10 mM Na2HPO4 
2.8 mM KH2PO4 
2.7 mM KCl 
pH 7.4 
Hepes buffer 0.3 M Hepes 
pH 7.3 
Hank´s buffered salt solution (HBSS) 0.14 M NaCl 
5.4 mM KCl 
0.25 mM Na2HPO4 
5.6 mM glucose 
0.44 mM KH2PO4 
1.3 mM CaCl2 
1.0 mM MgSO4 
4.2 mM NaHCO3 
borate buffer 40 mM boric acid 
10 mM sodium tetra borate 
pH 8.5 
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1.4.4 Buffer for protein biochemistry 
buffer composition 
4x Lämmli sample buffer 4% SDS,  
20% glycerol,  
5% β-mercaptoethanol,  
200 mM Na2HPO4 
pH 7.4 
RIPA buffer 50 mM TrisHCl  
150 mM NaCl  
2 mM EDTA  
1% NP-40  
0.1% SDS 
pH 7.4 
stacking gel buffer 0.5 M Tris 
0.4 % (w/v) SDS 
pH 6.8 
separating gel buffer 1.5 M Tris  
0.4 % (w/v) SDS 
pH 8.8 
running buffer 25 mM Tris 
0,2 M Glycine 
0.1 % SDS 
blotting buffer 25 mM Tris 
0,2 M Glycine 
TBSTx 20 mM Tris 
0.14 M NaCl 
0.2 % TritonX100 
pH 7.6 
Coomassie fixing solution 10 % acetic acid 
50 % methanol 
Coomassie staining solution 20 % stainer A (Colloidal Blue 
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Staining Kit) 
5 % stainer B (Colloidal Blue Staining 
Kit) 
20 % methanol 
 
1.4.5 Buffer for immunofluorescence 
buffer composition 
4 % PFA fixing solution 4 % PFA 
0.15 mM NaOH 
0.13 mM NaH2PO4 
0.12 mM sucrose 
pH 7.6 
2x GDB buffer 0.2 % Gelatine powder 
0.33 M Na2HPO4 
0.9 M NaCl 
0.6 % TritonX100 
pH 7.4 
HBSS/Hepes buffer 7 mM Hepes in HBSS 
 
1.4.6 Buffer for mass spectrometry 
buffer composition 
ammonium bicarbonate buffer 100 mM NH4HCO3 
Coomassie destaining solution 50 % ammonium bicarbonate buffer 
50 % acetonitrile 
tryptic digest solution 13 ng / µl trypsin 
10 mM NH4HCO3 
10 % acetonitrile 
extraction buffer 1.7 % formic acid 
67 % acetonitrile 
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1.5 Services 
Service Supplier 
DNA Sequencing GATC Biotech AG 
Antibody production Eurogentec SA 
Oligonucleotide synthesis Sigma-Aldrich 
 
1.6 Software and Online tools 
Software Supplier 
ImageJ / Fiji National Institutes of Health 
MS Office Microsoft 
GraphPad Prism GraphPad Software 
Adobe Photoshop CS5 Adobe 
Adobe Acrobat Professional Adobe 
MetaMorph Molecular Devices 
Carl Zeiss Axiovision Carl Zeiss 
CLC Main Workbench 6 CLC bio 
BioRad CFX manager  Bio-Rad 
NCBI databases 
(http://www.ncbi.nlm.nih.gov)  
National Institutes of Health 
ensembl (http://www.ensembl.org)  EMBL-EBI and Wellcome Trust 
Sanger Institute 
APE – A plasmid editor v1.17 Wayne Davis 
i-score designer (http://www.med.nagoya-
u.ac.jp/neurogenetics/i_Score/i_score.html) 
(Ichihara et al., 2007) 
 
Spidey web tool 
(http://www.ncbi.nlm.nih.gov/spidey/).  
National Institutes of Health 
Primer3 web tool 
(http://bioinfo.ut.ee/primer3/) 
(Untergasser et al., 2007) 
Proteome Discoverer 1.2  Thermo Scientific 
The International Protein Index database EMBL-EBI and Wellcome Trust 
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for rat (version 3.87) Sanger Institute 
 
1.7 Cell lines and bacteria strains 
 supplier 
DH5α chemically competent Escherichia coli (E. coli)  Life Technologies 
TOP10 Chemically competent E.coli Life Technologies 
HEK293-FT  Life Technologies 
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2. Methods 
2.1 Molecular Biology 
2.1.1 Molecular cloning 
Cloning strategy  
For cloning of complete complementary DNAs (cDNAs) or cDNA fragments, the 
region of interest was either excised with restriction enzymes from a plasmid based 
vector or PCR amplified from a cDNA library or a plasmid based vector. Restriction 
sites in the donor construct for subcloning or sites attached with primers to PCR 
products were chosen according to the available restriction sites in the acceptor 
plasmid. For cloning of shRNAs, oligonucleotides containing the desired sequence 
were ordered and hybridized as follows: 
Component amount 
Forward oligonucleotide 
(100µM) 
1 µl 
Reverse oligonucleotide 
(100µM) 
1 µl 
NEB buffer 4 2 µl 
MilliQ water Ad 20µl 
 
The mixture was incubated at 95°C for 4 min and let cool down slowly to RT. The 
acceptor plasmid was digested with the corresponding restriction enzymes but not 
dephosphorylated prior to ligation with the annealed oligonucleotides. 
shRNA design  
Oligonucleotides with a length of 25 nucleotides binding to ideally unique seed 
region on the target of interest were designed using the iScore designer 
(http://www.med.nagoyau.ac.jp/neurogenetics/i_Score/i_score.html) and the NCBI 
Blast web tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Usually, shRNAs were 
initially tested in HEK293-FT cells coexpressing an overexpression construct. 
Knockdown efficiency was tested on protein level using immunoblotting. All 
constructs were verified by DNA sequencing.  
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Polymerase chain reaction (PCR)  
For standard PCR reaction Pfu DNA polymerase was used and the PCR mix was set 
as follows: 
Component amount 
DNA template 100 ng 
Forward primer (20 µM) 1 µl 
Reverse primer (20 µM) 1 µl 
dNTPs (10 mM each) 1 µl 
10x Pfu buffer 5 µl 
Pfu DNA polymerase 1 µl 
MilliQ water ad 50 µl 
 
Standard protocol comprised 30 PCR cycles, annealing temperature 𝑇𝑎 = 𝑇𝑚(𝑝𝑝𝑝𝑚𝑝𝑝) −5°𝐶 and elongation time of 1 min per 1000 base pairs.  
 
Step Temperature 
[°C] 
Time # of 
cycles 
Initial 
denaturation 
95 2 min 1 
Denaturation 95 20 s  
30 Annealing 𝑇𝑚(𝑝𝑝𝑝𝑚𝑝𝑝) − 5 20 s 
Extension 72 1 min / 1kb 
Final Extension 72 8 min 1 
 
For special applications other polymerases (Taq, PWO, Pfu II Ultra) were used 
according to the manufacturer’s instructions. 
Restriction digest and dephosphorylation  
Plasmid based vectors (3 µg) were cut with the respective restriction enzymes 
typically at 37°C for 1 h. PCR products were cut typically at 37°C overnight. The 
amount of the restriction enzymes, conditions and buffer system was chosen 
according the manufacturer´s instruction or the NEB double digest finder 
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(https://www.neb.com/tools-and-resources/interactive-tools/double-digest-finder). 
The ends of plasmid backbones were dephosphorylated with calf intestine 
phosphatase (CIP) for 1 hour at 37°C after the restriction digest in order to prevent 
self-ligation. To purify the digested and dephosphorylated DNA, the plasmid was 
subjected to agarose gel electrophoresis, the respective bands excised, purified and 
eluted in 50µl MilliQ water (see chapter: Agarose-gelelectrophoresis).  
Ligation  
The digested, dephosphorylated vector backbone was incubated with the digested 
PCR product or vector fragment, Ligase buffer and Ligase added for at least 1 hour 
at room temperature. The ligation mix was set as follows: 
Component amount 
vector backbone 3 µl 
PCR product / plasmid 
fragment 
9 µl  
10x ligase buffer 2 µl 
ligase 2 µl 
MilliQ water ad 20 µl 
 
Transformation  
The complete ligation mixture was gently mixed with 100 µl freshly thawed 
chemical competent DH5α E. coli bacteria. Bacteria were incubated for 25 min on 
ice, heat shocked for 1 min at 42°C to facilitate uptake of the DNA and put back on 
ice for 1 min. Afterwards, 500 µl LB medium was added and the transformation mix 
incubated at 37°C under gentle shaking for 1 h. After incubation, the whole ligation 
mix was plated on LB plates containing selection antibiotics and incubated for 8 to 
12 h at 37°C. 
DNA preparation  
To prepare DNA from E.coli bacteria, single clones were picked with sterile pipette 
tips and added to 5 ml antibiotics containing LB medium (miniprep) or to 100 ml 
antibiotic containing LB medium (midiprep). The liquid culture was incubated under 
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gentle shacking at 37°C overnight. Afterwards, the culture was centrifuged with xx 
g for 5 min (miniprep) or 10 min (midiprep) at 4°C and the supernatant discarded. 
The bacteria pellet was resuspended and plasmid DNA was purified with the 
NucleoBond Plasmid kit (miniprep) or the NucleoBond Xtra Midi EF kit (midiprep) 
according to the manufacturer´s instructions. 
Control digestion 
To verify successful cloning purified plasmids were control digested. One or several 
restriction enzymes were chosen to ensure a distinct restriction pattern. The amount 
of the restriction enzymes, conditions and buffer system was chosen according the 
manufacturer´s instruction or the NEB double digest finder 
(https://www.neb.com/tools-and-resources/interactive-tools/double-digest-finder). 
Agarose-gelelectrophoresis  
To purify digested plasmid fragments or PCR products, to separate several DNA 
fragments from a single digestion mix or to visualize the restriction pattern after 
control digestion one dimensional electrophoresis was used. DNA was mixed with 
the respective amount of 5x DNA loading buffer and applied to agarose gels (0.7 % 
to 2 % agarose in SB buffer) containing 0.2 µg/ml ethidiumbromide. Electrophoresis 
was performed in sodium borate buffer at a constant voltage of 300 V. Gels were 
examined under UV light (xx nm).  
Sequencing  
To further verify successful cloning and check for small deletions, insertions or 
point mutations in the insert purified plasmids were sequenced at GATC Biotech AG 
(Konstanz). One or several primers which bound to or upstream of the region of 
interest were used to sequence each construct. 
2.1.2 Reverse transcription and quantitative PCR (RT-qPCR) 
RNA isolation 
RNA from primary neurons was isolated using the Qiagen RNAeasy kit following 
the manufacturer's instructions. For storage RNA was kept at -80°C. To avoid 
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interference of residual genomic DNA, a DNase digest step was performed during 
RNA extraction, according to manufacturer's instructions. 
Reverse transcription-PCR (RT-PCR) 
To generate complementary DNA (cDNA) isolated RNA was reversely transcribed 
with random hexamer primers (N6) using TaqMan MicroRNA Reverse Transcription 
Kit following the manufacturer’s instructions. For the cDNA standard curve, equal 
amounts of all RNA samples were pooled and the mixture was serially diluted in a 
1:10 ratio. The reaction mix was set as follows. For each reaction the RNA sample 
was diluted in 15µl nuclease-free H2O and combined with 30μL reaction mix. 
Component amount 
100 mM dNTPs 0.45 µl 
MultiScribe™ Reverse Transcriptase (50 
U/μL) 
3 µl  
RNase inhibitor 0.56 µl 
10X RT buffer 4.5 µl 
N6 primer (50 ng/μl) 4.5 µl 
diluted RNA 15 µl 
nuclease-free H2O ad 45 µl 
 
The standard program for the RT-PCR reaction was: 
time temperature 
30 min 16 °C 
30 min 42 °C  
5 min 85 °C 
hold 4 °C 
 
Quantitative PCR (qPCR) 
The qPCR reaction was performed using the SsoFast™ EvaGreen (BioRad) reaction 
mix according to the manufacturer’s instructions. cDNA was diluted in a ratio of 1:1 
in nuclease free H2O, was mixed with the reaction mix and gene specific primers 
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were added. Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, zeta (YWHAZ) was usually as housekeeping gene. The relative mRNA 
expression was calculated using the BioRad CFX manager software with the Δ- Δ -
Ct method. The reaction mix was set as follows: 
Component amount 
SsoFast™ EvaGreen 2.5 µl 
Forward primer (400 nM) 0.05µl 
Reverse primer (400 nM) 0.05 µl 
cDNA template 2 µl 
Nuclease free H2O ad 5µl 
 
The qPCR was performed in a CFX384 Real-Time System quantitative PCR 
(BioRad) with the following program: 
Step Temperature [°C] Time # of cycles 
Initial 
denaturation 
95 30 s 1 
Denaturation 95 5 s  
50 Annealing and 
extension 
60 5 s 
Extension 95 10 s 
Melt curve 65 - 95 5 s (increment 0.5 °C) 1 
 
Quantitative PCR primer design 
qPCR primers were design based on the genomic and mRNA sequences of the gene 
of interest provided by the NCBI database. A multiple alignment between sequences 
was generated using the Spidey web tool (http://www.ncbi.nlm.nih.gov/spidey/). To 
avoid detection of genomic DNA, intron spanning primers (intron size >1000 bp) 
were selected using the Primer3 web tool (http://bioinfo.ut.ee/primer3/). Primers 
were chosen for a product size of 200-300 bp and for PCR temperature of 60°C. 
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2.2 Cell biology  
2.2.1 HEK293 cells 
Cultivation of HEK293 cells 
Human embryonic kidney cells (HEK293FT) were cultivated in DMEM-Glutamax 
medium supplemented with 10% FCS, 1% Penicillin/streptomycin and 1% NEAA at 
37°C / 5 % CO2. At a confluency of 80-90% HEK293FT cells were split in a ratio of 
1:1 to 1:10. For that purpose the medium was removed, cells were washed once with 
PBS, 2ml 0.05% Trypsin/EDTA was added and cells were incubated for 1 min at 
37°C. Afterwards, 2 ml medium was added to stop trypsin activity, cells were 
carefully detached and centrifuged for 5 min at 1000 rpm. The cell pellet was 
resuspended in 10 ml medium and plated in the desired concentration in cell culture 
dishes.  
Transfection of HEK293 cells 
For transfection HEK293FT cells were split in a ratio of 1:1 on day one. On day 
two, 1,000,000 - 2,000,000 cells were plated in a 10 cm dish and transfected with 
Lipofectamin 2000 on day three following the manufacturer`s instruction:  
Component Amount 
Total DNA 10 µg 
in OptiMEM 1.5 ml 
After 5 min combine with: 
Lipofectamin 2000 30 µl 
in OptiMEM 1.5 ml 
 
The transfection mix incubated for 20 min at room temperature. Meanwhile, medium 
was removed from the cells and replaced by 5 ml prewarmed OptiMEM. After 
incubation, the transfection mix was added to the cells for 4 to 8 h before OptiMEM 
was replaced by normal culture medium. Cells were harvested and analyzed 36 to 48 
h later.  
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Lentivirus production  
For production of lentivirus, low passage HEK293FT cells were used as packaging 
cell line. Full confluency of HEK293-FT cells was avoided to increase virus titer. 
Three 10 cm dishes per virus with 5.5 million cells each were plated 24 hours prior 
to transfection with Lipofectamin 2000. Transfection mix was set as follows: 
Component Amount 
LTR vector 18.6 µg 
pSPAX2 11 µg 
pVSVg 6.4 µg 
Total DNA 36 µg 
in OptiMEM 4.5 ml 
After 5 min combine with: 
Lipofectamin 2000 108 µl 
in OptiMEM 4.5 ml 
 
LTR vector contains the lentiviral expression construct, pSPAX2 and pVSVg allow 
packaging of the virus particles. Transfection mix was incubated for 20 min at room 
temperature. In the meantime, media was exchanged with 5 ml OptiMEM 
supplemented with 10 % FCS per 10 cm dish. After incubation, 3 ml transfection 
mix was added drop-wise to each plate. After 24 h incubation, the medium was 
changed to DMEM Glutamax supplemented with 10 % FCS, 1 % penicillin 
/streptomycin, 1 % NEAA and 1.3 % BSA for another 24 hours and collected 
subsequently. The virus containing medium was centrifuged with 600 g for 10 min 
at room temperature (RT) and the resulting supernatant filtered through a sterile 
0.45 µm PES membrane filter. The filtrate was centrifuged with 66,000 g for 2 h at 
4°C, the supernatant discarded and the resulting virus containing pellet resuspended 
in 160 µl Neurobasal medium. Virus was stored in aliquots at -80°C until usage. 
2.2.2 Primary neuron culture 
Preparation of neurons  
Embryonic day 18 (E18) to E19 pregnant Sprague-Dawly rats were sacrificed with 
CO2 treatment and subsequent cervical dislocation. The abdomen of the mother was 
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opened, pubs were removed, decapitated and the heads placed in ice cold HBSS. The 
brain was detached from the skull, the meninges were removed and hippocampi and 
cortices prepared and washed four times with ice cold HBSS under a cell culture 
hood. Hippocampi were incubated for 15 min at 37°C with 150 µl 2.5 % trypsin in 5 
ml HBSS. Cortices were incubated for 20 min at 37°C with 300 µl 2.5 % trypsin and 
500 µl DNAse (2,000 U/mg) in 5 ml HBSS. Afterwards, hippocampi and cortices 
were washed four times with prewarmed HBSS and neurons dissociated by gently 
pipetting up and down several times. The concentration of neurons was determined 
in a hemocytometer and 85,000 hippocampal neurons respectively 400,000 cortical 
neurons in 1 ml medium for 12 well plates, 14,000 hippocampal neurons in 100 µl 
medium for 96 well plates or 50,000 hippocampal neurons in 3 ml medium for 3.5 
cm glass bottom dishes were plated. Following electroporation 500,000 hippocampal 
neurons for a 6 cm dish were plated on astrocyte feeder cells in N2 medium.  
Preperation of coverslips  
18 mm coverslips were treated with 65 % nitric acid for 2 days to remove lipids and 
washed four times with milliQ-water afterwards. For subsequent sterilization, 
coverslips were incubated at least 6 h at more than 200°C in a heating cabinet. 
Preparation of cell culture dishes  
Plastic dishes were coated with 1.5% PDL in 0.1 M borate buffer glass bottom 
dishes and dishes with cover slips with 1.5% PDL and 0.625% laminin in 0.1 M 
borate buffer for at least 4 h. After coating, dished were washed four times with 
sterile MilliQ water and equilibrated with neurobasal medium in the cell culture 
incubator until plating the neurons.  
Cultivation of primary neurons 
Primary rat neurons were cultivated with Neurobasal medium supplemented with 2 
% B27, 1% Penicillin/streptomycin, 0.25 % glutamine (cortical neurons) 
respectively Neurobasal medium supplemented with 2 % B27, 1% 
Penicillin/streptomycin, 0.25 % glutamine, 0.125% glutamate (hippocampal 
neurons) at 37°C / 5 % CO2. After seven days in culture or one day prior to 
transfection neurons were fed: 300 µl medium was exchanges with 500 µl fresh 
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medium per well for 12 well plates or 100 µl fresh medium was added per well for 
96 well plates. 
Transfection of primary neurons 
Neurons were transfected with Lipofectamin 2000. Transfection mix was set as 
follows and incubated for 20 min:  
Component Amount 
Total DNA 1.8 µg 
in OptiMEM 100 µl 
After 5 min combine with: 
Lipofectamin 2000 3.2 µl 
in OptiMEM 100 µl 
 
In the meantime, coverslips with neurons were dipped once in prewarmed 
Neurobasal medium and transferred to a new well with 1 ml prewarmed Neurobasal 
medium supplemented with 1 % Penicillin/streptomycin and 0.25% glutamine. After 
incubation, 200 µl transfection mix was added drop-wise to the coverslips. After 45 
min, coverslips were dipped twice in prewarmed Neurobasal medium and transferred 
back into the original medium. Neurons were analyzed three or five days after 
transfection. 
Transduction of primary neurons 
For neurons grown in 12 well plates, 500 µl medium was withdrawn and stored in 
the cell culture incubator to avoid pH value changes. The desired amount of virus 
was added to the neurons and incubated for 6 to 8 h. Thereafter, medium was 
discarded and replaced by the previously withdrawn medium. 500 µl of freshly 
prepared Neurobasal medium supplemented with 2 % B27, 1% 
Penicillin/streptomycin, 0.25 % glutamine was added to each well. Neurons were 
analyzed five or six days after transduction. For rescue experiments with 
TMEM106B virus, transduction was performed one day prior to transfection. 
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Electroporation of primary neurons 
Neurons were electroporated with the Amaxa 4D-Nucleofector and the primary 
culture kit P3 according to the manufacturer`s instructions prior to plating. Briefly, 
500,000 neurons were centrifuged for 5 min with 80 g at room temperature. 
Supernatant was removed and replaced by 100 µl Amaxa Rat Neuron Nucleofector 
Solution, up to 5 µg DNA was added and neurons were resuspended. After transfer 
to the cuvette, neurons were electroporated with the program EM110, resuspended 
in 500 µl prewarmed N2 medium and plated. 
Nocodazole treatment  
Neurons were treated every 36 h with 10 nM freshly thawed nocodazole (stock 
solution: 10µM in DMSO) or the same volume of DMSO as control. 
2.2.3 Cell viability Assay 
XTT-assay  
For the 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
(XTT)-assay, hippocampal neurons were cultivated in a 96 well plate. The assay was 
performed according to the manufacturer´s instructions: freshly thawed XTT 
labeling reagent and Electron-coupling reagent were mixed in the ratio of 50:1. 50 
µl of the mix was added per well and the plate incubated for 18 to 24 h in the cell 
culture incubator. Absorbance was measured in a plate reader at a wavelength of 480 
nm and a reference wavelength at 650 nm. Relative cell viability was calculated by 
subtraction of A650nm from A480nm Untreated or control treated neurons were set as 
100 % viable, while staurosporine treatment (1 µM for 4 h) was used as positive 
control. 
 
2.3 Protein biochemistry 
2.3.1 Generation and affinity purification of rabbit polyclonal antibodies 
Antigen purification for immunization  
For affinity purification with the corresponding maltose-binding-protein (MBP)-
fusion protein, 800 ml LB liquid culture of E.coli bacteria transformed with MBP 
tagged antigen coding vectors was expanded and induced with 1 mM IPTG 30°C 
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when bacteria suspension reached an OD600 = 0.6. After centrifugation with 600 g 
for 10 min at 4°C the resulting pellet was resuspended in STE buffer. 100 µg / ml 
lysozyme was added and incubated for 15 min on ice to disrupt the cells and extract 
the antigen. Afterwards, 5 mM DTT and was added and the lysate sonicated for 1 
min. After centrifugation with 10,000 g for 10 min at 4°C the supernatant was 
incubated with 4 ml maltose beads under vigorous shacking for 30 min. Afterwards 
beads were washed three times with in STE buffer. Antigen was eluted using. The 
antigen was eluted with glycine elution buffer and collected in 1 ml fractions. 
Fractions were neutralized with 100 µl 1M Tris pH 9.5. Protein concentration was 
measured using OD280. Samples from all steps of the purification protocol were 
taken to check purity of the antigen by SDS-PAGE and subsequent commassie 
staining (see sections 2.4.2 and 2.4.4). Protease and phosphatase inhibitor were 
present in all steps of the purification.  
Antibody production  
Polyclonal antibodies were generated by immunizing rabbits with MBP-tagged 
antigens at Eurogentec SA, Belgium. The serum of several large bleeds and the final 
bleed were collected and stored at -20°C until affinity purification of the antibodies 
 
Antibody antigen for immunization 
polyclonal TMEM106B antibodies 344 
and 345 
MBP fused withrat TMEM106B AA1-91: 
MGKSLSHLPLHSNKEDGYDGVTSTDNMR
NGLVSSEVRNEDGRSGDVSQFPYVEFTG
RDSVTCPTCQGTGRIPRGQENQLVALIP
YSDQRLR 
for polyclonal MAP6 antibody MBP fused with rat MAP6 AA793-952: 
NASIMASLKNEAPVASESVKNQGLGGPE
PAKDTGTDLKGHGSVFVAPVKSQGPVVP
EPTKGQDPIIPALAKDQGPILPEPPKNQ
GPPVVLGPIKNQDPVIPVPLKGQDPVVP
APTKDPGPTAPDPLKSQGPRGPQLPTVS
PSPPVMIPTVPHAEYIEGSP* 
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Antigen generation and crosslinking for affinity purification  
For affinity purification of the antibodies glutathione-S-transferase (GST)-fusion 
proteins with the corresponding antigen were generated. 800 ml LB liquid culture of 
E.coli bacteria transformed with GST tagged antigen coding vectors was expanded 
and induced with 1 mM IPTG 30°C when bacteria suspension reached an OD600 = 
0.6. After centrifugation with 600 g for 10 min at 4°C the resulting pellet was 
resuspended in STE buffer. 100 µg / ml lysozyme was added and incubated for 15 
min on ice to disrupt the cells and extract the antigen. Afterwards, 5 mM DTT and 1 
% TritonX100 was added and the lysate sonicated for 1 min. After centrifugation 
with 10,000 g for 10 min at 4°C the supernatant was incubated with 4 ml glutathione 
beads under vigorous shacking for 30 min. Afterwards beads were washed three 
times with 0.5 % TritonX100 in STE buffer. Washed beads were poured into a 
column, washed another four times with conjugation buffer and crosslinked to the 
antigen with 5 mM BS3. Protease and phosphatase inhibitor were present in all steps 
of the purification.  
Antibody purification  
For affinity purification, serum from immunized rabbits was diluted 1:1 with PBS 
and passed three times over the column described above. Beads were washed three 
times with column buffer. The antibody was eluted with glycine elution buffer and 
collected in 1 ml fractions. Fractions were neutralized with 100 µl 1M Tris pH 9.5. 
Protein concentration was measured using OD280. Samples from all steps of the 
purification protocol were taken to check purity of the antibody by western blotting. 
2.3.2 Immunoblotting 
Lysate preparation 
Neurons in 12 well plates were washed with PBS, directly lysed in 250 µl 2x 
Lämmli sample buffer and boiled for 10 min at 96°C. HEK293FT cells were scraped 
in PBS, centrifuged with 5000 rpm for 5 min at 4°C. The cell pellet was lysed in 
RIPA buffer or 1% TritonX100 in PBS for 15 min at 4°C. The lysate was 
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centrifuged with 17,000 g for 20 min at 4°C, the supernatant subsequently diluted 
with 2x Lämmli sample buffer in a ratio of 1:1 and boiled at 96°C for 10 min. 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE)  
Proteins in the cell lysate were separated under denaturizing conditions using a 
discontinuous SDS polyacrylamide gel electrophoresis system. Acrylamide 
concentration was 4% for the stacking gel and 7.5 to 12.5 % for the separating gel 
depending on the hydrodynamic radius of the denatured proteins. Gels were cast as 
described below (mixture for 4 10 % gels): 
Stacking gel 6.5 ml H2O  
2.5 ml stacking gel buffer 
1 ml acrylamide 
added for polymerization: 
100 µl 10% APS 
10 µl TEMED 
Seperating gel 10 ml H2O  
5 ml separating gel buffer  
5 ml acrylamide  
added for polymerization: 
200 µl 10% APS 
20 µl TEMED 
 
Between 10 µl and 15 µl total protein lysate was used per lane. Electrophoresis was 
carried out in running buffer with a voltage of 90 V for the first 15 min and 120 to 
180 V until the dye front reached the end of the gel. 
Immunoblotting (IB) 
For immunodetection, proteins separated by SDS-PAGE were blotted onto 
previously ethanol activated polyvinylidene difluoride (PVDF) membranes. Protein 
transfer was performed in methanol free blotting buffer at a constant current of 400 
mA per blotting chamber for 75 min.  
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Immunodetection of proteins  
PVDF membranes were blocked in 0.8 % I-Block in TBSTx for at least 1 h and 
incubated with primary antibodies in 0.8 % I-Block in TBSTx overnight at 4°C. 
After five washing steps with TBSTx for ten min each, a HRP coupled secondary 
antibody in 0.8 % I-Block in TBSTx, appropriate for the species of the primary 
antibody used, was incubated for 1 h at room temperature. Membranes were washed 
another five times with TBSTx and incubated with 2 ml of the chemiluminescence 
substrates ECL or ECLplus depending on the expected intensity of the emitted 
signal. For detection of the signal, X-ray films were exposed to the membrane in 
complete darkness and developed using a CaWo X-ray film processor. Signals on 
the films were quantified densitometrically using ImageJ software. 
2.3.3 Immunoprecipitation (IP) 
Immunoprecipitation from rat brain 
Three P15 Sprague-Dawley rat brains were extracted and immediately snap frozen. 
The frozen brains were homogenized with an automated potter cell homogenizer in 
20 ml homogenization buffer and centrifuged with 1,000 g for 10 min in a JA25.50 
rotor at 4°C. The supernatant S1 was further centrifuged with 75,465 g for 30 min at 
4°C, the resulting pellet P2 (membrane fraction) resuspended in 15 ml PBS and after 
addition of 1 % Triton X100 lysed for 15 min on ice. The lysate was centrifuged 
with 100,000 g for 20 min rotor at 4°C in a TLA55. The supernatant was 
immunoprecipitated with 10 µg of the respective antibodies crosslinked with BS3 to 
50 µl protein G dynabeads for 1.5 h at room temperature. Input was taken right 
before the immunoprecipitation. Beads were washed five times for 5 min each with 
lysis buffer at 4°C. Protein was eluted for 5 min with 30 µl glycine elution buffer at 
room temperature, diluted in a ratio of 1:1 with 4x Lämmli sample buffer and boiled 
for 10 min at 96°C. Samples were subjected to SDS-PAGE and either western 
blotting or colloidal Coomassie staining and subsequent mass spectrometric 
analysis. Protease and phophatase inhibitors were present in all steps of the 
immunoprecipitation. 
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Immunoprecipitation from HEK293FT cells  
HEK293FT cells were washed and scraped in PBS, centrifuged with 5000 rpm for 5 
min at 4°C and lysed in 1% Triton X100 in PBS for 15 min at 4°C. The lysate was 
centrifuged with 17,000 g for 40 min at 4°C, the resulting supernatant subsequently 
diluted with PBS to a concentration of 0.5 % TritonX100 and precleared with 
protein A sepharose beads for 30 min at 4°C under light agitation. The cleared 
lysate was subjected to immunoprecipitation with 30 µl myc-agarose beads for 1 h at 
4°C. Input samples were taken directly before beginning the immunoprecipitation. 
Beads were washed five times for 5 min each with 0.5 % Triton X100 in PBS at 4°C 
and boiled in 2x Lämmli sample buffer for 10 min at 96°C to elute the proteins. 
Samples were subjected to SDS-PAGE and western blotting. Protease and 
Phophatase inhibitors were present in all steps of the immunoprecipitation.  
2.3.4 Other protein biochemistry techniques 
Colloidal Coomassie  
For detection of total proteins, SDS polyacrylamide gels were stained with the 
NOVEX Colloidal Blue Staining Kit according to the manufacturer´s instruction. 
Gels were lightly agitated in fixing solution for at least 2 h, incubated with staining 
solution for 3 h and washed several times with MilliQ water until protein bands 
appeared. 
Subcellular fractionation  
The brain of an adult female Sprague-Dawley rat was extracted and immediately 
snap frozen. The frozen brain was homogenized with a manual potter cell 
homogenizer in 20 ml homogenization buffer and centrifuged with 1,500 g for 10 
min at 4°C. The postnuclear supernatant was further centrifuged in a TH641 rotor 
with 100,000 g for 30 min at 4°C and the pellet (membrane fraction) was 
resuspended in homogenization buffer. A 10 % volume fraction was loaded on 15 ml 
of a discontinuous iodixanol gradient (2.5 %, 5 %, 7,5 %, 10 %, 12.5 %, 15 %, 17.5 
%, 20 %, 30 % in homogenization buffer). The gradient was centrifuged at 274,044 
g for 2.5 h at 4°C in a TH-641 rotor. Fractions (1 ml each) were collected manually 
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by puncturing the bottom of the centrifugation tube with a needle and further 
processed for SDS-PAGE and western blotting as described above. 
 
2.4 Imaging techniques 
2.4.1 Immunofluorescence 
Fixation 
Hippocampal neurons grown on coverslips were washed with PBS and fixed with 4% 
PFA fixing solution for 15 min at RT. 
Immunostaining  
Fixed neurons were washed three times for at least 5 min each with PBS. Neurons 
were incubated with the respective primary antibody in 1x GDB buffer overnight at 
4°C. After additional three washing steps with PBS, neurons were incubated with 
the appropriate Alexa-488, Alexa-555 or Alexa-647 coupled secondary antibody in 
1x GDB buffer for 1 h at RT and washed another three times with PBS. If necessary, 
nuclei were stained with 1:1000 TO-PRO 3 in PBS for 10 min at room temperature 
directly before mounting the immunostained coverslips. All incubation steps were 
conducted in a light-protected, humidified incubation chamber. 
Mounting 
Directly after staining, coverslips were dipped in MilliQ water and mounted on 
microscope slides with Vectashield mounting medium. Excess mounting medium 
was aspirated and coverslips were sealed with clear nail polish.  
Image acquisition  
Confocal images were taken on a confocal laser scanning Carl Zeiss LSM510 or 
LSM710 system. 40x or 63x oil immersion objectives (NA=1.3/1.4) were used. 
Pinhole was set to 1 Airy unit for the longest wavelength used and maintained for 
all other wavelengths. For filter sets, excitation and emission wavelengths precast 
parameters for the respective Alexa dyes were used. Laser intensity and detector 
gain was chosen that all pixels were in linear range and not oversaturated. Distance 
between two adjacent confocal planes of a z stack was set that every pixel was 
covered by two confocal planes to get an optimal resolution in z direction. The x-y-
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Resolution of confocal images was set to at least 1024 x 1024 pixels. Scanning 
speed was chosen according to the purpose of the experiment. For quantitative and 
semi quantitative measurements all settings were maintained for every image of the 
respective experiment.  
For analysis of axonal length, images were taken on a Carl Zeiss Axio imager.A2 
epifluorescence microscope with a 40x oil immersion objective (NA=1.3). 
2.4.2 Live imaging 
Movie acquisition 
For Time-lapse microscopy a Carl Zeiss Cell observer SD spinning disc system was 
used. Images were taken with a 63x oil immersion objective (NA=1.4) on an air 
cooled Evolve 512 electron-multiplying charged-coupled device (EMCCD) camera 
with a frame rate of 1 Hz for 5 min. For filter sets, excitation and emission 
wavelengths precast parameters for the respective fluorescent proteins were used. 
Velocity of the spinning disc was 5000 rpm. Laser intensity and gain was set that all 
pixels in the region of interest were in linear range and not oversaturated. The x-y 
resolution of the images was set to 512 x 512 pixels due to camera limitations. For 
live imaging Neurons were grown in 3.5 cm glass bottom dishes and imaged either 
in their normal culture medium or in prewarmed and equilibrated HBSS/Hepes 
buffer. During image acquisition neurons were kept at 37°C/5 % CO2 in a climate 
chamber. 
2.4.3 Image analysis 
Image processing  
Confocal images were processed with ImageJ software. Z-stacks and color channels 
were separated and if required a maximum intensity projection from a z-stack or a 
merged image from different color channels generated. 
Quantitative analysis of colocalization 
Colocalization of pixels in different channels of the same confocal plane of an 
image was analyzed using the JaCoP plugin of ImageJ software (Bolte and 
Cordelieres, 2006). As quantitative parameter for the correlation of two channels 
Pearson´s coefficient Rr was used: 
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𝑅𝑝 =  ∑(𝑅𝑝 − 𝑅�) ∗ (𝐺𝑝 − ?̅?)
�∑(𝑅𝑝 − 𝑅�)2 ∗ ∑(𝐺𝑝 − ?̅?)2 
For every pixel i in the images, R and G are intensities of the red and green channel 
respectively. At which 𝑅𝑝 = 1 denotes perfect colocalization, 𝑅𝑝 = 0 denotes random 
localization and 𝑅𝑝 = −1 denotes perfect exclusion. 
Morphological analysis  
For the analysis of axonal length, the longest tau1 positive neurite of a developing 
neuron kept 4 days in vitro (DIV4) was chosen. Its length was measured using the 
Carl Zeiss Axio Vision software. For the analysis of the length of the longest 
dendrite mature neurons (DIV19) were analyzed. The longest dendrites were 
identified morphologically and measured using ImageJ software.  
Sholl analysis (Sholl, 1953) was used to assess the complexity of the total dendritc 
arbor of a growing (DIV12) or mature (DIV19) neuron. To that end, a mask with 
nine concentric circles in distances between 12.5 µm and 112.5 µm (12.5 µm 
intervals) was laid around the center of the cell soma in MetaMorph software. For 
each circle the number of dendrite crossings was counted and plotted against the 
respective distance to the soma.  
Spine length, width and density (spine number per 100 µm) was measured using 
MetaMorph software. Two dendrite segments per neuron (DIV19) with preferably no 
axonal crossings and a total length of at least 150 µm were chosen. Maximal length 
and width and the total number of every structure below 10 µm on these segments 
were determined with the software.  
All analysis were done manually and blinded to the experimental conditions 
2.4.4 Movie analysis  
Generation of kymographs  
5 min time laps movies from single neurons were used to analyze organelle 
movement with ImageJ software. Kymographs were generated along a line (width: 3 
pixels) from dendrite tip to soma in at least four dendritic segments per neuron. The 
Kymograph-plugin (http://www.embl.de/eamnet/html/body_kymograph.html) was 
used to generate the kymographs. 
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Analysis of organelle dynamics  
The dynamics of organelle movement was manually analyzed in kymographs. The 
numbers of stationary (horizontal lines in the kymograph), moving (sloped lines in 
the kymograph) and the total number of organelles were determined. The direction 
of moving organelles was assigned and classified as retrograde movement (net 
movement to the soma), anterograde movement (net movement to the dendrite tip) or 
no net movement. Speed (𝑣 = 𝑙𝑟𝑟𝑟
𝑡𝑟𝑟𝑟
) and run length 𝑙𝑝𝑟𝑟 of all movement events longer 
than 5 µm was determined as shown below and mean values calculated.  
 
Co-migration assay  
For co-migration assays of two fluorescently labeled proteins time laps movies with 
two different wavelengths were acquired. Kymographs were generated as explained 
above for each wavelength individually and merged images generated. 
 
2.5 Mass spectrometry (in collaboration with Sebastian Hogl) 
Sample preparation  
Bands cut from colloidal Coomassie stained SDS-polyacrylamide gels were excised 
and tryptic in-gel digestion of the proteins was performed (Shevchenko et al., 2006). 
Gel fragments were destained with 100 µl 100 mM ammonium 
bicarbonate/acetonitrile (1:1, v/v) for 30 min and subsequent addition of 500 µl 
acetonitrile. After withdrawal of the destaining solution at least 50 µl trypsin buffer 
were added and incubated for 2 h on ice to saturate the gel pieces. To cover the gel 
piece up to 20 µl ammonium bicarbonate buffer was added and the whole mixture 
was incubated at 37°C overnight for the tryptic digest. To extract the digested 
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proteins 100 µl extraction buffer was added, incubated for 15 min at 37°C under 
light agitation. The supernatant was withdrawn and analyzed. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)  
The trypsin digested peptides were analyzed on a LC-MS/MS setup. A Proxeon Easy 
nLCII (Thermo Fisher Scientific) with 15 cm columns (2.4 µm C18 beads, Dr. 
Maisch GmbH) was coupled to a LTQ Velos Orbitrap mass spectrometer (Thermo 
Fisher Scientific). A bilinear gradient of 60 to 85 min was applied for peptide 
separation. MS1 scans were acquired in the orbitrap massanalyzer applying a target 
value of 1,000,000 and a resolution of 60,000. Subsequently, collision induced 
dissociation (CID) fragmentation was performed for the 14 most intensive ions of 
the MS1 spectrum using an isolation width of 2 Da. Centroid MS2 spectra were 
acquired for the TOP 14 peptides in the linear ion trap with a target value of 10,000 
in the normal scanning mode. Enabled charge state screening, a monoisotopic 
precursor selection, 35% normalized collision energy, an activation time of 10 ms, 
wide band activation and a dynamic exclusion list were applied.  
Data analysis  
Peptide identification was performed using the Proteome Discoverer 1.2 software 
with the embedded SEQUEST algorithm. The International Protein Index database 
for rat (version 3.87) was used for the database search with carbamidomethylation 
of cysteine as a static and oxidation of methionine as a dynamic modification. Only 
full tryptic peptides with a maximum of 2 missed cleavages and an false discovery 
rate (FDR) below 5 % were included in the analysis. 
 
2.6 Statistical analysis  
Statistical analysis with Student’s t-test were calculated with MS Excel software, 
analysis with One-way and Two-way Analysis of Variance (ANOVA)-tests were 
calculated with GraphPad Prism software. Statistical significance was indicated as: 
* p<0.05, ** p<0.01, *** p<0.001. 
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IV. Results 
1. Generation and validation of TMEM106B shRNA and antibodies 
In order to investigate the role of TMEM106B in primary neurons, I used shRNA 
mediated knockdown of the endogenous protein using either transfection or 
lentiviral transduction. I generated two shRNAs against TMEM106B and compared 
the knockdown efficiency to a control shRNA (shLuc). qPCR analysis of transduced 
neurons (DIV7+5) demonstrated a knockdown of almost 90% for shT106b#1 and 
more than 95% for shT106b#2 (Figure 6A). Moreover, it was essential for all 
localization and functional studies to use antibodies which reliably detect the 
endogenous protein in immunoblot and immunofluorescence. Thus, polyclonal 
antibodies specific for the N-terminus of rat TMEM106B were generated. To this 
end, two rabbits were immunized with a peptide consisting of the first 91 amino 
acids of rat TMEM106B fused to MBP. The antibodies were affinity purified from 
rabbit serum with a homologous GST fusion protein (compare method section). In 
order to test the antibodies, primary cortical neurons (DIV7+5) were transduced 
with a shRNA against TMEM106B or a control shRNA. In the immunoblot, the 
signal for endogenous TMEM106B was drastically reduced for in TMEM106B 
knockdown samples compared to control samples (Figure 6B). In order to test the 
TMEM106B antibody additionally in immunofluorescence, primary hippocampal 
neurons (DIV7+5) were transfected with two different shRNAs against TMEM106B 
or the control shRNA. In shT106b transfected neurons – identified by cotransfected 
EGFP – TMEM106B staining was strongly reduced whereas a strong staining was 
still visible in the control cells. These experiments confirm good specificity of the 
antibodies in immunoblot and immunofluorescence (Figure 6C).  
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Figure 6: Validation of polyclonal TMEM106B antibodies 
(A) Primary rat cortical neurons (DIV7+5) were transduced with a lentivirus expressing control shRNA 
(shCtrl), TMEM106B shRNA (shT106b#2), empty vector control or rat TMEM106B. Immunoblots with 
two different polyclonal antibodies against the first 91 N-terminal amino acids of rat TMEM106B. Arrow 
points to correct bands. (B) Primary hippocampal neurons were transfected with a control shRNA, 
shT106b#1 or shT106b#2 and GFP as transfection marker. Neurons were stained with an antibody against 
TMEM106B (red). Staining confirms TMEM106B knockdown in the two dimensional projection. Scale 
bar represents 50 µm in the overview or 10 µm in the magnification of the nucleus. 
A B 
C 
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2. Effects of TMEM106B knockdown in primary neurons 
2.1 TMEM106B knockdown does not affect viability of primary neurons 
Next, I tested whether the knockdown of TMEM106B had any influence on FTLD 
related proteins. As above, I transduced cortical neurons (DIV7) with TMEM106B 
shRNA #1, #2 or the control shRNA for 6 days and assessed the levels of GRN, 
TDP-43, FUS and Tau by immunoblotting. No change was detected in the overall 
expression levels comparing knockdown cell lysates with the control lysates. 
Moreover, the protein levels of the important neuronal marker ß-III-tubulin 
remained unchanged, too (Figure 7A).  
 
 
Figure 7: TMEM106B knockdown does not affect general neuron viability 
(A) Primary rat cortical neurons (DIV7+6) were transduced with a lentivirus expressing either 
TMEM106B shRNA (shT106b) #1 or #2 or a control shRNA (shCtrl). Immunoblots with the indicated 
antibodies for neuronal marker proteins or FTLD associated proteins. Protein levels are not changed. (B) 
A B 
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Primary rat cortical neurons (DIV7+6 or DIV 14+6) were transduced with the indicated lentivirus. Cell 
viability upon TMEM106B knockdown was measured using an XTT assay. TMEM106B knockdown had 
no statistically significant effect (one-way ANOVA). n≥3 independent experiments, mean +/- SEM. 
 
Additionally, I performed a metabolic-based XTT-cell-viability assay, to assess if 
the knockdown of TMEM106B had any influence on neuronal survival. Young 
neurons (DIV7+5) as well as fully mature neurons (DIV14+5) were transduced with 
both shRNAs for TMEM106B and the control shRNA and incubated with the XTT 
reagents. Notably, loss of TMEM106B protein exhibited no obvious toxicity in this 
context (Figure 7B). Altogether this data demonstrates that loss of TMEM106B 
protein in primary neuronal culture influences neither the protein levels of several 
FTLD-associated proteins nor the general viability of the cell and thus likely 
contributes to FTLD pathogenesis by other mechanisms.  
 
2.2 TMEM106B is mainly localized in dendritic lysosomes 
In order to determine the subcellular compartment of TMEM106B in a disease 
relevant cell type, I performed colocalization experiments for the endogenous 
protein in primary hippocampal neurons. Hence, I stained untransfected neurons 
after seven days in vitro with antibodies against TMEM106B and several organelle 
marker among them, lysosomal-associated membrane protein 1 (LAMP1). 
Endogenous TMEM106B showed a vesicular pattern which overlapped to a high 
extent with the lysosomal marker LAMP1. In the merged image a substantial overlap 
of the two color signals verifies the predominantly late endosomal / lysosomal 
localization (Figure 8A). The TMEM106B staining was especially abundant in soma 
and the main dendrites. This finding could be confirmed later on by others in tumor 
cell lines and primary neuronal culture (Brady et al., 2013; Chen-Plotkin et al., 
2012; Lang et al., 2012) 
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Figure 8: TMEM106B is localized in late endosomes / lysosomes of primary neurons 
(A) Primary rat hippocampal neurons (DIV12) were stained with antibodies against TMEM106B (green) 
and the lysosomal marker LAMP1 (red). Scale bar represents 50 µm in the overview or 10 µm in dendrite 
segments. Merged image indicates widespread co-localization in a single confocal plane. (B) Primary 
hippocampal neurons (DIV12) were stained with antibodies against TMEM106B (red) and LAMP1 for 
lysosomes, SV2 for synaptic vesicles or transferrin receptor TfR for early endosomes (green). Scale bar 
represents 50µm. The amount of colocalization was analyzed in at least 15 confocal fields using the JaCoP 
plugin of ImageJ. (C) Quantitative analysis of colocalization using the Pearson´s coefficient. (Mean +/- 
SEM). Substantial Colocalization was detected only for TMEM106B with the lysosomal marker LAMP1. 
A 
B C 
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In order to confirm this observation I quantified the amount of colocalization 
between TMEM106B and various organelle markers. To this end, I stained primary 
hippocampal neurons with an antibody against TMEM106B and antibodies against 
LAMP1, against SV2, a marker for synaptic vesicles or against Transferrin Receptor 
(TfR), a marker for early- and recycling-endosomes. The correlation of the intensity 
distribution between the individual color channels was calculated using the 
Pearson’s coefficient 𝑅𝑝. The correlation coefficient between TMEM106B and 
LAMP1 staining was in the expected range for a pronounced colocalization (𝑅𝑝 = 0.66 ±  0.02) (Zinchuk and Grossenbacher-Zinchuk, 2011) and thereby significantly 
higher than the correlation between TMEM106B and the other two vesicular marker 
proteins (𝑅𝑝 =  0.15 ±  0.01 for SV2 and 𝑅𝑝 =  0.31 ±  0.02 for TfR) (Figure 8B and 
8C). 
Axonal architecture is quite complex in mature neurons and it is often impossible to 
trace the full length of an axon. Thus I focused the analysis of TMEM106B 
localization in axons on an earlier time-point (DIV4) when functional dendrites are 
not established yet but the axon is already formed. Axons were defined 
morphologically as the longest neurite or by the presence of a gradient of 
unphosphorylated tau (Tau-1 staining) (Mandell and Banker, 1996). Costaining of 
TMEM106B with Tau-1 or LAMP1 showed clear overlap of the signals, indicating 
that TMEM106B is also found in axonal lysosomes, although to a lesser extent 
compared to dendritic lysosomes (Figure 9). 
Taken together these findings demonstrate a strong late endosomal / lysosomal 
localization of TMEM106B in neurons especially in the soma and the main dendrites 
and to a lesser extent in the axonal compartment.  
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Figure 9: TMEM106B is also occurring in axons of primary neurons 
Primary rat hippocampal neurons (DIV4) were stained with antibodies against TMEM106B (red) and the 
axonal marker Tau-1 (green) or the lysosomal marker LAMP1 (green). Scale bar represents 50 µm in the 
overview or 10 µm in axonal segments. Merged images indicate widespread co-localization in a single 
confocal plane.  
 
2.3 TMEM106B knockdown does not change lysosomal parameters 
Since it was previously described that overexpression of TMEM106B in HeLa and 
N2a cells resulted in enlarged lysosomes and vacuolar structure (Brady et al., 2013; 
Chen-Plotkin et al., 2012), I aimed to test morphology, localization and degradative 
function of lysosomes in primary neuronal culture. However, plasmid-based 
overexpression of TMEM106B in neurons leads to large vacuoles with TMEM106B 
aggregates in soma and dendrites with little resemblance to endogenous staining 
(data not shown). Thus, I used shRNA mediated knockdown to examine the 
influence of TMEM106B on lysosomal parameters. TMEM106B shRNA transfected 
hippocampal neurons (DIV7+5) were stained with an antibody against the lysosomal 
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marker LAMP1. There was no obvious change visible in the appearance and size of 
the vesicles in comparison to control transfected neurons (Figure 10).  
 
Figure 10: Lysosomal morphology is unchanged upon TMEM106B knockdown 
Primary rat hippocampal neurons (DIV7+5) were cotransfected with shCtrl, shT106b#1 or shT106#2 and 
GFP as transfection marker. Immunofluorescence of neurons stained with an antibodies against LAMP1 
(red). Scale bar represents 50 µm in the overview or 10 µm in the magnification of the soma. No obvious 
change in morphology and a slight tendency to perinuclear distribution of lysosomes was detected.  
 
Next, I assessed lysosomal function by measurement of the intravesicular pH value 
directly with Lysotracker staining and indirectly by measuring the pH-dependent 
maturation of the lysosomal protease Cathepsin D. Live labeling of lysosomes 
revealed bright Lysotracker staining in shT106B#2 transfected neurons as well as in 
control neurons demonstrating acidic environment under both conditions (Figure 
11A). Additional evidence for working lysosomes was provided by the unaltered pH 
dependent proteolytic processing of Cathepsin D. Total lysates of TMEM106B 
shRNA and control transduced neurons showed no difference in the band pattern on 
immunoblot (Figure 11B. Taken together, my results show no obvious difference in 
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lysosomal localization and function in TMEM106B knockdown neurons and thereby 
rather argue for other defects than in lysosomal degradation. 
 
 
 
A 
B 
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Figure 11: Lysosomal pH-value is unchanged upon TMEM106B knockdown 
(A) Primary rat hippocampal neurons (DIV7+5) were cotransfected with shCtrl, shT106b#1 or shT106#2 
and RFP as transfection marker. Neurons were live labeled with Lysotracker green and imaged 
immediately. Scale bar represents 50 µm in the overview or 10 µm in the magnification of the soma. No 
obvious change in Lysotracker staining was detected. (B) Primary cortical neurons (DIV7+6) were 
lentivirally transduced with shCtrl or shT106b#2. Immunoblot with the indicated antibodies. No change in 
the pH-dependent maturation of Cathepsin D was detected.  
 
3. Effect of TMEM106B knockdown on neuronal morphology 
3.1 TMEM106B knockdown inhibits dendritic branching 
Interestingly, knocking down TMEM106B in primary neurons, although not toxic, 
led to a dramatic reduction in dendritic branching (compare Figure 6B). To examine 
this observation in more detail and to quantify the effect I utilized Sholl analysis, a 
technique which analyzes dendritic complexity by combined measurement of 
dendrite length and branching (Sholl, 1953). For this analysis, Hippocampal neurons 
were transfected at DIV7 with the TMEM106B shRNAs or the control shRNA and a 
filler protein (EGFP) to visualize neuron morphology. Five days after transfection, 
neurons were fixed and confocal images of individual cells acquired. On each image 
nine concentric circles at intervals of 12.5 µm were placed around the cell soma and 
the number of crossings between the dendrites and each circle was counted. The 
quantification clearly confirmed the initial impression: with both shRNAs, dendrite 
branching is drastically reduced compared to control transfected neurons, especially 
in the proximal part of the dendrite (Figure 12A and 12B). Next, I set out to 
elucidate if this effect reflects a deficiency only in dendrite outgrowth – which 
indicates the phenotype seen in the still developing neurons at DIV7+5 – or also a 
deficit in dendrite maintenance. Therefore mature neurons (DIV14+5) were 
transfected likewise with TMEM106B shRNAs or the control shRNA. Again, the 
complexity of the dendritic arbor was drastically reduced with both shRNAs 
compared to control shRNA transfected neurons (Figure 12C and 12D), clearly 
pointing to impairment in both, dendrite outgrowth and maintenance.  
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Figure 12: TMEM106B knockdown impairs dendrite branching and maintenance 
(A, B) Primary rat hippocampal neurons (DIV7+5 and DIV14+5) were cotransfected with the indicated 
shRNAs and GFP to visualize cell morphology. Dendritic arborization was quantified manually and 
blinded to the experimental condition by Sholl analysis using MetaMorph software. Neurons transfected 
with either TMEM106B shRNA #1 or #2 show significantly reduced branching pattern compared to 
control shRNA transfected cells (Analysis at DIV7+5: shT106b#1: from 25 µm to 62.5 µm radius 
p<0.001, 100 µm and 112.5 µm p<0.001; shT106b#2: from 25 µm to 75 µm p<0.001; Analysis at 
DIV14+5: shT106b#1: from 37.5 µm to 62.5 µm p<0.001, at 75 µm p<0.05; shT106b#2: 37.5 µm to 62.5 
µm p<0.001, at 25 µm and 87.5 µm p<0.05). n>38 neurons per condition, 3 independent experiments, 
mean +/- SEM. Two-way ANOVA. Scale bar represents 100 µm.  
 
In order to exclude that the dendritic phenotype is due to off-target effects of the 
short hairpin, I used two shRNAs with different target sites which both led to the 
same phenotype (Figure 12A-12D). Moreover, I generated a TMEM106B 
overexpression construct (TMEM106B*) with silent mutations rendering the mRNA 
resistant to both TMEM106B shRNAs used, to perform rescue experiments. Since 
already mild overexpression of TMEM106B in the neurons leads to unphysiological 
aggregation of the exogenously expressed protein (Brady et al., 2013; Chen-Plotkin 
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et al., 2012), I used lentivirus to titrate the shRNA resistant construct back to 
endogenous protein levels (Figure 13A). This careful reintroduction of TMEM106B 
into shT106b transfected neurons prevented unphysiological aggregation of the 
exogenous protein. Under these conditions, I achieved a complete prevention of the 
dendrite loss for shRNA #1 and a partial prevention for the more potent shRNA #2 
(Figure 13B and 13C, compare Figure 6), confirming the specificity of the short 
hairpin sequences used.  
 
Figure 13: Validation of the TMEM106B knockdown phenotype by expression of a shRNA resistant 
mutant 
(A) Primary cortical neurons (DIV7+6) were transduced with a shRNA-expressing lentivirus (shCtrl or 
shT106b#2) and a lentivirus expressing shRNA-resistant TMEM106B (T106b*) or GFP as control to 
titrate TMEM106B expression. (B, C) Primary rat hippocampal neurons were virally infected (DIV6) with 
either mCherry (RFP) or shRNA-resistant TMEM106B mutant (T106b*) and cotransfected (DIV7+5) 
with either a control shRNA or the indicated TMEM106B shRNA and GFP to outline neuron morphology. 
Sholl analysis was done as above. ShRNA-resistant TMEM106B overexpression fully rescued the 
phenotype of the less potent TMEM106B shRNA #1 and partially rescued the more potent shRNA #2. 
(Analysis of shT106b#1: shCtrl+RFP vs. shT106b+RFP: from 25 µm to 50 µm p<0.001, shT106b+RFP 
vs. shT106b+T106b*: 25 µm and 62.5 µm p<0.05, 37.5 µm and 50 µm p<0.001; Analysis of shT106b#2: 
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shCtrl+RFP vs. shT106b+GFP: from 12.5 µm to 50 µm p <0.001, shT106b+RFP vs. shT106b+T106b*: 
from 12.5 µm to 25 µm p<0.001, at 37.5 µm p<0.05). n>38 neurons per condition, three independent 
experiments, mean +/- SEM, two-way ANOVA. Scale bar represents 100 µm.  
 
Since the observed dendrite loss affected primarily the proximal arborization (see 
Figure 12B and 12D), I specifically tested if the length of the main (longest) 
dendrite was also affected upon TMEM106B knockdown. Notably, the main dendrite 
of shTMEM106B #1 or #2 transfected neurons (DIV14+5) was about 30 % longer 
than the main dendrite of shCtrl transfected neurons (Figure 14), suggesting that 
especially secondary and higher order dendrites are affected by the loss of 
TMEM106B. 
 
 
Since I observed a strong dendritic phenotype upon knockdown of a lysosomal 
protein, I set out to test if general defects in lysosomal activity can alter dendritic 
architecture. I expressed the dominant negative mutant of RAB7A to block of 
lysosomal function. This GDP/GTP exchange factor is important for cargo transport 
to the lysosome, endosomal/lysosomal fusion events and lysosomal biogenesis in 
general. The T22N mutation of the protein, which impairs the affinity for GTP and 
the nucleotide exchange acts dominant negative and inhibits these functions (Bucci 
et al., 2000; Mukhopadhyay et al., 1997; Spinosa et al., 2008). Primary hippocampal 
neurons (DIV7+5) were transfected with either wild type (wt) RAB7A, dominant 
negative (dn) RAB7A T22A or constitutive active (ca) RAB7A Q67L together with 
Figure 14: TMEM106B knockdown increases length of the 
main dendrite 
Primary hippocampal neurons (DIV7+5) were transfected with 
either of the two shRNAs against TMEM106B or a control 
shRNA and GFP to visualize the cell morphology. In projections 
of confocal z-stacks the length of the longest dendrite of each 
neuron was measured using ImageJ software. Image acquisition 
and analysis was done blinded to the experimental condition. 
Dendrites of shRNA treated neurons were significantly longer 
than of ctrl treated neurons. 40 neurons per condition were 
analyzed. Mean +/- SEM, one-way ANOVA: *** denotes 
p<0.001.  
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EGFP as transfection marker and to outline neuronal morphology. The dendritic 
branching of these transfected neurons was assessed with Sholl analysis as described 
above. Whereas neurons expressing constitutive active RAB7A had only a slightly 
but not significantly increased dendrite complexity compared to wt RAB7A 
overexpressing neurons, neurons expressing RAB7A T22N showed a significant 
decrease in dendrite branching (Figure 15A and 15B). This finding argues for a 
causal link between lysosomal function and the growth and maintenance of 
dendrites. 
 
Figure 15: Dominant-negative RAB7a impairs dendritic arborization 
(B, C) Primary rat hippocampal neurons (DIV7+5) were cotransfected with the indicated RAB7a wild-
type or mutant constructs and GFP to visualize the neuronal morphology. Dendritic arborization was 
quantified by Sholl analysis as above. Neurons transfected with dominant negative RAB7a T22N (dn) are 
significantly different from wild-type RAB7a (wt) or constitutive active RAB7a Q67L (ca) transfected 
cells (wt RAB7a vs. dn RAB7a: from 50µm to 75µm radius p<0.05). n>40 neurons per condition, three 
independent experiments, mean +/- SEM, two-way ANOVA. Scale bar represents 100 µm. 
 
3.2 TMEM106B knockdown impairs spines and synaptic markers 
Since changes in dendrite morphology and function are often accompanied by 
alterations in dendritic protrusions / spines (Koleske, 2013), the previous findings 
raised the question if also spine morphology is affected by TMEM106B knockdown 
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in primary neurons. Hence, I analyzed spine density and morphology in mature 
neurons (DIV14+5) treated with shRNA against TMEM106B. On these images I 
quantified the overall density of dendritic spines as well as their width and length 
from a total of 100-200 / µm dendrite segments per neuron. Spine size and 
morphology is a good correlate of their function. The width of the spine head is 
proportional to the number of postsynaptic receptors and thereby to the strength of 
the transmission. Especially mushroom-shaped protrusions are a sign for strong 
synaptic activity (Hering and Sheng, 2001). As can be seen on the representative 
images (Figure 16A), the control shRNA transfected neurons exhibited normal spine 
density and most protrusions were mushroom shaped. In contrast, spines in 
shTMEM106B #1 or #2 transfected neurons were significantly less dense and were 
much thinner and more filopodia like – a sign for reduced synaptic strength (Figure 
16A and 16B). Again, this effect was more pronounced in neurons treated with the 
stronger shRNA #2. Moreover, also the length of the protrusions was reduced by 
approximately 20 percent upon TMEM106B knockdown (Figure 16B).  
Next, I confirmed these findings on a biochemical level. Cortical neurons (DIV7+6) 
were transduced with a lentivirus expressing either TMEM106B shRNA #2 or the 
control shRNA. The levels of the presynaptic marker protein synaptophysin and the 
postsynaptic density protein PSD-95 were analyzed by immunoblotting (Figure 
16C). Synaptophysin and PSD-95 levels, normalized on the housekeeping protein ß-
actin, were reduced by 60 percent and 40 percent, respectively, upon TMEM106B 
knockdown (Figure 16D) corroborating the morphological data.  
 
3.3 TMEM106B knockdown increases axonal length 
For a complete picture of neuronal morphology upon TMEM106B knockdown, 
axonal length was measured additionally. For axonal analysis, neurons were used at 
an early stage of development to avoid the complex architecture at later time points, 
which hinders tracing of neurites (compare Figure 9B). Neurons were nucleofected 
with the shRNA constructs directly before plating and axonal length was measured 
four days later. The criteria for identifying axons were the same as described above 
(see chapter 2.2). ShT106b#2 nucleofected neurons had about 30 percent longer 
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axons than control shRNA nucleofected neurons (Figure 16E and 16F). Together 
with the data from the XTT-assay (compare Figure 7B) and the increased length of 
the main dendrite (compare Figure 14D), the above finding provides an additional 
sign for unaltered neuronal viability since decrease in axonal length is often an early 
sign of toxicity in neurons. 
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Figure 16: Changes in spine and axon morphology upon TMEM106B knockdown 
(A, B) Hippocampal neurons were co-transfected with the indicated shRNAs and GFP (DIV14+5). Spine 
morphology (length and width) and density was assed manually and blinded to the experimental condition 
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using MetaMorph software. Neurons show shorter, thinner and less dense dendritic protrusions upon 
TMEM106B knockdown. (n>38 per condition; one-way ANOVA; *: p<0.05, ***: p<0.001). (C) Primary 
cortical neurons were transduced with the lentivirus expressing the indicated shRNAs. Immunoblots with 
antibodies against presynaptic synaptophysin and postsynaptic PSD-95 show a reduction of protein levels 
upon TMEM106B knockdown. (D) Quantification of the immunoblots from (C) normalized to β-actin. 
(n=4, mean +/- SEM, Student´s t-test, ** denotes p<0.01). Reduction of synaptic marker proteins 
corroborates synapse loss at the biochemical level. (E, F) Primary rat hippocampal neurons were 
nucleofected with either TMEM106B shRNA #2 or control shRNA together with YFP to outline neuron 
morphology prior to plating (DIV0+4). Neurons were immunostained with antibodies against YFP (green) 
and the axonal marker Tau-1 (red). Axonal length was measured using AxioVision software blinded to the 
experimental condition. Increased axonal length in TMEM106B knockdown cells indicates that 
TMEM106B knockdown does not cause unspecific toxicity. (n>80 per condition, three independent 
experiments; Student´s t-test, ** denotes p<0.01). Scale bar represents 100 µm.  
 
Taken together I was able to demonstrate that knockdown of TMEM106B in primary 
neurons leads to a pronounced inhibition of dendritic branching and maintenance. 
Although this is accompanied by dramatic changes in spine morphology and density, 
no overall neurotoxicity is observed. This point is further strengthened by the 
increase in the length of the developing axon and the main dendrite observed upon 
loss of TMEM106B. 
 
4. TMEM106B interacts with MAP6 
4.1 Identification of MAP6 as TMEM106B binding partner in rat brain 
To further elucidate the cellular context of TMEM106Bs function and to identify the 
underlying mechanisms of the dendrite loss I set out to identify TMEM106B 
interacting proteins. Thus, I established a protocol for immunoprecipitation from rat 
brain samples. The protein was immunoprecipitated from the lysate (1% Triton 
X100) of a crude membrane fraction by the polyclonal TMEM106B antibody cross-
linked to magnetic protein-G-coupled beads. The eluted precipitates were subjected 
to SDS-PAGE and the proteins thereon stained with colloidal coomassie dye (Figure 
17A). TMEM106B-IP specific bands and their corresponding areas in the control 
lanes were excised, the containing proteins subjected to tryptic digest and 
subsequently identified by LC-MS/MS. The only protein found specifically in 
TMEM106B immunoprecipitates in all three independent experiments (with a total 
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of five biological replicates) was the MT-binding protein MAP6. This protein, also 
referred to as stable tubule-only polypeptide (STOP), is known to mainly interact 
with and stabilize microtubules (Bosc et al., 1996). However, additional targeting to 
the actin cytoskeleton and the Golgi apparatus is reported (Baratier et al., 2006; 
Gory-Faure et al., 2006). LC-MS/MS specifically identified eleven unique peptides 
(table 1) of the protein with a total sequence coverage of 23 % in IP samples (Figure 
17B).  
 
Figure 17: MAP6 peptides identified by LC-MS/MS 
(A) Proteins coimmunoprecipitating with TMEM106B in rat brain (P15) were analyzed. Colloidal 
coomassie stained SDS-PA gel of control and TMEM106B immunoprecipitates. Boxed regions were cut 
out and further processed for LC-MS/MS. BSA served as marker for amount of recovered protein. 
Asterisk denotes TMEM106B band. Brightness/contrast in the image was adjusted in a linear manner to 
better identify bands on the gel. (B) Proteins coimmunoprecipitating with TMEM106B in rat brain (P15) 
were analyzed by LC-MS/MS. MAP6 was identified by 11 peptides highlighted in green throughout the 
whole protein sequence. The region with five tandem repeats binding microtubules is underlined. Mass 
spectrometry was performed by Sebastian Hogl.  
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Table 1: Unique peptides for MAP6 identified by LC-MS/MS 
 
peptide sequence charge m/z [Da] MH+ [Da] 
TEGHEETPLPPAQSQTQEGGPAAGK 3 839.73142 2517.17969 
AVAIETQPAQGESDAVAR 2 906.95901 1812.91074 
YSEATEHPGAPPQPPAPPQPGLAPPSR 3 916.12646 2746.36484 
GPIQLSADARDPEGAGGAGVPAAGK 3 754.72241 2262.15268 
DPEGAGGAGVPAAGK 2 627.31016 1253.61304 
AQSPLLPEPLKNQSPVVPAR 3 714.40826 2141.21024 
SEYQPSDAPFER 2 713.32019 1425.63310 
NKDSVPLAPAK 2 570.32367 1139.64006 
EEVTSTVSSSYR 2 672.81799 1344.62871 
AGPAWMVTR 2 494.75421 988.50115 
AVADALNR 2 415.23001 829.45275 
 
 
Moreover, the endogenous interaction of both proteins could also be corroborated on 
immunoblot level. With this method, I confirmed the specific interaction of 
TMEM106B and MAP6 in both directions (Figure 18A and 18B). 
 
 
Figure 18: TMEM106B interacts with MAP6 in rat brain 
TMEM106B (A) and MAP6 (B) were immunoprecipitated from P15 rat brain. Immunoblots with the 
indicated antibodies demonstrate MAP6 coimmunoprecipitating in TMEM106B IP and TMEM106B 
coimmunoprecipitating in MAP6 IP. 
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In order to provide further evidence for the interaction of TMEM106B and MAP6 in 
a shared cellular compartment, subcellular fractionation from adult rat brain was 
performed. The 100,000 g membrane fraction of homogenized brain was further 
separated via a discontinuous iodixanol density gradient. Mitochondrial and 
endoplasmic reticulum (ER) components (identified by their marker proteins 
translocase of outer mitochondrial membrane 20 (TOM20) and calnexin 
respectively) accumulated in denser fractions of the gradient whereas plasma 
membrane components (Na+-K+-ATPase) and remaining microtubule components 
(βIII-tubulin) accumulated in light fractions. Remarkably, TMEM106B and MAP6 
peaked together with markers for the secretory and endocytic pathway (γ-adaptin for 
the Golgi apparatus and RAB7 for late-endosomes and lysosomes) in the middle 
fractions (Figure 19). This finding suggests close contact between TMEM106B and 
MAP6 in the same subcellular compartments, including lysosomes. 
Results 
 
103 
 
  
 
4.2 Mapping of the MAP6/TMEM106B interaction domain in HEK293 cells 
In the next step, I aimed to map the protein domains crucial for the interaction of 
TMEM106B and MAP6. For that purpose several deletion mutants were generated 
and expressed in HEK293 cells. Due to the type II transmembrane topology of 
TMEM106B (Lang et al., 2012), it was predicted that only the extravesicular N-
terminal part (AA 1-97) of the protein is able to take part in the binding. For better 
expression and stability a GFP-tagged human TMEM106B N-terminal fragment 
(GFP-TMEM106B-NT, AA1-93) was cloned. Additionally, three different myc-
tagged MAP6 constructs were generated as potential binding partner: full length rat 
MAP6 (NP_058900.1), human MAP6 isoform 1 (NP_149052.1) lacking four of the 
five central repeats and human isoform 2 (NP_997460.1) lacking additionally the c-
Figure 19: TMEM106B and MAP6 
peak in the lysosomal fraction of a 
density gradient 
Subcellular compartments from adult 
rat brain were fractionated using a 
discontinuous iodixanol density 
gradient (2.5 – 30%). Immunoblots of 
1 ml fractions with the indicated 
antibodies. TMEM106B and MAP6, 
both peak in the same, RAB7-positive 
fractions. 
 
Results 
104 
 
terminal repeat domain (Figure 18C). As expected, full length rat MAP6 co-
immunoprecipitated GFP-TMEM106B-NT that was co-expressed in HEK293 cells. 
The same was true for coIP experiments with human MAP6 isoform 1. However, the 
shorter, c-terminally truncated isoform two of human MAP6 did not bind to the 
TMEM106B N-terminal domain. This result indicates binding of the cytoplasmic N-
terminus of TMEM106B to the C-terminal repeat region of MAP6 (Figure 18C and 
18D). Taken together these results confirm the interaction of TMEM106B and 
MAP6 which is mediated by the N-terminus of TMEM106B and the C-terminus of 
the MAP6.  
 
 
Figure 21: TMEM106B N-terminus binds to MAP6 C-terminus 
(A) Deletion mutants of TMEM106B and MAP6 used for analysis of interaction domains. The 
cytoplasmic N-terminal domain (NT) of TMEM106B fused to GFP. Transmembrane domain (TMD) and 
C-terminal domain (CT) were removed to avoid aggregation. MAP6 contains a central repeat domain, 
consisting of five repeats (R) of a 46 amino acid motif in rat but only one repeat in humans. The shorter 
isoform 2 lacks the C-terminal repeat domain (CTR) consisting of up to 28 imperfect repeats. (B) GFP-
TMEM106B-NT and the indicated myc-tagged MAP6 variants were co-expressed in HEK293FT cells. 
MAP6 variants were immunoprecipitated with myc-beads. Immunoblots with the indicated antibodies 
show coimmunoprecipitation of TMEM106B with CTR containing MAP6 variants. Figure 21B in 
collaboration with Christina M Lang. 
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5. MAP6 function in dendrites  
5.1 MAP6 affects dendritic branching 
In my previous experiments I could demonstrate that TMEM106B and MAP6 
physically interact with each other. However, the functional relevance of this 
interaction remained elusive. In order to provide evidence for a functional 
cooperation, I transfected hippocampal neurons (DIV7+5) with a rat MAP6 
overexpression construct and analyzed the morphology of the dendritic arbor as 
described before. Strikingly, MAP6 overexpression led to a substantial decrease in 
dendritic complexity to almost the same extent as TMEM106B knockdown (Figure 
22A, compare Figure 12), as quantified by Sholl analysis (Figure 22B). Again, the 
most pronounced effect occurred in the proximal part of the dendrites. This 
similarity of MAP6 overexpression with TMEM106B knockdown suggested that the 
reduction of MAP6 would lead to the opposite effect. For this purpose, I generated a 
shRNA expression vector specific for rat MAP6. Lentiviral transduction of this 
shRNA in cortical neurons (DIV7+5) and subsequent immunoblotting clearly 
demonstrated a reduction of MAP6 protein level and confirmed the good knockdown 
efficiency of the short hairpin (Figure 23). However, loss of MAP6 in these neurons 
did not affect the protein level of TMEM106B (data not shown). Strikingly, 
knockdown of MAP6 in hippocampal neurons (DIV7+5) led to an increase in 
dendrite outgrowth compared to the control situation (Figure 22C and 22D).  
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Figure 22: Effects of MAP6 overexpression and knockdown on dendritic branching 
(A, B) Primary rat hippocampal neurons (DIV7+5) were cotransfected with either a MAP6 overexpression 
construct or an empty vector control and GFP. Dendritic arborization was analyzed by Sholl analysis as 
above. Neurons overexpressing MAP6 are significantly less branched than controls (at 12.5 µm, 25 µm, 
75 µm and 87.5 µm radius p<0.05, from 37.5 µm to 62.5 µm p<0.001). n>40 per condition, three 
independent experiments, mean +/- SEM, Two-way ANOVA. Scale bar represents 100 µm. (C, D) 
Primary rat hippocampal neurons (DIV7+5) were cotransfected with either with ctrl shRNA or MAP6 
shRNA and GFP. Dendritic arborization was analyzed by Sholl analysis as above. MAP6 knockdown 
neurons are significantly more branched than controls in distal parts of dendrites (at 62.5 µm and 75 µm 
radius p<0.05, at 87.5 µm and 112.5 µm p<0.01, at 100 µm radius p<0.001). n>40 per condition, three 
independent experiments, mean +/- SEM, Two-way ANOVA. Scale bar represents 100 µm. 
 
Figure 23: Knockdown of MAP6 in primary neurons 
Primary hippocampal neurons (DIV7+5) were transduced 
with MAP6 shRNA or a Ctrl shRNA lentivirus. Immunoblot 
with the indicated antibodies indicates specific MAP6 
knockdown. 
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To control also the MAP6 shRNA induced phenotype for unspecific off-target 
effects, I performed rescue experiments using the human MAP6 (isoform 1) 
overexpression construct, which is resistant to the shRNA targeting rat MAP6. 
Hence, I transfected hippocampal neurons with combinations of shCtrl or shMAP6 
and human MAP6 or an empty vector control. Yet again, dendritic branching was 
measured by Sholl analysis in DIV7+5 neurons. While shMAP6 transfected neurons 
cotransfected with an empty vector control, showed as expected increased dendrite 
outgrowth (Figure 24A and 24B, compare to Figure 22C and D), the cotransfection 
of human MAP6 led to a loss of dendrites comparable to the transfection of human 
MAP6 alone. These results are a clear indication for the specificity of the MAP6 
shRNA regarding the dendrite outgrowth phenotype. 
 
 
Figure 24: Validation of MAP6 shRNA using human MAP6 
(A, B) Primary rat hippocampal neurons (DIV7+5) were cotransfected with combinations of control 
shRNA (shCtrl), shRNA targeting rat MAP6 (shMAP6) and human MAP6 (hMAP6) or an empty vector 
(Ctrl) together with GFP. Dendritic complexity was quantified using Sholl analysis as above. MAP6 
knockdown increases distal branching while overexpression of human MAP6 prevents this effect 
(shCtrl+Ctrl vs shMAP6+Ctrl: 62.5 µm: p<0.05, from 75 µm to 112.5 µm radius p<0.001; shCtrl+Crtl vs. 
shCtrl+hMAP6 at 25 µm, 50 µm and 62.5 µm radius p<0.05, at 37.5 µm radius p<0.001; shMAP6+Ctrl vs 
shMAP6+hMAP6: from 12.5 µm to 112.5 µm radius p<0.001). n=25 neurons per condition, 3 
independent experiments, mean +/- SEM, two-way ANOVA. Scale bar represents 100 µm. 
Results 
108 
 
5.2 MAP6 depletion rescues TMEM106B knockdown phenotype 
Since MAP6 knockdown increased dendritic branching, I further speculated that the 
combination of both shRNAs, shMAP6 and shT106b, should consequently alleviate 
the TMEM106B knockdown phenotype. For these shMAP6 rescue experiments, I 
cotransfected shT106B #2 or shCtrl together with shMAP6 or shCtrl in the same 
settings as above. Importantly, the coexpression of both, TMEM106B shRNA and 
MAP6 shRNA, led to a complete rescue of dendrite loss compared to only 
TMEM106B shRNA treated neurons. Moreover, shMAP6 expression increased distal 
branching in both groups (shCtrl + shMAP6 and shT106b + shMAP6) compared to 
control shRNA only expressing neurons (Figure 25A and 25B) and thereby led to an 
“overrescue” of the TMEM106B knockdown phenotype.  
 
 
Figure 25: MAP6 knockdown rescues the branching effect of TMEM106B knockdown 
(A, B) Primary rat hippocampal neurons (DIV7+5) were cotransfected with combinations of control 
shRNA (shCtrl), TMEM106B shRNA #2 (shT106b) and MAP6 shRNA (shMAP6) together with GFP. 
Sholl analysis as above. MAP6 knockdown restores branching in TMEM106B knockdown neurons 
(shCtrl vs shT106b#2+shCtrl: from 25 µm to 62.5 µm radius p<0.001. shT106b#2+shCtrl vs 
shT106b#2+shMAP6: from 25 µm to 100 µm p<0.001, at 112.5 µm p<0.05. shCtrl vs shMAP6 + shCtrl: 
at 87.5µm p<0.05, from 100 µm to 112.5 µm p<0.001). n>40 per condition, 3 independent experiments, 
mean +/- SEM, two-way ANOVA. Scale bar represents 100 µm. 
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MAP6 belongs to the family of microtubule-associated proteins, among others 
responsible for the stabilization of microtubules. In order to test if the promotion of 
dendrite outgrowth is a common phenotype also seen upon loss of other microtubule 
stabilizing proteins, I analyzed dendrite arborization after shRNA mediated 
knockdown of the related microtubule-binding protein, MAP2. Hippocampal neurons 
(DIV7+5) were transfected with a shRNA targeting rat MAP2 and GFP to outline 
cellular morphology. Sholl analysis revealed that, in contrast to MAP6 knockdown, 
loss of MAP2 severely impaired dendrite outgrowth (compare Figure 20). Moreover, 
shMAP2 was not able to restore dendritic branching when cotransfected with the 
TMEM106B knockdown construct (Figure 26A and 26B).  
 
 
Figure 26: Validation of the specificity of shMAP6 rescue using shMAP2 
(A, B) Primary rat hippocampal neurons (DIV7+5) were cotransfected with combinations of control 
shRNA (shCtrl), shRNA targeting rat MAP2 (shMAP2) and TMEM106B shRNA #2 together with GFP. 
Dendritic complexity was quantified using Sholl analysis as above. MAP2 knockdown decreased 
branching and combination of shMAP2 and shT106b#2 did not alleviate branching defects (shCtrl vs. 
shT106b#2 + shCtrl: from 12.5 µm to 37.5 µm radius p<0.001, at 50 µm radius p<0.05; shCtrl vs. 
shMAP2 + shCtrl: at 12.5 µm radius p<0.001, at 25 µm radius p<0.05, at 37.5 µm radius p<0.01; 
shT106b#2 + shCtrl vs. shT106b#2 + shMAP2: no significant difference). n=40 neurons per condition, 3 
independent experiments, mean +/- SEM, two-way ANOVA. Scale bar represents 100 µm. 
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Taken together my data provides evidence for a specific function of TMEM106B 
interacting protein MAP6 in dendrite outgrowth and branching and thus for a 
functional interaction of both proteins in the same cellular pathway.  
 
6. Role of TMEM106B in lysosomal Transport 
6.1 TMEM106B knockdown affects lysosomal transport 
Microtubules are the major tracks on which organelles are transported through the 
cell (Hirokawa and Takemura, 2005). Since the results presented above demonstrate 
that a lysosomal protein interacting with a microtubule-binding protein affects 
dendrite outgrowth, I speculated that TMEM106B and MAP6 might influence the 
microtubule dependent transport of dendritic lysosomes. 
In order to test this hypothesis I performed live cell imaging experiments to analyze 
the movement of RAB7A-GFP labeled vesicles (late endosomes and lysosomes) in 
dendrites of hippocampal neurons. The neurons were cotransfected with RAB7A-
GFP and TMEM106B shRNA #2 or the control shRNA on DIV6. Time laps movies 
were taken from single neurons three days later (DIV6+3). Path-time diagrams 
(kymographs) were generated for every recorded neuron depicting the movement of 
RAB7A-GFP-positive vesicles in several dendritic segments (Figure 27A). In these 
kymographs, the total number of RAB7A-GFP labeled vesicles, the number of 
moving or stationary RAB7A-GFP labeled vesicles and the direction of the 
respective transport events was analyzed. While the total number of RAB7A-labeled 
vesicles remained constant in dendrites of knockdown and control neurons, the 
number of moving vesicles was significantly increased in neurons devoid of 
TMEM106B (Figure 27B and 27C). In the control situation only about 10 % of all 
vesicle did move in the 5 min time frame, however, in shT106b #2 transfected 
neurons almost 30 % of vesicles were mobile. Interestingly, a specific increase in 
the number of retrogradely transported lysosomes was primarily responsible for the 
overall change while the number of anterogradely transported lysosomes and 
lysosomes without any net-movement remained almost unchanged (Figure 27D).  
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Figure 27: TMEM106B controls retrograde trafficking of dendritic late endosomes/lysosomes  
(A) Primary hippocampal neurons (DIV6+3) were transfected with either TMEM106B shRNA #2 or a 
Ctrl shRNA and RAB7a-GFP to visualize late endosomal / lysosomal trafficking in dendrites and live 
imaged for 5 minutes with a frequency of 1 Hz. Dendrite segments and the corresponding representative 
kymographs of dendritic movement of RAB7a-GFP labeled vesicles are shown. Scale bar represents 60 s 
(vertical) and 20 µm (horizontal). (B) Quantitative analysis of vesicle number in the dendrites of 
transfected neurons. The number of RAB7a-labeled vesicles per 100 µm of dendrite length did not 
change. (C) Quantitative analysis of vesicle movement from 5 minute kymographs. Vesicles were 
manually classified according to their movement. TMEM106B knockdown significantly increased overall 
and specifically retrograde movement of RAB7a-GFP labeled vesicles. Between five and eleven neurons 
per condition were analyzed per experiment in at least three independent experiments, mean +/- SEM, 
unpaired t-test: * denotes p<0.05, ** denotes p<0.01. 
 
To evaluate this process in more detail, velocity and run length of the RAB7A-GFP 
labeled vesicles was additionally determined from the kymographs. In the 5 min 
time frame of the movies, both parameters were increased upon loss of TMEM106B. 
Velocity of late endosomes / lysosomes increased from approximately 25 µm/s to 34 
µm/s. Remarkably, this elevation by more than 35 % was primarily due to enhanced 
velocity in retrogradely transported vesicles (Figure 28A and 28B). The speed of 
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lysosomal movement is in the expected range for organelle transport in dendrites 
(Bannai et al., 2004; Kwinter et al., 2009; van Spronsen et al., 2013). The increase 
in run length upon TMEM106B knockdown was in a similar range (approx. 40 %, 
from 7.3 µm to 10.5 µm). Also in this case only the run length of retrogradely 
moving vesicles was increased while the run length of anterogradely moving 
vesicles did not change (Figure 28C and 28D). 
 
Figure 28: TMEM106B knockdown enhances retrograde movement of late endosomes/lysosomes  
(A-C) Primary hippocampal neurons (DIV6+3) were transfected with either TMEM106B shRNA #2 or a 
Ctrl shRNA and RAB7a-GFP. Live cell imaging of RAB7a-GFP labeled vesicles was used to visualize 
late endosomal / lysosomal trafficking in dendrites. Velocity (A, B) and total run length (C, D) of 
individual moving vesicles in total (A, C) or separated for anterograde and retrograde movements (B, D) 
was analyzed from kymographs (compare Figure 17). At least 80 moving vesicles per condition were 
analyzed.  
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I tested the specificity of the TMEM106B shRNA additionally regarding the effect 
on dendritic trafficking of lysosomes. Similar to the rescue experiments before 
(compare Figure 13), the neurons were transduced with lentivirus expressing 
TMEM106b* or empty vector control one day before transfection of the shRNAs. 
Trafficking of RAB7A-GFP-labeld lysosomes was assessed as described above on 
DIV6+3. As expected, neurons expressing shT106b#2 and control virus showed an 
increased transport in retrograde direction compared to control neurons. However, 
viral expression of TMEM106b* together with shT106b#2 led to a complete 
rebalancing of anterograde and retrograde trafficking (Figure 29A and 29B). 
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Figure 29: Reintroduction of shRNA-resistant TMEM106B rescues impaired lysosomal trafficking  
(A) Primary rat hippocampal neurons were virally infected (DIV5) with either mCherry (RFP) or shRNA-
resistant TMEM106B mutant (T106b*) and cotransfected (DIV6+3) with either a control shRNA or the 
indicated TMEM106B shRNA and RAB7a-GFP to visualize late endosomal / lysosomal trafficking. 
Dendrite segments and the corresponding representative kymographs of dendritic movement of RAB7a-
GFP-labeled vesicles are shown. Scale bars represent 60 s and 15 µm. (B) Quantitative analysis of vesicle 
movement from 5 min kymographs. Vesicles were manually classified according to their movement. 
Expression of the shRNA-resistant TMEM106B mutant prevents the induction of retrograde lysosomal 
transport. Between five and nine neurons per condition were analyzed per experiment in at least three 
independent experiments, mean +/- SEM, unpaired t-test: *** denotes p<0.001. 
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As TMEM106B could be detected also in axons of primary neurons (compare Figure 
9) and the length of the axons was altered in neurons devoid of the protein (compare 
Figure 16), I wanted to investigate if trafficking of RAB7A-GFP labeled neurons 
was changed as well. I used developing neurons (DIV0+4), because at this early 
stage of development axons could be easily traced and image acquisition at the same 
axonal region for every neuron could be ensured. The neurons were nucleofected as 
described above with shCtrl or shT106B #2 and RAB7A-GFP to identify the desired 
vesicles. The overall motility of late endosomes and lysosomes in axons was higher 
than the motility in dendrites for both groups. However, there was no difference in 
total, anterograde or retrograde movement between control and TMEM106B 
knockdown neurons (Figure 30A and 30B).  
 
Figure 30: TMEM106B knockdown does not change trafficking of axonal lysosomes 
(A) Primary hippocampal neurons (DIV0+4) were nucleofected with either TMEM106B shRNA #2 or a 
Ctrl shRNA and RAB7a-GFP to visualize late endosomal / lysosomal trafficking and live imaged every 
second for 5 minutes. Axonal segments and the corresponding representative kymographs of axonal 
movement of RAB7a-GFP labeled vesicles are shown. Scale bar represents 60 s (vertical) and 25 µm 
(horizontal). (B) Quantitative analysis of vesicle movement from 5 minute kymographs. Vesicles were 
manually classified according to their movement. Overall motility and direction of transport does not 
change upon TMEM106B shRNA transfection. At least seven neurons per condition were analyzed per 
experiment in at least three independent experiments, mean +/- SEM.  
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As an additional control for a specific lysosomal effect of TMEM106B knockdown, 
the dendritic transport of mitochondria was analyzed. I visualized mitochondria in 
primary hippocampal neurons with a construct expressing the mitochondrial 
targeting sequence of cyclooxygenase 8 (COX8) fused to red fluorescent protein 
(RFP) (mitoRFP). In the 5 min time frame analyzed approximately 50 % of mitoRFP 
labeled mitochondria were moving in control shRNA transfected neurons whereas 
the other half remained stationary. In contrast to the dendritic transport, no change 
of this 1:1 ratio could be detected in shT106b #2 transfected neurons (Figure 31A 
and 31B). Moreover, the total number of mitochondria remained constant in both 
groups investigated (Figure 31C).  
 
 
Figure 31: TMEM106B knockdown does not change mitochondrial trafficking in dendrites 
(A) Primary rat hippocampal neurons were transfected (DIV6+3) with either a control shRNA or 
TMEM106B shRNA #2 and mito-dsRed to visualize mitochondrial trafficking in dendrites. Dendrite 
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segments and the corresponding representative kymographs of dendritic movement of mitochondria are 
shown. Scale bars represent 60 s and 25 µm. TMEM106B knockdown had no effect on mitochondrial 
density (B) and movement (C) in dendrites. At least seven neurons per condition were analyzed per 
experiment in at least three independent experiments, mean +/- SEM.  
 
Taken together I demonstrated that the dendritic trafficking of lysosomes is affected 
by TMEM106B knockdown. Particularly the number of retrogradely transported 
RAB7A-GFP labeled vesicles is increased, as is the speed and length of their 
individual movements. In contrast, movement of mitochondria in dendrites as well 
as late endosomes / lysosomes in axons is not changed upon TMEM106B 
knockdown.  
 
6.2 MAP6 affects lysosomal transport 
Since TMEM106B and its interaction partner MAP6 both regulate dendrite 
outgrowth and knockdown of MAP6 even compensates for loss of TMEM106B, the 
question arose if overexpression of MAP6 would also phenocopy the impact of 
TMEM106B knockdown on lysosomal trafficking. Therefore, I transfected 
hippocampal neurons (DIV6+3) with rat MAP6 or an empty vector control and 
RAB7A-GFP to identify late endosomes and lysosomes. The trafficking of these 
vesicles was analyzed as described above. Strikingly, the number of retrogradely 
transported vesicles was similarly increased by almost two-fold, reminiscent of the 
TMEM106B knockdown effect. However, in the case of MAP6 overexpression the 
overall movement of RAB7A-GFP labeled vesicles in dendrites showed only a slight 
and non-significant elevation. This discrepancy to TMEM106B knockdown could be 
explained by the slight decrease observed in anterograde trafficking (Figure 32A, 
32C and 32D). Also in these experiments, similar to the situation in TMEM106B 
knockdown neurons, the total number of RAB7A-GFP labeled vesicles in dendrites 
remained constant for both groups (Figure 32B, compare Figure 27). 
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Figure 32: MAP6 regulates retrograde trafficking of late endosomes / lysosomes in dendrites 
(A) Primary hippocampal neurons were transfected (DIV6+3) with either rat MAP6 or empty vector and 
RAB7a-GFP to visualize late endosome / lysosome trafficking in dendrites. Dendrite segments and the 
corresponding representative kymographs are shown. Scale bar represents 60 s and 20 µm. (B) 
Quantitative analysis of vesicle number in the dendrites of transfected neurons. The number of RAB7a-
labeled vesicles per 100 µm of dendrite length did not change. (C) Analysis of RAB 7a-positive vesicle 
movement as above. Expression of MAP6 enhances retrograde mobility of RAB7a-GFP labeled vesicles. 
Between five and eleven neurons per condition were analyzed per experiment in at least three independent 
experiments, mean +/- SEM, unpaired t-test: * denotes p<0.05, ** denotes p<0.01.  
 
6.3 MAP6 depletion rescues TMEM106B knockdown effect on lysosomal 
transport 
Next, I tested if knockdown of MAP6 could - similar to the rescue of the dendrite 
outgrowth phenotype - also compensate for the enhanced retrograde trafficking in 
TMEM106B knockdown neurons. Hippocampal neurons (DIV6+3) were either 
transfected with shCtrl, shT106b#2 or shMAP6 individually or in combinations. 
RAB7A-GFP was used to visualize late endosomes and lysosomes in the dendritic 
compartment. On the one hand, neurons transfected with shT106b#2 alone exhibited 
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enhanced retrograde transport of the fluorescently labeled vesicles when compared 
to control neurons, as expected from the previous experiments. On the other hand, 
MAP6 knockdown alone slightly increased trafficking of both retrogradely and 
anterogradely transported vesicles. Strikingly, co-transfection of TMEM106B and 
MAP6 shRNA increased anterograde transport of late endosomes / lysosomes when 
compared to TMEM106B knockdown alone, thereby rebalancing the ratio of both 
directions (Figure 33A and 33B).  
Altogether, these results further strengthen the connection between TMEM106B and 
MAP6 as they provide another cellular function affected by both proteins. 
Moreover, MAP6 knockdown also compensates the unbalanced dendritic trafficking 
of lysosome upon TMEM106B knockdown. 
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Figure 33: MAP6 knockdown rebalances lysosomal trafficking in TMEM106B knockdown neurons 
(A) Primary hippocampal neurons (DIV6+3) were transfected with either shCtrl, shT106b#2+shCtrl, 
shCtrl+shMAP6 or shT106b#2+shMAP6 and RAB7a-GFP to visualize late endosomal / lysosomal 
trafficking. Dendrite segments and the corresponding representative kymographs of dendritic movement 
of RAB7a-GFP-labeled vesicles are shown. Scale bars represent 60 s and 20 µm. (B) Quantitative analysis 
of vesicle movement from 5 min kymographs. Vesicles were manually classified according to their 
movement. Coexpression of MAP6 shRNA rebalances altered retrograde trafficking upon TMEM106B 
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knockdown. Between six and ten neurons per condition were analyzed per experiment in at least three 
independent experiments, mean +/- SEM, unpaired t-test: * denotes p < 0.05, *** denotes p<0.001. 
 
6.4 Overexpressed MAP6 co-migrates with dendritic lysosomes 
My results indicate that TMEM106B and MAP6 together regulate late endosomal / 
lysosomal transport in dendrites and thereby influence dendrite morphology. This 
mechanism would require close contact of TMEM106B and MAP6 on microtubule 
and / or lysosomes. Above, I have already demonstrated that both proteins 
physically interact and that they are present in the same subcellular fraction as 
RAB7 (compare Figures 17, 18 and 20). Remarkably, live imaging of MAP6-GFP 
and LAMP1-RFP coexpressed in primary neurons (DIV6+3) displayed comigration 
of MAP6-GFP with some LAMP1-RFP-positive lysosomes in dendrites (Figure 
34A). Although endogenous MAP6 shows - as expected for a microtubule-binding 
protein - a wide-spread distribution in axons and dendrites (Figure 34B), the 
comigration of MAP6-GFP with a fraction of moving lysosomes indicated that 
excess, non-MT-bound MAP6 can still bind to TMEM106B on lysosomes. This 
suggests a dominant negative effect of overexpressed MAP6.  
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Figure 34: MAP6-GFP comigrates with some LAMP1-RFP-positive lysosomes in dendrites 
(A) Primary hippocampal neurons (DIV6+3) were transfected with MAP6-GFP and LAMP1-RFP and live 
cell imaged for 5 min with a frequency of 1 Hz to visualize movement of the fluorescently tagged 
proteins. Dendrite segments and the corresponding representative kymographs are shown. Merged images 
show excess MAP6 bound to moving LAMP1-positive late-endosomes/lysosomes in dendrites. Scale bars 
represent 60 s and 15 µm. (B) Primary rat hippocampal neurons (DIV12) were immunostained with 
antibodies against MAP6 (green) and TMEM106B (red) or LAMP1 (red). A commercial mouse 
monoclonal and a home-made rabbit polyclonal anit-MAP6 antibody were used in the upper and lower 
panel, respectively. Confocal images show cytoskeletal staining in dendrites and axon and some vesicular 
staining in the soma for MAP6 and vesicular staining pattern for TMEM106B and LAMP1. Scale bar 
represents 50 µm. 
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6.5 Low dose Nocodazole rebalances lysosomal trafficking and partially rescues 
dendrite withering 
Since it was reported that stabilizing the microtubule network is a major function of 
MAP6 (Bosc et al., 1996), it seems likely that reduction of the protein would 
increase the dynamics of the very same network. Thus, pharmacological 
enhancement of microtubule dynamics might also rescue lysosomal trafficking 
defects and the dendrite loss upon TMEM106B knockdown. Nocodazole is an anti-
neoplastic agent, which inhibits polymerization of microtubules and thereby 
destroys the cytoskeletal network. However, Giannakakou and colleagues could 
demonstrate that subtherapeutical doses of nocodazole apparently enhance the 
dynamics of microtubules without destroying them, thus enhancing nucleus directed 
(that is retrograde) transport of adenovirus particles (Giannakakou et al., 2002).  
With this in mind, I tried to restore the alterations in dendritic trafficking of 
lysosomes as well as the deficiency in dendrite outgrowth and maintenance upon 
loss of TMEM106B with chronic treatment of low dose nocodazole. Neurons 
(DIV6+3) were transfected with either a shRNA against TMEM106B or a control 
shRNA. Both groups were treated either with DMSO or 10 nM nocodazole every 36 
h starting with transfection. The relative number of anterogradely and retrogradely 
moving RAB7A-GFP labeled vesicles was measured as described above. Again, 
vesicles in shCtrl transfected neurons exhibited an evenly balanced ratio of both 
types of movements whereas shT106b#2 transfected neurons showed an increase in 
retrograde trafficking (compare Figure 27). Upon addition of nocodazole, the 
balanced ratio between anterograde and retrograde movement was restored (Figure 
35A and 35B), comparable to MAP6 knockdown. 
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Figure 35: Nocodazole treatment rebalances lysosomal trafficking in TMEM106B knockdown 
neurons 
(A) Primary hippocampal neurons (DIV6+3) were transfected with either shCtrl or shT106b#2 and 
RAB7a-GFP. After transfection fresh nocodazole (10nM) was added every 36 hours to neurons of the 
treatment group. Dendrite segments and the corresponding representative kymographs of RAB7a-labeled 
vesicle movement are shown. (B) Quantitative analysis of vesicle movement from 5 min kymographs. 
Vesicles were manually classified according to their movement. Low dose nocodazole treatment 
rebalances altered retrograde lysosomal trafficking upon TMEM106B knockdown. Between six and ten 
neurons per condition were analyzed per experiment in at least three independent experiments, mean +/- 
SEM, unpaired t-test: * denotes p < 0.05 
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If both phenotypes – dendritic vesicle trafficking and dendrite outgrowth – were in 
fact connected, rebalancing anterograde and retrograde transport would naturally 
lead also to an attenuation of the deficits in arborization. In order to test this, 
hippocampal neurons were transfected on DIV7 with shCtrl or shT106b #2 for five 
days. All shRNA transfected neurons co-expressed EGFP to visualize the dendritic 
morphology. As described above, images of individual neurons were taken and 
dendritic branching quantified by Sholl analysis. Neurons transfected with shRNA 
against TMEM106B showed deficits in dendritic arborization, as expected. 
Remarkably, neurons additionally treated with 10 nM nocodazole every 36 h, 
showed an alleviation of this phenotype albeit not a full restoration (Figure 36A and 
36B).  
 
 
Figure 36: Nocodazole treatment rescues the branching effect of TMEM106B knockdown 
(A, B) Primary rat hippocampal neurons (DIV7+5) were cotransfected with either shCtrl or shT106b#2 
and GFP to visualize dendritic morphology. 10 nM nocodazole was added freshly every 36 hours for a 
total of 5 days to the neurons in the treatment group. Nocodazole-treated neurons branched significantly 
more than untreated T106b#2 transfected neurons (shCtrl vs shT106b#2: from 12.5 µm to 50 µm p<0.001, 
62.5 µm p<0.05. shT106b#2 vs shT106b#2+Noco: from 12.5µm to 25 µm p<0.001, at 37.5 µm p<0.01). 
n>40 cells per condition, three independent experiments, mean +/- SEM, two-way ANOVA. Scale bar 
represent 100 µm. 
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Taken together, enhancing microtubule dynamics pharmacologically by low dose 
treatment with nocodazole is able to rebalance lysosomal trafficking and restore 
dendritic outgrowth in TMEM106B knockdown neurons comparable to MAP6 
knockdown. 
 
6.6 Enhancing anterograde transport by dnRILP stimulates dendrite growth 
and rescues TMEM106B knockdown phenotype 
Endosomal and lysosomal trafficking, microtubule dynamics and dendrite 
morphology are tightly connected (Conde and Caceres, 2009; Dehmelt and Halpain, 
2005; Kapitein and Hoogenraad, 2011; Villarroel-Campos et al., 2014). Therefore it 
is tempting to speculate that in the case of TMEM106B knockdown the misbalanced 
dendritic transport of lysosomes causes the decreased dendrite arborization. In order 
to provide evidence that such a mechanism is responsible for the observed 
phenotypes I searched for a way to manipulate lysosomal trafficking independent of 
TMEM106B and MAP6 and studied the subsequent impact on dendrite outgrowth. I 
took advantage of the dominant negative c-terminal fragment of Rab-Interacting-
Lysosomal-Protein (RILP). Several studies have demonstrated that upon expression 
of wild-type RILP, dynein-dynactin motor protein complexes are recruited to 
lysosomes. As a consequence, this recruitment induces trafficking toward the minus-
end of microtubules and the MTOC whereas the expression of dnRILP leads to 
dispersion of lysosomes throughout the cell (Cantalupo et al., 2001; Jordens et al., 
2001).  
In my experimental context (DIV6+3), overexpression of dnRILP increases the 
number of anterograde moving RAB7A-GFP labeled vesicles. In contrast, the 
number of late endosomes / lysosomes which moved retrogradely or exhibited no net 
movement did not change (Figure 37A and 37B). Next, I analyzed dendrite 
branching in hippocampal neurons (DIV7+5) upon dnRILP expression. Strikingly, 
neurons transfected with dnRILP showed a significantly higher complexity of the 
dendritic arbor compared to control transfected cells as quantified by Sholl analysis 
(Figure 37C and 37D), indicating that anterograde lysosomal transport promotes 
dendritic branching.  
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Figure 37: Overexpression of dominant negative RILP increases anterograde movement of 
lysosomes and dendritic branching  
(A) Primary hippocampal neurons (DIV6+3) were transfected with either empty vector (Ctrl) or dnRILP 
and RAB7a-GFP to visualize late endosomal / lysosomal trafficking in dendrites and live imaged every 
second for 5 minutes. Dendrite segments and the corresponding representative kymographs of dendritic 
movement of RAB7a-GFP labeled vesicles are shown. Scale bar represents 60 s (vertical) and 15 µm 
(horizontal). (B) Quantitative analysis of vesicle movement from 5 minute kymographs. Vesicles were 
manually classified according to their movement. Anterograde movement of RAB7a-GFP labeled vesicles 
is increased upon dnRILP expression. Mean +/- SEM, unpaired t-test: *** denotes p<0.001. (C, D) 
Primary hippocampal neurons (DIV7+5) were cotransfected with an empty vector (Ctrl) or dnRILP 
together with GFP. Sholl analysis as above to quantify dendritic complexity which is increased upon 
dnRILP expression (50 µm p<0.001, 62.5 µm p<0.01, 75 µm p<0.05). n=25 per condition, 3 independent 
experiments, mean +/- SEM, two-way ANOVA Scale bar represents 100 µm.  
 
Therefore, I asked whether promoting anterograde transport with dnRILP may 
rescue impaired branching in TMEM106B knockdown neurons. ShRNA-mediated 
knockdown of TMEM106B in hippocampal neurons (DIV6+3) led to the expected 
induction of lysosomal transport (compare Figure 23). Remarkably, the coexpression 
of dnRILP in these cells restored the increased number of retrogradely transported 
late endosomes / lysosomes to the control level. Coexpression of dnRILP with 
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shCtrl even slightly increased the number of anterogradely transported late 
endosomes / lysosomes, similar to the effect of shMAP6 (Figure 38A and 38B). 
Importantly, the coexpression of dnRILP in TMEM106B knockdown neurons 
(DIV7+5) alleviated the branching defect in line with my proposed mechanism 
(Figure 38C and 38D). 
Taken together, the functional rescue with dnRILP implicates that dendritic 
trafficking of late endosomes / lysosomes is indeed directly controlling dendrite 
outgrowth.  
 
Figure 38: dnRILP restores dendritic branching in TMEM106B knockdown neurons. 
(A) Primary hippocampal neurons (DIV6+3) were transfected with combinations of control shRNA 
(shCtrl) or TMEM106B shRNA#2 (shT106b) and dnRILP or an empty vector (Ctrl) and RAB7a-GFP to 
visualize late endosomal / lysosomal trafficking in dendrites. Dendrite segments and the corresponding 
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representative kymographs are shown. Scale bars represent 60 s and 15 µm. (F) Quantitative analysis of 
vesicle movement from 5 min kymographs. Vesicles were manually classified according to their 
movement. Coexpression of dnRILP restores balance of anterograde and retrograde vesicle movement in 
TMEM106B knockdown neurons. At least seven neurons per condition were analyzed per experiment in 
at least three independent experiments, mean +/- SEM, unpaired t-test: ** denotes p < 0.01. (G, H) 
Primary rat hippocampal neurons (DIV7+5) were cotransfected with combinations of control shRNA 
(shCtrl) or TMEM106B shRNA#2 (shT106b) and dnRILP or an empty vector (Ctrl) together with GFP. 
Sholl analysis as above to quantify dendritic complexity. Coexpression of dnRILP ameliorates the 
branching phenotype upon TMEM106B knockdown (shCtrl+Ctrl vs shT106b#2+Ctrl: from 12.5 µm to 50 
µm radius p<0.001. shT106b#2+Ctrl vs shT106b#2+dnRILP: from 12.5 µm p<0.001, 25 µm p<0.01. 
shCtrl+Ctrl vs shCtrl+dnRILP: from 62.5µm to 75 µm p<0.01). n>25 per condition, 3 independent 
experiments, mean +/- SEM, two-way ANOVA. Scale bar represents 100 µm. 
 
In summary, I could show on a biochemical and cell biological level that the FTLD 
risk factor TMEM106B functionally interacts with microtubule-associated-protein 6 
(MAP6) at the lysosome. Together, both proteins regulate dendrite outgrowth and 
maintenance by controlling lysosomal trafficking in dendrites. Moreover, I could 
corroborate this causal link between trafficking and outgrowth by manipulating 
lysosomal transport independent of TMEM106B/MAP6. 
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V. Discussion 
1. Genome-wide association study identified TMEM106B risk variants  
The identification of TMEM106B as a risk factor for FTLD-TDP was based on a 
genome-wide association study (GWAS) (Van Deerlin et al., 2010). This type of 
study links certain SNPs in and around a gene to a disease, a syndrome or clinical 
symptoms. However, identified SNPs do not necessarily provide a direct and causal 
link between the gene and the disease but are sometimes only marker for other, still 
unidentified alterations (Manolio, 2010). The first genome-wide association study 
was conducted in 2005 in patients with aged-related macular degeneration (ARMD) 
and successfully identified two SNPs which exhibit altered allele frequency 
compared to controls (Haines et al., 2005). The challenge of such studies consists in 
the translation of a genetic association between a genomic region and a disease into 
mechanistic insight in the disease and benefit for the patient. Thus following the 
identification of genes in the GWAS, candidate based studies are needed to address 
such questions. Nevertheless, sceptics criticize the often small odd ratios thus the 
consequentially small impact of the SNP on the disease penetrance (Ku et al., 2010) 
and that associations rather exist between the disease and a certain genetic 
haploblock and not necessarily a distinct gene. However, several GWAS have been 
successfully transformed into better understanding the disease (Budarf et al., 2009). 
Moreover, other results have already been adopted in the clinics for example in the 
prevention of adverse effects of widely used remedies such as antiviral drugs and 
statins (Fellay et al., 2010; Maggo et al., 2011). Hence linking TMEM106B to FTLD 
was the first step of a long process that may lead eventually to the development of 
new, evidence-based pharmaceuticals. The study presented here is an effort to 
clarify the physiological role of the encoded protein and linking it also 
mechanistically to the disease. 
 
2. Neuronal Phenotype: Loss of TMEM106B impairs dendrite and spine growth 
and maintenance 
Previous work in cell lines uncovered basic biochemical properties as protein 
topology and glycosylation pattern (Lang et al., 2012) but neuronal function of 
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TMEM106B remained largely unknown. In this study I combined knock-down 
experiments in primary neuron culture, proteomics and live cell imaging to 
investigate the physiological role of TMEM106B and tie it to cellular functions 
affected in FTLD (reviewed in (Ling et al., 2013)). I demonstrate that TMEM106B 
is almost completely localized in late endosomes and lysosomes in primary neurons. 
This confinement to the late endocytic pathway was also reported in several other 
publications (Brady et al., 2013; Chen-Plotkin et al., 2012; Lang et al., 2012; 
Nicholson et al., 2013). Some of these studies claim that overexpression of 
TMEM106B influences lysosomal properties – for example an increase in lysosomal 
pH leading to impairment in maturation of lysosomal proteases or an enlarged and 
altered morphology (Brady et al., 2013; Chen-Plotkin et al., 2012). However, 
accumulation and probably aggregation of TMEM106B in lysosomes has been 
observed in neurons upon overexpression of the protein probably causing the 
lysosomal phenotype (Chen-Plotkin et al., 2012). Also in my hands plasmid-based 
overexpression of TMEM106B in primary neurons led to the formation of 
aggregates, especially in dendrites. Moreover, shRNA-mediated knockdown of the 
protein did not affect the aforementioned lysosomal features, both pointing towards 
an unphysiological effect of the highly overexpressed protein. TMEM106B similar 
to many other transmembrane proteins (Kopito, 2000) tends to aggregate when 
overexpressed due to its hydrophobic transmembrane domain thus questioning the 
relevance of the published findings. Therefore, I titrated the protein carefully back 
to endogenous protein levels in all rescue experiments to avoid unphysiological 
TMEM aggregation.  
Overexpression and knockdown of many FTLD related proteins as TDP-43, FUS, 
and TAU lead to marked toxicity in cellular or animals models (Igaz et al., 2011; 
Shahani et al., 2006; Sun et al., 2011; Zhang et al., 2009b). However, loss of 
TMEM106B in primary neurons did not affect cellular viability in a metabolic 
assay. This finding and the increase in axonal length, despite the loss of dendrites, 
argue for a modifying role of TMEM106B on FTLD pathogenesis rather than a 
direct impact on neuronal survival. 
The most obvious phenotype upon knockdown of TMEM106B was a pronounced 
loss of dendrites. The morphology of the dendrites was evaluated with Sholl 
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analysis, which measures the dendritic complexity combining length and branching 
(Sholl, 1953). The experiments in younger neurons and mature neurons with an 
already completely established dendritic arbor show that TMEM106B is required 
both for the growth and maintenance of dendrites. The decrease in dendrite 
complexity was especially marked in proximal dendrites in TMEM106B knockdown 
neurons while the main dendrite was in all cases protected from the shRNA 
treatment and even was increased in its length. This was not entirely unexpected as 
the main dendrite seems to be particularly resilient (Hoogenraad et al., 2005).  
Emerging evidence points to an involvement of endosomes and lysosomes in neurite 
outgrowth and maintenance (Sann et al., 2009), for instance impairing the function 
of recycling endosomes by dominant negative RAB11 caused a collapse of 
developing axons in drosophila larvae (Bhuin and Roy, 2009). In order to confirm 
that lysosomes are indeed involved in neurite outgrowth, I inhibited lysosomal 
biogenesis by expressing dominant-negative RAB7 and observed a defect in 
dendritic arborization. Effectively, these experiments prove that compromising 
lysosomal function is actually able to impair dendrite architecture. Importantly, 
enhancing transport of lysosomes by dominant-negative RILP, a binding partner of 
RAB7, increased dendritic branching compared to control conditions. Together these 
findings point towards a direct impact of TMEM106B on dendrite morphology by 
modulating dendritic trafficking of lysosomes. 
In line with the often observed phenomenon that function and morphology of 
dendrites and spines are regulated through overlapping pathways (reviewed in 
(Koleske, 2013)), a dramatic decrease in spine number is seen upon TMEM106B 
knockdown. Moreover the remaining dendritic protrusions are much smaller and 
thinner than their control counterparts. The density and morphology of spines 
correlates with synaptic strength and is often used as surrogate marker for a 
functional neuronal transmission (reviewed in (Hering and Sheng, 2001; Lamprecht 
and LeDoux, 2004)). I also observed a reduction of pre- and postsynaptic marker 
proteins, which corroborates the morphological findings on a biochemical level. 
Dysfunction and loss of synapses is a major hallmark of many neurodegenerative 
diseases such as AD (Davies et al., 1987; Masliah et al., 2001; Spires-Jones and 
Knafo, 2012), and might be also a common feature in FTLD (Petkau et al., 2012). 
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However, the role of synapses and synaptic plasticity still needs to be studied more 
comprehensively in this disease. 
Taken together the data obtained in primary neurons clearly demonstrate that loss of 
the lysosomal protein TMEM106B lead to severely blunted dendrites and reduced 
spines number and dimensions without mediating obvious toxicity at the time point 
the experiments were done.  
 
3. Interaction of TMEM106B with MAP6 
To link TMEM106B to known cellular pathways and to the morphological phenotype 
observed, I sought to identify interacting proteins by coimmunoprecipitation and 
subsequent LC-MS/MS analysis of individual Coomassie stained bands that were 
enriched compared to the negative control. The only protein found in all three 
experiments was the microtubule-binding protein MAP6. Importantly, I could 
confirm the interaction by immunoblotting afterwards. Furthermore, I managed to 
map the interaction to the cytoplasmic N-terminus of TMEM106B and the C-
terminal region of MAP6 by using deletion mutants and different isoforms of the 
proteins. The binding on the cytoplasmic part of TMEM106B excludes the 
possibility that intravesicular MAP6, designated for lysosomal degradation, 
mediates the interaction. Subcellular fractionations showing MAP6 and TMEM106B 
in the same (RAB7 and LAMP1 positive lysosomal) fractions further corroborate the 
interaction of these proteins in the lysosomal compartment. Interestingly, MAP6 was 
found to interact with another vesicular protein, the endocytic adaptor intersectin 1 
(ITSN1) (Morderer et al., 2012). Moreover, depending on posttranslational 
modifications MAP6 is associated with other non-MT compartments such as the 
Golgi apparatus, actin rich spines and dendritic branch points (Baratier et al., 2006; 
Gory-Faure et al., 2006). 
Moreover, I also provide evidence for a functional cooperation of TMEM106B and 
MAP6. While the overexpression of MAP6 phenocopies the blunted dendritic 
arborization, the additional knockdown of MAP6 in TMEM106B shRNA transfected 
neurons is able to rescue the knockdown effect and even increase dendritic 
branching. Although the main cellular function of MAP6 is regulating microtubule 
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stability, a study by Arama and colleagues demonstrates, in line with my results, a 
role for the protein in the regulation of cell morphology (Arama et al., 2012). 
Furthermore, MAP6 was found to coaggregate in spheroid neurofilaments in ALS 
patients already providing a connection to neurodegenerative diseases (Letournel et 
al., 2003). 
Drawing a functional link between MAP6 and the control of dendrite outgrowth is 
very appealing, since microtubule-dependent processes and neurite outgrowth are 
tightly connected (reviewed in (Georges et al., 2008)). There is ample evidence of a 
huge impact of other structural MAPs such as MAP1B and MAP2 on both 
microtubule dynamics and neurite outgrowth (Caceres et al., 1992; Meixner et al., 
2000). Moreover, axonal growth is a direct consequence arising from the ability of 
Collapsin Response Mediator Protein-2 (CRMP2) to bind and stabilize microtubules 
(Hensley et al., 2011). Notably, I provided additional experimental evidence for the 
connection of both processes, since I was able to rescue dendrite loss in TMEM106B 
knockdown neurons also by pharmacological enhancement of microtubule dynamics 
with low doses of nocodazole. However, whole proteome analysis of TMEM106B 
immunoprecipitate will probably reveal additional interacting proteins which may 
also contribute to the TMEM106B dependent regulation of dendritic outgrowth. 
Taken together I provide here ample evidence for a physical and functional 
interaction of TMEM106B with the microtubule-binding protein MAP6. 
 
4. Dendritic trafficking of lysosomes is affected by TMEM106B and MAP6 
Microtubules and vesicles converge on the level of microtubule dependent organelle 
transport, a tightly regulated process influencing almost all functions in neurons 
(reviewed in (Hirokawa et al., 2010)). Thus it was intuitive to analyze this crucial 
process in the context of TMEM106B knockdown in primary neurons, especially as 
experiments from TMEM106B siRNA treated HeLa-cells show lysosomal clustering 
at the MTOC ((Schwenk et al., 2014) data by Christina Lang). 
I analyzed lysosomal transport in dendrites by acquiring time-laps movies from 
RAB7-GFP labeled vesicles that were converted into kymographs (path-time 
diagrams) (Chen et al., 2012; Zhang et al., 2013). Previously, little was known on 
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the mechanisms of dendritic trafficking of lysosomes and no data on direction and 
velocity was available. However, my results (0.24 μm/s for control and 0.35 μm/s 
for TMEM106B knockdown neurons) fall in the range of values reported for 
comparable transport events such as endosome movement in axons or mitochondrial 
movement in dendrites (Bannai et al., 2004; Kwinter et al., 2009; van Spronsen et 
al., 2013). Soon after transfection, at a time point before dendrite blunting became 
apparent, lysosomal trafficking in TMEM106B knockdown neurons was enhanced 
compared to controls. However, I observed not only an increase in the number of 
moving vesicles but also in the mean velocity and distance traveled. Interestingly, 
the increased vesicle trafficking could be attributed to enhanced retrograde transport 
(to the soma) whereas anterograde transport (to the dendrite tip) and transport 
events without net movement stayed roughly the same. Under control conditions the 
ratio of directions was balanced, while under knockdown conditions up to three 
times more vesicles moved towards the soma. The observed increase in organelle 
transport is a most unexpected finding in a neurodegenerative disease, as usually 
reduced organelle transport is found under pathological conditions (reviewed in 
(Franker and Hoogenraad, 2013; Millecamps and Julien, 2013)). Consistent with a 
functional interaction of MAP6 with TMEM106B, MAP6 overexpression had also an 
effect on lysosomal transport in dendrites. Similar to TMEM106B knockdown, 
retrograde transport was increased three days after transfection thus already before 
dendrite loss became apparent. In line with that, double knockdown of TMEM106B 
and MAP6 ameliorated this effect and reestablished the balance between anterograde 
and retrograde trafficking. The same was true for treatment with low doses of 
nocodazole which also rebalanced directed transport of lysosomes in TMEM106B 
knockdown neurons. Higher amounts of the anti-cancer drug nocodazole inhibit the 
polymerization of microtubules thus blocking MT-dependent transport (Samson et 
al., 1979). However, a study by Giannakakou et al. finds that subtherapeutical doses 
of this compound enhances transport presumably by increasing the dynamics of MT 
without causing complete collapse (Giannakakou et al., 2002). Moreover, 
knockdown of MAP6 or nocodazole treatment not only rebalanced the direction of 
lysosomal transport but mildly increased the number of total transport events in both 
directions. 
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The control of lysosomal trafficking and dendrite outgrowth by the same factors and 
the chronological order of the two phenotypes (lysosomal trafficking before dendrite 
withering), suggests that the first causes the latter. Neurite outgrowth relies heavily 
on the secretory and endocytic pathway (Horton et al., 2005; Jan and Jan, 2010; 
Sann et al., 2009) and also the involvement of lysosomes has been reported 
(Martinez-Arca et al., 2000). Furthermore, the fusion of lysosomes with the plasma 
membrane during lysosomal exocytosis provides lipids and other membrane 
components during cell growth and wound sealing (Chakrabarti et al., 2003; Huynh 
et al., 2004; Reddy et al., 2001). Moreover, ALS causing mutations in VABP, an ER 
targeted protein, diminish membrane delivery to dendrites and by that restrain 
dendritic outgrowth (Kuijpers et al., 2013; Nishimura et al., 2004). Thus, imbalance 
and the shift of lysosomal transport to the soma in the case of TMEM106B 
knockdown might affect the membrane and protein turnover in the dendrites and 
dendritic protrusions and directly lead to the observed loss of dendrites and spines. 
To corroborate a causal link between misbalanced lysosomal transport and dendrite 
growth, I manipulated lysosomal movement in neurons independently of 
TMEM106B/MAP6 with dnRILP. When overexpressed in cell-lines, wild-type RILP 
leads to lysosomal clustering near the nucleus, while dnRILP disperses lysosomes 
throughout the cell body (Cantalupo et al., 2001; Jordens et al., 2001). In contrast to 
TMEM106B knockdown, dnRILP promotes anterograde transport of lysosomes in 
dendrites and consequently elevates the complexity of the dendritic arbor compared 
to control cells. Importantly, in a functional rescue experiment I could reestablish 
the equilibrium of directed transport in TMEM106B knockdown neurons with 
dnRILP and by this achieve a partial rescue of the dendritic withering.  
Taken together I provide here several lines of evidence supporting that TMEM106B 
knockdown impairs dendritic arborization by enhancing retrograde trafficking of 
lysosomes in dendrites: First, The interaction partners TMEM106B and MAP6 
influence both phenotypes, trafficking and outgrowth. Second, lysosomal transport 
defects precede the dendrite loss. Third, altering directed lysosomal transport 
independently of TMEM106B and MAP6 changes dendrite growth. 
It is of course not possible to exclude that additional factors influence this process. 
Lysosomal misrouting might affect growth factor signaling such as GRN signaling 
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via sortilin and tumor necrosis factor receptor (TNFR) (Hu et al., 2010; Tang et al., 
2011) or nerve growth factor (NGF) via neurotrophic tyrosine kinase receptor type 1 
(TrKA) (Snider, 1988) by impairing the availability of the respective receptors on 
the cell surface. Furthermore, MAP6 might play an additional role in intracellular 
transport by its binding to MTs and the Golgi apparatus or by directly affecting MT-
stability (Gory-Faure et al., 2006). In line with this assumption MAP6 interacts with 
ITSN1, a protein which affects endocytosis and signal transduction by receptor 
tyrosine kinases (Morderer et al., 2012; Tsyba et al., 2011).  
 
5. Axonal phenotype 
Fast axonal transport of organelles is one of the most widely studied transport 
process in neurons and neurodegenerative disorders (reviewed in (Hinckelmann et 
al., 2013; Millecamps and Julien, 2013). Thus investigating the effect of 
TMEM106B on axonal transport was only consequential given the dramatic changes 
in dendritic trafficking of lysosomes. Colocalization experiments revealed that 
TMEM106B is present in axonal lysosomes as well, even though to a lesser extent 
than in dendritic lysosomes. Surprisingly, I could not detect any changes in the total 
number and more important in the direction of lysosomes transported in axons upon 
knockdown of TMEM106B, although at this time point, axons were 40 % longer 
than in controls. Several reasons could explain that discrepancy. First, dendrites and 
axons rely on largely different mechanisms to promote their growth. While axons 
are strongly dependent on guidance cues, dendritic growth is mainly regulated by 
limited membrane supply from the secretory and the endocytic pathway (Ye et al., 
2007). Second, different motor proteins and regulatory factors are needed for 
organelle transport in axons and dendrites (Kapitein and Hoogenraad, 2011). Thus, 
it might be possible that, while TMEM106B and MAP6 control outgrowth in 
dendrites, other proteins regulate axonal growth by a comparable mechanism. Third, 
due to the fast growth of axons, I analyzed axonal length and axonal transport in 
still developing neurons at DIV4, when dendrites are not yet established. It might be 
possible that axonal transport or axonal morphology is regulated differently in older 
neurons, at a time the dendritic phenotypes were observed. However, this scenario is 
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not very likely as the crucial machinery for axonal growth is already established 
early in neurodevelopment (da Silva and Dotti, 2002; Neukirchen and Bradke, 
2011).  
6. Model 
All findings in this study combined are compatible with a model describing 
TMEM106B as a molecular brake for the retrograde transport of lysosomes in 
dendrites thereby regulating dendrite growth and maintenance: TMEM106B – at the 
lysosomal membrane – binds with its cytoplasmic N-terminus to the C-terminus of 
microtubule-bound MAP6. This interaction apparently inhibits transport and stalls 
most dendritic lysosomes to the microtubule. Thus, only a limited amount of 
vesicles move retrogradely through the dendrite under control conditions (Figure 
39A). In the case of TMEM106B knockdown, this interaction is not possible any 
more and more lysosomes move undisturbed towards the soma. In the case of MAP6 
overexpression, the protein has a dominant negative effect. Excess MAP6 
molecules, not attached to the saturated binding sites on the microtubule, will bind 
to TMEM106B impeding its interaction with microtubule-bound MAP6. This 
dominant negative effect of overexpressed MAP6 thus mimics TMEM106B 
knockdown. This hypothesis is corroborated by live cell imaging experiments 
demonstrating that overexpressed MAP6-GFP occasionally moves together with 
lysosomes along dendrites. In contrast, anterograde transport, presumably regulated 
by different factors, remains constant upon manipulation of TMEM106B or MAP6. 
Due to the shift towards retrograde lysosomal transport, a net loss of lipid 
membranes and protein may occur that leads to loss off dendrite and spines (Figure 
39B). Knockdown of MAP6 mildly enhances dendritic trafficking of lysosomes in 
both directions but maintains the balance of anterograde and retrograde movement. 
Therefore, dendrite arborization is restored despite the loss of TMEM106B (Figure 
39C). Why loss of MAP6 also enhances anterograde transport is not completely 
clear, but may involve other interaction partners of MAP6. Another important factor 
might be enhanced microtubule dynamics upon knockdown of MAP6 - a widely 
reported phenomenon (Bosc et al., 1996; Delphin et al., 2012). This is supported by 
the fact that also nocodazole, a drug that decreases microtubule stability, is able to 
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increase both retrograde and anterograde lysosomal transport. Such additional 
factors might also explain why the overexpression of dominant-negative RILP only 
partially rescues the TMEM106B knockdown phenotype although lysosomal 
transport is completely rebalanced. 
A similar brake mechanism has already been reported for the axonal transport of 
mitochondria. Syntaphilin, like TMEM106B an integral membrane protein, halts 
mitochondrial transport in axons. When syntaphyilin is inserted in the mitochondrial 
outer membrane, it can interact with dynein light chain LC8 and thereby bind to the 
axonal cytoskeleton. This interaction which is completely independent of the motor 
function of LC8 stalls mitochondria at their current position on the microtubule 
(Chen et al., 2009; Kang et al., 2008). 
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 Figure 39 Model of the effects of TMEM106B and MAP6 on lysosomal transport 
(A) Interaction of TMEM106B and MAP6 inhibits retrograde transport of lysosomes in dendrites.  
(B) TMEM106B knockdown and MAP6 overexpression specifically enhance retrograde transport of 
lysosomes.  
(C) MAP6 knockdown moderately enhances trafficking of lysosomes in both direction and rescues 
TMEM106B knockdown. 
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None the less, the mechanism by which TMEM106B and MAP6 control vesicular 
transport and neurite outgrowth seems to be very specific for lysosomes and 
dendrites. On the one hand, dendritic trafficking of mitochondria is not affected 
upon TMEM106B knockdown, consistent with predominant lysosomal localization 
of the protein. On the other hand, no change in axonal transport of lysosomes could 
be detected. Additionally, knockdown of another microtubule stabilizing protein 
(microtubule-associated protein 2 (MAP2)) could not rescue the effect of 
TMEM106B knockdown on dendritic arborization but rather aggravated the 
branching defect. 
 
7. Implications for FTLD and other neurodegenerative diseases 
Although the association of TMEM106B with FTLD-TDP is now well accepted, the 
exact mechanism by which the lysosomal protein increases the risk of developing 
the disease is still unclear. Loss of neuronal TMEM106B does not obviously change 
the levels of FTLD associated proteins GRN, TDP-43, FUS and Tau. Although a 
slight elevation in GRN levels is reported for TMEM106B overexpression (Brady et 
al., 2013), this might also be caused by unspecific lysosomal impairment due to 
aberrant aggregation of the exogenous TMEM106B (Brady et al., 2013; Chen-
Plotkin et al., 2012). Just recently, it was discovered that TMEM106B variants 
increase the risk of developing also other forms of FTLD and even different 
neurodegenerative disease such as late onset Alzheimer´s disease (LOAD) 
(Gallagher et al., 2014; Lu et al., 2013; van Blitterswijk et al., 2014). Thus, it is 
likely that these variants rather render the neurons more vulnerable to general stress 
due to impaired protein homoeostasis than induce direct neurotoxicity.  
Although long debated at the beginning (van der Zee et al., 2011), emerging 
evidence suggest now that TMEM106B risk SNPs increase its mRNA and protein 
levels (Nicholson et al., 2013; Van Deerlin et al., 2010). Nevertheless, loss-of-
function studies are an appropriate way to elucidate the physiological function of a 
protein and its potential role in the disease. With knockdown experiments I was able 
to demonstrate an important contribution of TMEM106B to the regulation of 
lysosomal trafficking. This finding fits perfectly into the emerging concept that 
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lysosomal dysfunction is an important part in the pathogenesis of FTLD per se and 
especially of cases with GRN involvement. Several lines of evidence support this 
hypothesis: 
1. Mutations in the genes coding for VCP and CHMP2B, proteins involved in 
the maturation of endosomes and endolysosomal sorting and fusion events, 
are responsible for a small number of familial FTLD cases (FTLD-UPS) 
(Momeni et al., 2006a; Watts et al., 2004).  
2. The v-type ATPase inhibitor bafilomycin A1 and other agents that inhibit 
lysosomal acidification increase GRN expression and secretion in GRN +/- 
mice and lymphoblasts from GRN haploinsufficiency patients (Capell et al., 
2011).  
3. Homozygous GRN knockout mice exhibit apart from aberrantly 
phosphorylated TDP-43 and shorter life expectancy, a strong lysosomal 
dysfunction as mRNA and protein level of the lysosomal protease cathepsin D 
are highly elevated (Wils et al., 2012). Vice versa, in cathepsin D knockout 
mice, GRN mRNA level are almost doubled (Ahmed et al., 2010).  
4. Additionally, severe accumulation of lipofuscin aggregates is found in the 
brain of the GRN knockout animals, suggesting an impairment of the 
lysosomal system (Ahmed et al., 2010). While heterozygous GRN mutations 
carriers develop FTLD-TDP, humans with homozygous GRN mutations thus 
complete loss of the protein develop, in line with the findings from the 
knockout mice, neuronal ceroid lipofuscinosis (NCL) a lysosomal storage 
disorder (Smith et al., 2012). Another juvenile onset form of this syndrome – 
Batten disease - is caused by mutations in CLN3 (Tuxworth et al., 2009). 
Expression of mutated CLN3 in HeLa cells induces perinuclear clustering of 
lysosomes (Uusi-Rauva et al., 2012), reminiscent of the clustering phenotype 
seen in HeLa cells, treated with TMEM106B siRNA ((Schwenk et al., 2014) 
data by Christina Lang).  
All these facts argue for a strong lysosomal component in FTLD-TDP pathogenesis, 
especially in GRN mutation carriers, in whom TMEM106B SNPs have the strongest 
impact (Van Deerlin et al., 2010). Strikingly, TMEM106B, presumably together 
with lysosomes, accumulates in the soma and main dendrites of neurons in FTLD-
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TDP patients with GRN mutation (Busch et al., 2013; Chen-Plotkin et al., 2012) 
supporting the data of the present study. The aforementioned connection between 
lysosomes and FTLD, together with the findings of this study strongly indicates that 
lysosomal dysfunction is a crucial step in the pathological cascade leading to the 
disease. This dysfunction may easily be aggravated by lysosomal misrouting in 
TMEM106B risk carriers. 
 
8. Summary, open questions and future perspectives 
Taken together I demonstrated that the FTLD-TDP risk factor TMEM106B is located 
in late endosomes and lysosomes in primary neurons. Together with its interaction 
partner MAP6, TMEM106B acts as a molecular brake controlling the retrograde 
transport of lysosomes in the dendrite. Releasing that brake by knockdown of 
TMEM106B or the dominant negative effect of overexpressed MAP6 leads to 
increased transport of lysosomes to the soma and thus presumably to a higher and 
faster membrane and protein turnover in dendrites and spines. This could lead to a 
net loss of membranes and ultimately to pronounced withering of dendrites and 
spines. However, rebalancing the lysosomal transport by knockdown of MAP6, 
overexpression of dominant-negative RILP or treatment with low dose nocodazole 
can overcome the TMEM106B knockdown effect and restore dendritic branching.  
However, many questions remain:  
1. Further cell culture experiments are needed to clarify if and how altered 
microtubule dynamics contributes to the regulation of lysosomal transport by 
TMEM106B as suggested by rescue experiments with nocodazole. Moreover, 
it remains unclear if also other vesicular organelles (apart from lysosomes) 
are affected by TMEM106B or if comparable regulatory mechanisms exist 
which are affected in other familial forms of the disease. And although initial 
studies have been conducted to elucidate the role of TMEM106B in protein 
degradation and autophagy (Brady et al., 2013; Lang et al., 2012), it is 
unclear how the misrouting of lysosomes influences both processes.  
2. Electrophysiology experiments in primary neurons and slice cultures from 
disease models will need to confirm whether the transport phenotype by 
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TMEM106B knockdown indeed affects neurotransmission and synaptic 
strength as predicted by the loss of dendrites and spines. These model 
systems might also be helpful to identify and validate additional interaction 
partner for TMEM106B or MAP6 to generate a more complete insight into the 
mechanism by which the two proteins regulate vesicular transport and neuron 
morphology. 
3. TMEM106B knock-out animal models should be generated to confirm the 
findings from cell lines and primary neurons in vivo and identify additional 
phenotypes. Another useful approach to model the role of TMEM106B in the 
disease might be to introduce the T185S variant at the endogenous 
TMEM106B locus (Barger, 2013). A full examination including especially the 
analysis of lysosomal transport and function will eventually reveal if the 
knock-in is already enough to trigger certain disease related symptoms and if 
crossing with other FTLD models, such as the GRN knockout mouse, 
aggravates their symptoms.  
4. More studies in patients are needed to clarify the role of TMEM106B SNP in 
other sub classes of FTLD and in different neurodegenerative diseases (Lu et 
al., 2013; van Blitterswijk et al., 2014). Larger studies should also resolve 
the controversy how the risk variants affect RNA and protein levels of 
TMEM106B and GRN (Van Deerlin et al., 2010; van der Zee et al., 2011). 
Careful neuropathological assessment of patient brain samples is needed to 
evaluate the exact impact of the risk variants on vesicular localization and 
neuron morphology in affected brain regions. State-of-the-art techniques such 
as proteomics and transcriptomics from serum or cerebrospinal fluid (CSF) 
might identify additional dysregulated pathways in risk carriers. 
5. Finally, all approaches should focus on the identification of new rationale-
based drugs which have to proof their efficacy and safety in large clinical 
trials.  
 
In the end, mechanistic data from cell culture and animals, genetic and pathological 
data from patients and –omics data have to be combined to understand how 
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TMEM106B influences neurodegeneration in general and FTLD in particular and to 
diagnose and cure patients suffering from these devastating diseases. 
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